Document_And_Entity_Informatio
Document And Entity Information | 9 Months Ended | |
Sep. 30, 2014 | Jan. 01, 2015 | |
Document and Entity Information [Abstract] | ||
Entity Registrant Name | VIVEVE MEDICAL, INC. | |
Document Type | S-1 | |
Current Fiscal Year End Date | -19 | |
Entity Common Stock, Shares Outstanding | 12,347,121 | |
Amendment Flag | FALSE | |
Entity Central Index Key | 879682 | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Filer Category | Smaller Reporting Company | |
Entity Well-known Seasoned Issuer | No | |
Document Period End Date | 30-Sep-14 | |
Document Fiscal Year Focus | 2014 | |
Document Fiscal Period Focus | Q3 |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $) | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Dec. 30, 2013 | Sep. 30, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2007 | Dec. 31, 2006 |
Current assets: | |||||||||||||
Cash and cash equivalents | $1,976,980 | $430,107 | $359,894 | $448,754 | |||||||||
Accounts receivable | 3,750 | 849 | |||||||||||
Inventory | 136,902 | 228,163 | 360,214 | ||||||||||
Prepaids and other current assets | 188,006 | 308,183 | 64,522 | ||||||||||
Total current assets | 2,305,638 | 966,453 | 874,339 | ||||||||||
Property and equipment, net | 191,663 | 127,524 | 128,627 | ||||||||||
Other assets | 652,045 | 43,783 | 57,713 | ||||||||||
Total assets | 3,149,346 | 1,137,760 | 1,060,679 | ||||||||||
Current liabilities: | |||||||||||||
Accounts payable | 566,059 | 967,315 | 485,577 | ||||||||||
Accrued liabilities | 387,538 | 516,152 | 41,127 | ||||||||||
Note payable | 1,471,799 | 1,463,244 | 1,462,244 | 1,581,390 | |||||||||
Related party convertible bridge notes | 4,875,000 | 1,000,000 | |||||||||||
Total current liabilities | 2,425,396 | 7,821,711 | 3,412,611 | ||||||||||
Preferred stock warrant liabilities | 580,187 | 602,188 | 623,672 | 623,672 | 685,213 | 646,844 | |||||||
Total liabilities | 2,425,396 | 8,445,383 | 4,138,951 | ||||||||||
Stockholders’ equity (deficit): | |||||||||||||
Common stock | 35,066,274 | 6,556 | 6,556 | ||||||||||
Additional paid-in capital | 22,395,684 | 22,308,256 | |||||||||||
Accumulated deficit | -34,342,324 | -29,904,925 | -25,588,146 | ||||||||||
Total stockholders’ equity (deficit) | 723,950 | -7,307,623 | -3,078,272 | -6,710,944 | -1,740,093 | -349,091 | -618,346 | 2,515,830 | -492,985 | ||||
Total liabilities and stockholders’ equity (deficit) | 3,149,346 | 1,137,760 | 1,060,679 | ||||||||||
Series A Preferred Stock [Member] | |||||||||||||
Stockholders’ equity (deficit): | |||||||||||||
Convertible Preferred Stock | 23,863 | 23,863 | |||||||||||
Series B Preferred Stock [Member] | |||||||||||||
Stockholders’ equity (deficit): | |||||||||||||
Convertible Preferred Stock | $171,199 | $171,199 |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Apr. 30, 2012 |
Preferred Stock, par value (in Dollars per share) | $0 | $0 | ||
Preferred stock, shares issued | 0 | 0 | ||
Preferred stock, shares outstanding | 0 | 0 | ||
Common stock, par value (in Dollars per share) | $0 | $0.00 | $0.00 | |
Common stock, shares authorized | 612,000,000 | 612,000,000 | 612,000,000 | |
Common stock, shares issued | 18,016,662 | 6,555,305 | 6,555,305 | |
Common stock, shares outstanding | 18,016,662 | 6,555,305 | 6,555,305 | |
Series A Preferred Stock [Member] | ||||
Preferred Stock, par value (in Dollars per share) | $0.00 | $0.00 | $0.00 | |
Preferred stock, shares authorized | 24,543,626 | 24,543,626 | 24,543,626 | 24,543,626 |
Preferred stock, shares issued | 0 | 23,863,302 | 23,863,302 | |
Preferred stock, shares outstanding | 0 | 23,863,302 | 23,863,302 | |
Preferred stock, liquidation value (in Dollars) | $14,556,614 | $14,556,614 | ||
Series B Preferred Stock [Member] | ||||
Preferred Stock, par value (in Dollars per share) | $0.00 | $0.00 | $0.00 | |
Preferred stock, shares authorized | 227,000,000 | 227,000,000 | 227,000,000 | 227,000,000 |
Preferred stock, shares issued | 0 | 171,199,348 | 171,199,348 | |
Preferred stock, shares outstanding | 0 | 171,199,348 | 171,199,348 | |
Preferred stock, liquidation value (in Dollars) | $8,559,967 | $8,559,967 |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements of Operations (Unaudited) (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | 99 Months Ended | |||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Revenue | $17,180 | $4,610 | $64,475 | $147,660 | $152,270 | $249,408 | $421,678 |
Cost of revenue | 14,724 | 1,493 | 40,075 | 110,528 | 182,329 | 118,272 | 321,433 |
Gross profit | 2,456 | 3,117 | 24,400 | 37,132 | -30,059 | 131,136 | 100,245 |
Operating expenses: | |||||||
Research and development | 572,134 | 177,203 | 940,954 | 628,545 | 771,695 | 1,396,179 | 14,192,193 |
Selling, general and administrative | 1,790,014 | 532,369 | 3,085,580 | 2,517,791 | 3,129,234 | 3,076,875 | 14,288,499 |
Total operating expenses | 2,362,148 | 709,572 | 4,026,534 | 3,146,336 | 3,900,929 | 4,473,054 | 28,480,692 |
Loss from operations | -2,359,692 | -706,455 | -4,002,134 | -3,109,204 | -3,930,988 | -4,341,918 | -28,380,447 |
Interest income | 2 | 2 | 5 | 5 | 8 | 527 | 92,252 |
Interest expense | -152,296 | -156,727 | -486,582 | -334,380 | 447,340 | 743,359 | 2,208,688 |
Other income (expense), net | 7,827 | -8,713 | 51,312 | 11,230 | 61,541 | 124,731 | 591,958 |
Net loss | ($2,504,159) | ($871,893) | ($4,437,399) | ($3,432,349) | ($4,316,779) | ($4,960,019) | ($29,904,925) |
Net loss per share: | |||||||
Basic and diluted (in Dollars per share) | ($1.76) | ($16.52) | ($8.64) | ($65.05) | ($81.81) | ($106.78) | |
Weighted average shares used in computing net loss per common share | |||||||
Basic and diluted (in Shares) | 1,419,586 | 52,768 | 513,381 | 52,768 | 52,768 | 46,450 |
Condensed_Statements_of_Cash_F
Condensed Statements of Cash Flows (Unaudited) (USD $) | 9 Months Ended |
Sep. 30, 2014 | |
Cash flows from operating activities: | |
Net loss | ($4,437,399) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
Depreciation and amortization expense | 42,220 |
Stock-based compensation expense | 143,643 |
Revaluation of fair value of warrant liability | -50,762 |
Noncash interest expense | 369,677 |
Changes in assets and liabilities: | |
Accounts receivable | -3,750 |
Inventory | 91,261 |
Prepaid and other current assets | 120,177 |
Other noncurrent assets | 13,908 |
Accounts payable | -401,256 |
Accrued liabilities | 61,293 |
Net cash used in operating activities | -4,050,988 |
Cash flows from investing activities: | |
Purchase of property and equipment | -106,359 |
Net cash used in investing activities | -106,359 |
Cash flows from financing activities: | |
Net cash proceeds from issuance of common stock in connection with private placement offering | 4,204,220 |
Proceeds from related party convertible bridge notes | 1,500,000 |
Net cash provided by financing activities | 5,704,220 |
Net increase (decrease) in cash and cash equivalents | 1,546,873 |
Cash and cash equivalents - beginning of period | 430,107 |
Cash and cash equivalents - end of period | 1,976,980 |
Supplemental disclosure: | |
Cash paid for interest | 116,905 |
Cash paid for income taxes | 800 |
Supplemental disclosure of cash flow information as of end of period: | |
Conversion of certain bridge notes and related accrued interest in connection with private placement offering | 1,545,678 |
Extinguishment of convertible bridge notes and related accrued interest pursuant to Merger Agreement | 5,397,278 |
Extinguishment of warrant liabilities pursuant to Merger Agreement | 572,910 |
Payable to non-accredited investors in connection with Merger Agreement | 16,498 |
Notes Payable to Banks [Member] | |
Supplemental disclosure of cash flow information as of end of period: | |
Issuance of warrants in connection with note payable | $622,170 |
Balance_Sheets
Balance Sheets (USD $) | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Dec. 30, 2013 | Sep. 30, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2007 | Dec. 31, 2006 |
Current assets: | |||||||||||||
Cash and cash equivalents | $1,976,980 | $430,107 | $359,894 | $448,754 | |||||||||
Accounts receivable | 3,750 | 849 | |||||||||||
Inventory | 136,902 | 228,163 | 360,214 | ||||||||||
Prepaids and other current assets | 188,006 | 308,183 | 64,522 | ||||||||||
Total current assets | 2,305,638 | 966,453 | 874,339 | ||||||||||
Property and equipment, net | 191,663 | 127,524 | 128,627 | ||||||||||
Other assets | 652,045 | 43,783 | 57,713 | ||||||||||
Total assets | 3,149,346 | 1,137,760 | 1,060,679 | ||||||||||
Current liabilities: | |||||||||||||
Accounts payable | 566,059 | 967,315 | 485,577 | ||||||||||
Accrued liabilities | 387,538 | 516,152 | 345,644 | ||||||||||
Note payable | 1,471,799 | 1,463,244 | 1,462,244 | 1,581,390 | |||||||||
Related party convertible bridge notes | 4,875,000 | 1,000,000 | |||||||||||
Total current liabilities | 2,425,396 | 7,821,711 | 3,412,611 | ||||||||||
Accrued liabilities, noncurrent | 387,538 | 516,152 | 41,127 | ||||||||||
Preferred stock warrant liabilities | 580,187 | 602,188 | 623,672 | 623,672 | 685,213 | 646,844 | |||||||
Total liabilities | 2,425,396 | 8,445,383 | 4,138,951 | ||||||||||
Stockholders’ deficit: | |||||||||||||
Common stock: par value $0.001, 612,000,000 shares authorized, 6,555,305 shares issued and outstanding as of December 31, 2012 and 2013 | 35,066,274 | 6,556 | 6,556 | ||||||||||
Additional paid-in capital | 22,395,684 | 22,308,256 | |||||||||||
Deficit accumulated during the development stage | -34,342,324 | -29,904,925 | -25,588,146 | ||||||||||
Total stockholders’ deficit | 723,950 | -7,307,623 | -3,078,272 | -6,710,944 | -1,740,093 | -349,091 | -618,346 | 2,515,830 | -492,985 | ||||
Total liabilities and stockholders’ deficit | 3,149,346 | 1,137,760 | 1,060,679 | ||||||||||
Series A Preferred Stock [Member] | |||||||||||||
Stockholders’ deficit: | |||||||||||||
Converitble preferred stock | 23,863 | 23,863 | |||||||||||
Series B Preferred Stock [Member] | |||||||||||||
Stockholders’ deficit: | |||||||||||||
Converitble preferred stock | $171,199 | $171,199 |
Balance_Sheets_Parentheticals
Balance Sheets (Parentheticals) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Apr. 30, 2012 |
Preferred Stock, par value (in Dollars per share) | $0 | $0 | ||
Preferred stock, shares issued | 0 | 0 | ||
Preferred stock, shares outstanding | 0 | 0 | ||
Common stock, par value (in Dollars per share) | $0 | $0.00 | $0.00 | |
Common stock, shares authorized | 612,000,000 | 612,000,000 | 612,000,000 | |
Common stock, shares issued | 18,016,662 | 6,555,305 | 6,555,305 | |
Common stock, shares outstanding | 18,016,662 | 6,555,305 | 6,555,305 | |
Series A Preferred Stock [Member] | ||||
Preferred Stock, par value (in Dollars per share) | $0.00 | $0.00 | $0.00 | |
Preferred stock, shares authorized | 24,543,626 | 24,543,626 | 24,543,626 | 24,543,626 |
Preferred stock, shares issued | 0 | 23,863,302 | 23,863,302 | |
Preferred stock, shares outstanding | 0 | 23,863,302 | 23,863,302 | |
Preferred stock, liquidation value (in Dollars) | $14,556,614 | $14,556,614 | ||
Series B Preferred Stock [Member] | ||||
Preferred Stock, par value (in Dollars per share) | $0.00 | $0.00 | $0.00 | |
Preferred stock, shares authorized | 227,000,000 | 227,000,000 | 227,000,000 | 227,000,000 |
Preferred stock, shares issued | 0 | 171,199,348 | 171,199,348 | |
Preferred stock, shares outstanding | 0 | 171,199,348 | 171,199,348 | |
Preferred stock, liquidation value (in Dollars) | $8,559,967 | $8,559,967 |
Statement_of_Operations
Statement of Operations (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | 99 Months Ended | |||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Revenue | $17,180 | $4,610 | $64,475 | $147,660 | $152,270 | $249,408 | $421,678 |
Cost of revenue | 14,724 | 1,493 | 40,075 | 110,528 | 182,329 | 118,272 | 321,433 |
Gross margin | 2,456 | 3,117 | 24,400 | 37,132 | -30,059 | 131,136 | 100,245 |
Operating expenses: | |||||||
Research and development | 572,134 | 177,203 | 940,954 | 628,545 | 771,695 | 1,396,179 | 14,192,193 |
General and administrative | 1,790,014 | 532,369 | 3,085,580 | 2,517,791 | 3,129,234 | 3,076,875 | 14,288,499 |
Total operating expenses | 2,362,148 | 709,572 | 4,026,534 | 3,146,336 | 3,900,929 | 4,473,054 | 28,480,692 |
Loss from operations | -2,359,692 | -706,455 | -4,002,134 | -3,109,204 | -3,930,988 | -4,341,918 | -28,380,447 |
Interest income | 2 | 2 | 5 | 5 | 8 | 527 | 92,252 |
Interest expense | 152,296 | 156,727 | 486,582 | 334,380 | -447,340 | -743,359 | -2,208,688 |
Other income (expense), net | 7,827 | -8,713 | 51,312 | 11,230 | 61,541 | 124,731 | 591,958 |
Net loss | ($2,504,159) | ($871,893) | ($4,437,399) | ($3,432,349) | ($4,316,779) | ($4,960,019) | ($29,904,925) |
Net loss per share | |||||||
Basic and diluted (in Dollars per share) | ($1.76) | ($16.52) | ($8.64) | ($65.05) | ($81.81) | ($106.78) | |
Weighted average shares used in computing net loss per common share | |||||||
Basic and diluted (in Shares) | 1,419,586 | 52,768 | 513,381 | 52,768 | 52,768 | 46,450 |
Statements_of_Stockholders_Equ
Statements of Stockholders' Equity (Deficit) (USD $) | 12 Months Ended | 99 Months Ended | |||||||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2007 | Dec. 31, 2006 | Dec. 31, 2013 | |
Issuance of restricted common stock at $0.001 per share for cash in February and June 2006 | $4,000 | ||||||||
Stock-based compensation expense | 87,428 | 109,197 | 31,238 | 28,770 | 20,834 | 10,866 | 2,522 | 360 | |
Comprehensive and net loss | -4,316,779 | -4,960,019 | -5,001,782 | -5,414,535 | -5,684,452 | -3,145,042 | -884,971 | -497,345 | |
Balances at December 31 | -7,307,623 | -3,078,272 | -6,710,944 | -1,740,093 | -349,091 | -618,346 | 2,515,830 | -492,985 | -7,307,623 |
Issuance of Series convertible preferred stock | 8,474,159 | 3,994,763 | 1,429,919 | 3,891,264 | |||||
Repurchase of common stock | -565 | 565 | |||||||
Exercise of stock options | 9,335 | 9 | 19,343 | ||||||
Repurchase of restricted stock options in September 2011 | -316 | ||||||||
Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | |||||||||
Balances at December 31 | 23,863 | 23,863 | 23,863 | 23,863 | 17,216 | 7,380 | 7,380 | 23,863 | |
Balances at December 31 (in Shares) | 23,863,302 | 23,863,302 | 23,863,302 | 23,863,302 | 17,216,184 | 7,380,119 | 7,380,119 | 23,863,302 | |
Issuance of Series convertible preferred stock | 6,647 | 2,459 | 7,380 | ||||||
Issuance of Series convertible preferred stock (in Shares) | 6,647,118 | 2,459,017 | 7,380,119 | ||||||
Series B Preferred Stock [Member] | Series B Preferred Stock [Member] | |||||||||
Balances at December 31 | 171,199 | 171,199 | 171,199 | ||||||
Balances at December 31 (in Shares) | 171,199,348 | 171,199,348 | 171,199,348 | ||||||
Issuance of Series convertible preferred stock | 171,199 | ||||||||
Issuance of Series convertible preferred stock (in Shares) | 171,199,348 | ||||||||
Common Stock [Member] | |||||||||
Issuance of restricted common stock at $0.001 per share for cash in February and June 2006 | 4,000 | ||||||||
Issuance of restricted common stock at $0.001 per share for cash in February and June 2006 (in Shares) | 4,000,000 | ||||||||
Stock-based compensation expense | 755 | ||||||||
Stock-based compensation expense (in Shares) | 754,635 | ||||||||
Balances at December 31 | 6,556 | 6,556 | 3,934 | 3,930 | 3,757 | 4,000 | 4,000 | 4,000 | 6,556 |
Balances at December 31 (in Shares) | 6,555,305 | 6,555,305 | 3,933,767 | 3,930,017 | 3,756,562 | 4,000,000 | 4,000,000 | 4,000,000 | 6,555,305 |
Repurchase of common stock | -565 | ||||||||
Repurchase of common stock (in Shares) | -565,833 | ||||||||
Exercise of stock options | 1,867 | 9 | 173 | 322 | |||||
Exercise of stock options (in Shares) | 1,866,903 | 9,000 | 173,455 | 322,395 | |||||
Repurchase of restricted stock options in September 2011 | -5 | ||||||||
Repurchase of restricted stock options in September 2011 (in Shares) | -5,250 | ||||||||
Additional Paid-in Capital [Member] | |||||||||
Stock-based compensation expense | 87,428 | 108,442 | 31,238 | 28,770 | 20,834 | 10,866 | 2,522 | 360 | |
Balances at December 31 | 22,395,684 | 22,308,256 | 13,889,386 | 13,858,459 | 9,841,746 | 3,897,632 | 3,886,766 | 360 | 22,395,684 |
Issuance of Series convertible preferred stock | 8,302,960 | 3,988,116 | 1,427,460 | 3,883,884 | |||||
Exercise of stock options | 7,468 | -173 | 19,021 | ||||||
Repurchase of restricted stock options in September 2011 | -311 | ||||||||
Accumulated Deficit during Development Stage [Member] | |||||||||
Comprehensive and net loss | -4,316,779 | -4,960,019 | -5,001,782 | -5,414,535 | -5,684,452 | -3,145,042 | -884,971 | -497,345 | |
Balances at December 31 | ($29,904,925) | ($25,588,146) | ($20,628,127) | ($15,626,345) | ($10,211,810) | ($4,527,358) | ($1,382,316) | ($497,345) | ($29,904,925) |
Statements_of_Stockholders_Equ1
Statements of Stockholders' Equity (Deficit) (Parentheticals) (USD $) | 12 Months Ended | ||||
Dec. 31, 2012 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2007 | Dec. 31, 2006 | |
Common stock, per share | $0.00 | ||||
Conversion of notes payable (in Dollars) | $501,873 | ||||
Net issuance cost (in Dollars) | $85,807 | $59,978 | $70,082 | $610,609 | |
Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | |||||
Preferred stock, per share | $0.05 | $0.61 | $0.61 | $0.61 | |
Exercise of stock options, per share | $0.06 | ||||
Series A Preferred Stock [Member] | |||||
Preferred stock, per share | $0.00 | ||||
Series B Preferred Stock [Member] | |||||
Preferred stock, per share | $0.00 | ||||
Common Stock [Member] | |||||
Common stock, per share | $0.00 |
Statements_of_Cash_Flows
Statements of Cash Flows (USD $) | 9 Months Ended | 12 Months Ended | 99 Months Ended | |
Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Cash flows from operating activities: | ||||
Net loss | ($3,432,349) | ($4,316,779) | ($4,960,019) | ($29,904,925) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||
Depreciation and amortization expense | 35,871 | 66,120 | 57,173 | 239,475 |
Stock-based compensation expense | 66,001 | 87,428 | 109,197 | 291,215 |
Revaluation of warrant liability | -11,230 | -61,541 | -156,163 | -622,824 |
Noncash interest expense | 227,911 | 305,917 | 545,165 | 1,228,529 |
Loss on disposal of property and equipment | 31,433 | 31,433 | ||
Changes in assets and liabilities: | ||||
Accounts receivable | 849 | 849 | -849 | |
Inventory | -574 | 71,247 | -242,861 | -288,967 |
Prepaid and other current assets | -209,711 | -243,661 | 123,605 | -308,183 |
Other noncurrent assets | 13,908 | 13,930 | -48,300 | -43,783 |
Accounts payable | 439,849 | 481,738 | -13,175 | 967,315 |
Accrued liabilities | -80,357 | -159,868 | -888,960 | 337,095 |
Net cash used in operating activities | -2,949,832 | -3,754,620 | -5,443,754 | -28,073,620 |
Cash flows from investing activities: | ||||
Proceeds from sale of property and equipment | 50 | 50 | ||
Purchase of property and equipment | -4,214 | -4,213 | -23,331 | -337,678 |
Net cash used in investing activities | -4,214 | -4,213 | -23,281 | -337,628 |
Cash flows from financing activities: | ||||
Net proceeds from issuance of common stock | 4,000 | |||
Proceeds from exercise of stock options | 9,335 | 28,687 | ||
Repurchase of common stock | -565 | |||
Repurchase of restricted stock options | -316 | |||
Proceeds from related party convertible bridge notes and warrants | 3,000,000 | 3,875,000 | 2,000,000 | 9,375,400 |
Repayments of notes payable | -134,814 | -134,814 | -2,165,475 | -4,163,361 |
Net cash provided by financing activities | 2,865,186 | 3,740,186 | 5,743,210 | 28,841,355 |
Net increase (decrease) in cash and cash equivalents | -88,860 | -18,647 | 276,175 | 430,107 |
Proceeds from notes payable | 2,135,159 | 6,107,159 | ||
Cash and cash equivalents | 359,894 | 430,107 | 448,754 | 430,107 |
Supplemental disclosure | ||||
Cash paid for interest | 106,469 | 141,423 | 198,194 | 783,482 |
Cash paid for income taxes | 800 | 800 | 800 | 6,400 |
Supplemental schedule of noncash investing and financing activities: | ||||
Issuance of warrants in connection with loans | 20,069 | |||
Tranfer of equipment between inventory and property and equipment | 60,804 | 60,804 | ||
Preferred Class A [Member] | ||||
Cash flows from financing activities: | ||||
Proceeds from issuance of convertible preferred stock and warrants, net of issuance costs | 13,726,160 | |||
Supplemental schedule of noncash investing and financing activities: | ||||
Conversion of notes payable (in Dollars) | 501,873 | |||
Preferred Class B [Member] | ||||
Cash flows from financing activities: | ||||
Proceeds from issuance of convertible preferred stock and warrants, net of issuance costs | 3,764,191 | 3,764,191 | ||
Supplemental schedule of noncash investing and financing activities: | ||||
Conversion of notes payable (in Dollars) | 4,709,968 | 4,709,968 | ||
Bridge Loan [Member] | ||||
Supplemental schedule of noncash investing and financing activities: | ||||
Cancellation of warrants in connection with bridge loans | 15,091 | |||
Notes Payable to Banks [Member] | ||||
Supplemental schedule of noncash investing and financing activities: | ||||
Issuance of warrants in connection with loans | 100,584 | |||
April 2012 Term Loan [Member] | ||||
Supplemental schedule of noncash investing and financing activities: | ||||
Issuance of warrants in connection with loans | 70,082 | |||
Related Party Convertible Bridge Notes [Member] | ||||
Supplemental schedule of noncash investing and financing activities: | ||||
Issuance of warrants in connection with loans | $167,090 | $670,090 |
Note_1_The_Company_and_Basis_o
Note 1 - The Company and Basis of Presentation | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2014 | Dec. 31, 2013 | |||
Disclosure Text Block [Abstract] | ||||
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1 | The Company and Basis of Presentation | 1 | Formation and Business of the Company |
On September 23, 2014, PLC Systems, Inc., a Yukon Territory corporation (“PLC”) completed an Agreement and Plan of Merger (“Merger Agreement” or “Merger”) with Viveve®, Inc., a Delaware corportation (“Viveve”). As of that date, Viveve operates as a wholly-owned subsidiary of PLC and PLC is known as Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”). Viveve Medical will compete in the women’s health market with a focus on the Viveve System™ to improve women’s overall sexual well-being and quality of life, will retain all its personnel and continue to be headquartered in Sunnyvale, California. | Viveve, Inc. (the “Company”) was incorporated in the state of Delaware on September 21, 2005 for the purpose of the design, development, manufacture and marketing of medical devices for the non-invasive treatment of vaginal laxity. | |||
At the effective time of the Merger, PLC divested its ownership of its former operating subsidiaries, PLC Medical Systems, Inc. and PLC Systemas Medicos Internacionais, which will operate as independent entities going forward under new ownership. | The Company is considered to be in the development stage and, since inception, has devoted substantially all of its time and effort to developing products, raising capital and recruiting personnel. The Company has not generated substantial revenues to date from its planned principal operations. As such, it is subject to risks common to companies in the development stage including but not limited to, development of new products, markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital to fund its product plans. The Company may require additional resources to complete the commercialization of its proposed products. Therefore, the Company may need to raise additional capital in the future to fund its operations. The Company may at that time be unable to raise such funds when needed or on acceptable terms. If the Company fails to raise additional funds as needed it may have to delay or terminate its product development. | |||
In preparation for the stock exchange pursuant to the Merger, Viveve convertible bridge notes in the aggregate amount of $4,875,000 and related accrued interest of approximately $522,000 were extinguished. | The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses and negative cash flows from operations since inception. The Company has not generated significant revenues and has funded its operating losses through the sale of preferred stock and the issuance of debt. The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the industry. These risks include, but are not limited to, the uncertainty of availability of additional financing and the uncertainty of achieving future profitability. Management of the Company intends to raise additional funds through the issuance of equity securities. There can be no assurance that such financing will be available or on terms which are favorable to the Company. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not contain any adjustments that might result from the outcome of this uncertainty. | |||
Additionally, Viveve warrant liabilities of approximately $573,000 were extinguished in preparation of the stock exchange pursuant to the Merger. | ||||
Pursuant to the Merger Agreement, all shares of capital stock (including common and preferred stock) of Viveve were converted into 3,743,282 shares of the Company's common stock which represented approximately 62% of the issued and outstanding shares of common stock of the Company on a fully diluted basis. In addition, non-accredited investors were entitled to receive approximately $16,500 upon closing. Upon the closing of the Merger, the Company issued an additional 943,596 shares of common stock upon the automatic conversion of a warrant issued in exchange for the cancellation of related party convertible bridge notes. | ||||
The acquisition was accounted for as a reverse merger and recapitalization effected by a share exchange. Viveve is considered the acquirer for accounting and financial reporting purposes. The assets and liabilities of the acquired entity have been brought forward at their book value and no goodwill has been recognized. | ||||
Concurrent with the Merger, Viveve Medical completed a private placement for total gross proceeds of approximately $6 million (including approximately $1.5 million of convertible bridge note conversion). As a result, Viveve Medical issued 11,305,567 shares of common stock and 5-year warrants to purchase up to 940,189 shares of common stock at an exercise price of $0.53 per share. | ||||
Interim Unaudited Financial Information | ||||
The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the financial statements have been included. | ||||
The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, included in the proxy statement which was filed with the Securities and Exchange Commission on August 11, 2014. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results for the year ending December 31, 2014 or any future interim period. |
Note_2_Summary_of_Significant_
Note 2 - Summary of Significant Accounting Policies | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||||||||||
Accounting Policies [Abstract] | ||||||||||||||||||||||||||
Significant Accounting Policies [Text Block] | 2 | Summary of Significant Accounting Policies | 2 | Summary of Significant Accounting Policies | ||||||||||||||||||||||
Financial Statement Presentation | Basis of Presentation and Use of Estimates | |||||||||||||||||||||||||
The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation. | The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | |||||||||||||||||||||||||
Use of Estimates | Cash and Cash Equivalents | |||||||||||||||||||||||||
The preparation of condensed consolidated financial statements in conformity with US GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect on our operating results. | The Company considers all highly liquid investments purchased with an original maturity of three months or less, at the time of purchase, to be cash equivalents. The Company’s cash and cash equivalents are deposited in demand and money market accounts at one financial institution. Deposits in this institution may, from time to time, exceed the federally insured amounts. | |||||||||||||||||||||||||
Reclassifications | Concentration of Credit Risk and Other Risks and Uncertainties | |||||||||||||||||||||||||
Certain prior year financial statement amounts have been reclassified to conform to the current year’s presentation. These reclassifications had no impact on previously reported total assets, stockholders’ deficit or net loss. | To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows. | |||||||||||||||||||||||||
Revenue Recognition | The Company’s future products may require approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no assurance that the Company’s future products will receive any of these required approvals. If the Company was denied such approvals or such approvals were delayed, it would have a material adverse impact on the Company’s financial results, financial position and future cash flows. | |||||||||||||||||||||||||
The Company recognizes revenue from the sale of its product, the Viveve® System, and single-use treatment tips. Revenue is recognized upon delivery, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of Viveve’s products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance outside the U.S. and currently sells the Viveve System in Canada, Hong Kong and Japan. | The Company is subject to risks common to companies in the medical device industry including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products. | |||||||||||||||||||||||||
The Company does not provide its customers with a contractual right of return. | During the years ended December 31, 2012 and 2013, three customers accounted for 100% of the Company’s revenue. | |||||||||||||||||||||||||
Recently Issued and Adopted Accounting Standards | Inventory | |||||||||||||||||||||||||
In May 2014, as part of its ongoing efforts to assist in the convergence of US GAAP and International Financial Reporting Standards (“IFRS”), the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The ASU provides alternative methods of initial adoption and is effective for annual and interim periods beginning after December 15, 2016. We are currently evaluating the impact that this standard will have on our condensed consolidated financial statements. | Inventory is stated at the lower of cost or market. Cost is determined on a standard cost basis which approximates actual cost on a first-in, first-out method. Lower of cost or market is evaluated by considering obsolescence, excessive levels of inventory, deterioration and other factors. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolescence or impaired inventory. Excess and obsolete inventory is charged to cost of revenue and a new, lower-cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. | |||||||||||||||||||||||||
In June 2014, the FASB issued ASU No. 2014-12, “Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could be Achieved After a Requisite Service Period” (“ASU 2014-12”). Companies commonly issue share-based payment awards that require a specific performance target to be achieved in order for employees to become eligible to vest in the awards. ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period should be treated as a performance condition. The performance target should not be reflected in estimating the grant date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved. ASU 2014-12 will be effective for the Company’s fiscal years beginning fiscal 2016 and interim reporting periods within that year, using either the retrospective or prospective transition method. Early adoption is permitted. We are currently evaluating the effect of the adoption of this guidance on our condensed consolidated financial statements. | As part of the Company’s normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five years. The amortization of the demos is charged to general and administrative expense and the demos are included in the medical equipment line of the property and equipment balance on the balance sheet as of December 31, 2013. | |||||||||||||||||||||||||
In June 2014, the FASB issued ASU 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in topic 810, Consolidation” (“ASU 2014-10”). ASU 2014-10 removes the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. ASU 2014-10 also eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. The amendments in ASU 2014-10 will be effective retrospectively except for the clarification to Topic 275, which shall be applied prospectively for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued. We elected to early adopt the provisions of ASU 2014-10 in the second quarter of 2014. | Fair Value of Financial Instruments | |||||||||||||||||||||||||
In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 310-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”), to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Since ASU 2014-15 only impacts financial statement disclosure requirements regarding whether there is substantial doubt about an entity’s ability to continue as a going concern, we do not expect its adoption to have an impact on our condensed consolidated financial statements. | Carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities. Based on borrowing rates currently available to the Company for loans with similar terms, the carrying value of the notes payable approximates fair value. | |||||||||||||||||||||||||
Concentration of Credit Risk and Other Risks and Uncertainties | Property and Equipment | |||||||||||||||||||||||||
To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows. | Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight line method over their estimated useful lives of three to five years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful life or the life of the lease. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. | |||||||||||||||||||||||||
The Company’s future products may require approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no assurance that the Company’s future products will receive any of these required approvals. If the Company was denied such approvals or such approvals were delayed, it would have a material adverse impact on the Company’s financial results, financial position and future cash flows. | Impairment of Long-Lived Assets | |||||||||||||||||||||||||
The Company is subject to risks common to companies in the medical device industry including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products. | The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company has not identified any such impairment losses to date. | |||||||||||||||||||||||||
During the nine months ended September 30, 2014, three customers accounted for 94% of the Company’s revenue. | Preferred Stock Warrants | |||||||||||||||||||||||||
During the nine months ended September 30, 2013, one customer accounted for 100% of the Company’s revenue. | Freestanding warrants and other similar instruments related to shares that are redeemable are classified as liabilities at fair value on the balance sheets. The warrants are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense), net on the statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the preferred stock warrants. | |||||||||||||||||||||||||
During the three months ended September 30, 2014, two customers accounted for 79% of the Company’s revenue. | Income Taxes | |||||||||||||||||||||||||
During the three months ended September 30, 2013, one customer accounted for 100% of the Company’s revenue. | The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when management estimates, based on available objective evidence, that it is more-likely-than-not that the benefit will not be realized for the deferred tax assets. | |||||||||||||||||||||||||
Sales outside the U.S. accounted for 100% of the Company's revenue for all periods presented. | In September of 2013, the U.S. Department of the Treasury issued final regulations on the deduction and capitalization of expenditures related to tangible property for income tax purposes. These regulations apply to the Company’s fiscal year beginning on January 1, 2014. The Company is currently assessing the financial statement impact of these regulations, but does not expect that the new regulations will have a material impact on the effective rate. | |||||||||||||||||||||||||
Inventory | Revenue | |||||||||||||||||||||||||
Inventory is stated at the lower of cost or market, cost being determined on an actual cost basis on a first-in, first-out basis and market being determined as the lower of replacement cost or net realizable value. | The Company recognizes revenue from the sale of its product, the Viveve System ®, which has received the European CE (Conformité Européenne) approval. Revenue is recognized upon delivery, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. | |||||||||||||||||||||||||
Product Warranty | Revenue, continued | |||||||||||||||||||||||||
The Company’s products are generally subject to a one year warranty, which provides for the repair, rework or replacement of products (at its option) that fail to perform within stated specification. The Company has assessed the historical claims and, to date, product warranty claims have not been significant. The Company will continue to assess if there should be a warranty accrual. | The Company does not provide its customers with a contractual right of return. | |||||||||||||||||||||||||
Comprehensive Loss | Shipping and Handling Costs | |||||||||||||||||||||||||
Comprehensive loss represents the changes in equity of an enterprise, except those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and nine months ended September 31, 2014 and 2013, the Company’s comprehensive loss is the same as its net loss. There were no components of comprehensive loss for any of the periods presented. | The Company includes amounts billed for shipping and handling in revenues and shipping and handling costs in cost of revenue. | |||||||||||||||||||||||||
Net Loss per Share Attributable to Common Stockholders | Product Warranty | |||||||||||||||||||||||||
The Company’s basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, options and warrants to purchase common stock are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Potential common shares will always be anti-dilutive for periods in which the Company has reported a net loss. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders for the three and nine months ended September 30, 2014 and 2013. | The Company’s products are generally subject to a one year warranty, which provides for the repair, rework or replacement of products (at its option) that fail to perform within stated specification. The Company has assessed the historical claims and assumes that there is no outstanding products to be replaced that are subject to claims as of December 31, 2013. The Company will continue to assess if there should be a warranty accrual going forward. | |||||||||||||||||||||||||
For the three and nine months ended September 30, 2014 and 2013, the following weighted average common stock equivalent shares were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. | Advertising Costs | |||||||||||||||||||||||||
Three Months Ended | Nine Months Ended | Advertising costs are charged to general and administrative expenses as incurred. Advertising costs for the years ended December 31, 2012 and 2013 and, cumulatively, for the period from September 21, 2005 (date of inception) to December 31, 2013 were $264,834, $7,812, and $918,013, respectively. | ||||||||||||||||||||||||
September 30, | September 30, | |||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | Research and Development | ||||||||||||||||||||||
Stock options to purchase common stock | 476,671 | 409,488 | 445,804 | 491,609 | ||||||||||||||||||||||
Warrants to purchase convertible preferred stock | 72,322 | - | 24,107 | - | Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, prototype materials, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment depreciation, and utilities. | |||||||||||||||||||||
Stock-Based Compensation | ||||||||||||||||||||||||||
The Company accounts for stock-based employee compensation arrangements which requires the recognition of compensation expense, using a fair-value based method for costs related to all employee share-based payments, including stock options. The Company estimates the fair value of share-based payment awards on the date of grant using an option-pricing model. All option grants have been expensed on a straight-line basis over their vesting period. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest. | ||||||||||||||||||||||||||
Comprehensive Loss | ||||||||||||||||||||||||||
Comprehensive loss is the changes in equity of an enterprise, except those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended December 31, 2012 and 2013 and, cumulatively, for the period from September 21, 2005 (date of inception) to December 31 2013, the Company’s comprehensive loss is the same as its net loss. There were no components of comprehensive loss for any of the periods presented. | ||||||||||||||||||||||||||
Net Loss per Share Attributable to Common Stockholders | ||||||||||||||||||||||||||
The Company’s basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, options and warrants to purchase common stock are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Potential common shares will always be anti-dilutive for periods in which the Company has reported a net loss. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders for the years ended December 31, 2012 and 2013. | ||||||||||||||||||||||||||
For the years ended December 31, 2012 and 2013, the following common stock equivalent shares were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. | ||||||||||||||||||||||||||
Decemeber 31, | ||||||||||||||||||||||||||
2012 | 2013 | |||||||||||||||||||||||||
Convertible preferred stock | 462,331,603 | 462,331,603 | ||||||||||||||||||||||||
Stock options to purchase common stock | 44,788,104 | 45,146,118 | ||||||||||||||||||||||||
Warrants to purchase convertible preferred stock | 24,299,963 | 24,299,963 | ||||||||||||||||||||||||
Note_3_Fair_Value_Measurements
Note 3 - Fair Value Measurements | 9 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | ||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Text Block] | 3 | Fair Value Measurements | 3 | Fair Value Measurements | |||||||||||||||||||||||||||||||
The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value. | The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value. | ||||||||||||||||||||||||||||||||||
Level 1 | Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 investments generally does not require significant judgment, and the estimation is not difficult. | Level 1 | Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 investments generally does not require significant judgment, and the estimation is not difficult. | ||||||||||||||||||||||||||||||||
Level 2 | Pricing is provided by third party sources of market information obtained through investment advisors. The Company does not adjust for or apply any additional assumptions or estimates to the pricing information received from its advisors. | Level 2 | Pricing is provided by third party sources of market information obtained through investment advisors. The Company does not adjust for or apply any additional assumptions or estimates to the pricing information received from its advisors. | ||||||||||||||||||||||||||||||||
Level 3 | Inputs used to measure fair value are unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 instruments involves the most management judgment and subjectivity. | Level 3 | Inputs used to measure fair value are unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 instruments involves the most management judgment and subjectivity. | ||||||||||||||||||||||||||||||||
Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. | Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability. | ||||||||||||||||||||||||||||||||||
The Company’s Level 1 financial asset is a money market fund with a fair value that is based on quoted market prices. The money market fund is included in cash and cash equivalents on the Company’s condensed consolidated balance sheet. The Company’s Level 3 liability consists of convertible preferred stock warrant liabilities. The valuation of the warrant liabilities is discussed in Note 8. | The Company’s Level 1 financial asset is a money market fund with a fair value that is based on quoted market prices. The money market fund is included in cash and cash equivalents on the Company’s balance sheets. The Company’s Level 3 liability consists of convertible preferred stock warrant liabilities. The valuation of the warrant liabilities is discussed in Note 9. The following tables set forth the Company’s financial instruments that were measured at fair value on a recurring basis at December 31, 2012 and 2013 by level within the fair value hierarchy: | ||||||||||||||||||||||||||||||||||
For the period ended September 30, 2014, the Company did not have any transfers between Level 1, Level 2 and Level 3. | Assets and Liabilities at Fair Value as of December 31, 2012 | ||||||||||||||||||||||||||||||||||
Quoted prices in active markets for identical assets | Significant | Significant unobservable | |||||||||||||||||||||||||||||||||
The following tables set forth the Company’s financial instruments that were measured at fair value on a recurring basis as of September 30, 2014 and December 31, 2013 by level within the fair value hierarchy: | other observable inputs | inputs | |||||||||||||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||||||||||||||
Assets and Liabilities at Fair Value as of | Assets | ||||||||||||||||||||||||||||||||||
30-Sep-14 | Money market fund | $ | 503 | $ | - | $ | - | $ | 503 | ||||||||||||||||||||||||||
Quoted | Significant | Significant | Total assets | $ | 503 | $ | - | $ | - | $ | 503 | ||||||||||||||||||||||||
prices in | other | unobservable | Liabilities | ||||||||||||||||||||||||||||||||
active | observable | inputs | Preferred stock warrant liabilities | $ | - | $ | - | $ | 685,213 | $ | 685,213 | ||||||||||||||||||||||||
markets for | inputs | Total liabilities | $ | - | $ | - | $ | 685,213 | $ | 685,213 | |||||||||||||||||||||||||
identical | |||||||||||||||||||||||||||||||||||
assets | Assets and Liabilities at Fair Value as of December 31, 2013 | ||||||||||||||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | Quoted prices in active markets for identical assets | Significant | Significant unobservable | |||||||||||||||||||||||||||||
Assets | other observable inputs | inputs | |||||||||||||||||||||||||||||||||
Money market fund | $ | 190 | $ | - | $ | - | $ | 190 | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||
Total assets | $ | 190 | $ | - | $ | - | $ | 190 | Assets | ||||||||||||||||||||||||||
Liabilities | Money market fund | $ | 324 | $ | - | $ | - | $ | 324 | ||||||||||||||||||||||||||
Preferred stock warrant liabilities | $ | - | $ | - | $ | - | $ | - | Total assets | $ | 324 | $ | - | $ | - | $ | 324 | ||||||||||||||||||
Total liabilities | $ | - | $ | - | $ | - | $ | - | Liabilities | ||||||||||||||||||||||||||
Preferred stock warrant liabilities | $ | - | $ | - | $ | 623,672 | $ | 623,672 | |||||||||||||||||||||||||||
Assets and Liabilities at Fair Value as of | Total liabilities | $ | - | $ | - | $ | 623,672 | $ | 623,672 | ||||||||||||||||||||||||||
31-Dec-13 | |||||||||||||||||||||||||||||||||||
Quoted | Significant | Significant | The change in the fair value of the preferred stock warrant liabilities is summarized below: | ||||||||||||||||||||||||||||||||
prices in | other | unobservable | |||||||||||||||||||||||||||||||||
active | observable | inputs | Fair value as of December 31, 2011 | $ | 646,844 | ||||||||||||||||||||||||||||||
markets for | inputs | Fair value of warrants issued | 194,532 | ||||||||||||||||||||||||||||||||
identical | Change in fair value recorded in other income (expense), net | (156,163 | ) | ||||||||||||||||||||||||||||||||
assets | Fair value as of December 31, 2012 | 685,213 | |||||||||||||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | Fair value of warrants issued | - | ||||||||||||||||||||||||||||||
Assets | Change in fair value recorded in other income (expense), net | (61,541 | ) | ||||||||||||||||||||||||||||||||
Money market fund | $ | 324 | $ | - | $ | - | $ | 324 | Fair value as of December 31, 2013 | $ | 623,672 | ||||||||||||||||||||||||
Total assets | $ | 324 | $ | - | $ | - | $ | 324 | |||||||||||||||||||||||||||
Liabilities | All assets and liabilities have been valued using a market approach, except for Level 3. The following table describes the valuation techniques used to calculate fair value for Level 3 liabilities. For Level 3 liabilities, the Company determines the fair value measurement valuation policies and procedures. Annually, the Board of Directors assess and approve the fair value measurement policies and procedures. At least annually, the Company determines if the current valuation techniques used in the fair value measurements are still appropriate and evaluates and adjusts the unobservable inputs used in the fair value measurements based on current market conditions and third-party information. | ||||||||||||||||||||||||||||||||||
Preferred stock warrant liabilities | $ | - | $ | - | $ | 623,672 | $ | 623,672 | |||||||||||||||||||||||||||
Total liabilities | $ | - | $ | - | $ | 623,672 | $ | 623,672 | Fair Value as of | Range | |||||||||||||||||||||||||
31-Dec-12 | Valuation | Unobservable | (Weighted Average) | ||||||||||||||||||||||||||||||||
The change in the fair value of the preferred stock warrant liabilities is summarized below: | |||||||||||||||||||||||||||||||||||
Preferred stock warrant liabilities | $ | 685,213 | Black-Scholes option pricing model | Preferred series prices | $0.04 | - | 0.44 | (- | $0.06 | -) | |||||||||||||||||||||||||
Fair value as of December 31, 2013 | $ | 623,672 | Volatility | 74.20% | - | 91.60% | (- | 83% | -) | ||||||||||||||||||||||||||
Change in fair value recorded in other income (expense), net | (21,484 | ) | |||||||||||||||||||||||||||||||||
Fair value as of March 31, 2014 | 602,188 | Fair Value as of | Range | ||||||||||||||||||||||||||||||||
Change in fair value recorded in other income (expense), net | (22,001 | ) | 31-Dec-13 | Valuation | Unobservable | (Weighted Average) | |||||||||||||||||||||||||||||
Fair value as of June 30, 2014 | 580,187 | ||||||||||||||||||||||||||||||||||
Change in fair value recorded in other income (expense), net, as of September 23, 2014, date of the Merger Agreement | (7,277 | ) | Preferred stock warrant liabilities | $ | 623,672 | Black-Scholes option pricing model | Preferred series prices | $ | 0.04 | - | 0.44 | (- | $0.06 | -) | |||||||||||||||||||||
Extinguishment of warrant liabilities pursuant to the Merger Agreement (reclassified to equity) | (572,910 | ) | Volatility | 70.60% | - | 84.20% | (- | 76% | -) | ||||||||||||||||||||||||||
Fair value as of September 30, 2014 | $ | - | |||||||||||||||||||||||||||||||||
There were no changes in the valuation technique and related inputs from prior periods. | |||||||||||||||||||||||||||||||||||
All assets and liabilities carried at fair value have been valued using a market approach, except for Level 3. The following table describes the valuation techniques used to calculate fair value for Level 3 liabilities. For Level 3 liabilities, the Company determines the fair value measurement valuation policies and procedures. Annually, the Board of Directors assess and approve the fair value measurement policies and procedures. At least annually, the Company determines if the current valuation techniques used in the fair value measurements are still appropriate and evaluates and adjusts the unobservable inputs used in the fair value measurements based on current market conditions and third-party information. | |||||||||||||||||||||||||||||||||||
Fair Value as of | Valuation | Unobservable | Range | ||||||||||||||||||||||||||||||||
31-Dec-13 | Techniques | Input | (Weighted Average) | ||||||||||||||||||||||||||||||||
Preferred stock warrant liabilities | $ | 623,672 | Black-Scholes | Preferred series | |||||||||||||||||||||||||||||||
option pricing model | prices | $0.04 | - | $0.44 | (- | $0.06 | -) | ||||||||||||||||||||||||||||
Volatility | 70.62% | - | 84.23% | (- | 76% | -) | |||||||||||||||||||||||||||||
There were no changes in valuation technique from prior periods. |
Note_4_Accrued_Liabilities
Note 4 - Accrued Liabilities | 9 Months Ended | ||||||||
Sep. 30, 2014 | |||||||||
Payables and Accruals [Abstract] | |||||||||
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 4 | Accrued Liabilities | |||||||
Accrued liabilities consisted of the following as of September 30, 2014 and December 31, 2013: | |||||||||
September 30, | December 31, | ||||||||
2014 | 2013 | ||||||||
Accrued interest | $ | 13,792 | $ | 235,603 | |||||
Accrued professional fees | 125,671 | 15,000 | |||||||
Accrued loan balloon payment | 85,000 | 76,472 | |||||||
Accrued vacation | 73,809 | 81,499 | |||||||
Accrued loan restructuring fees | 47,500 | 27,288 | |||||||
Accrued severence pay | - | 58,846 | |||||||
Other accruals | 41,766 | 21,444 | |||||||
Total accrued liabilities | $ | 387,538 | $ | 516,152 | |||||
Note_5_Note_Payable
Note 5 - Note Payable | 9 Months Ended | 12 Months Ended | ||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||
Debt Disclosure [Abstract] | ||||||||||
Debt Disclosure [Text Block] | 5 | Note Payable | 5 | Note Payable | ||||||
In April 2012, the Company entered into a loan and security agreement for up to $2,135,159 in term loans that were used to pay off the existing loan with a financial institution. The full amount was drawn down in April 2012. In connection with the agreement, the Company issued a warrant to the lender to purchase a total of 73,770 shares of the Company’s Series A convertible preferred stock at $0.61 per share (Note 9). The borrowings were repayable in interest only payments until May 1, 2012 and then 30 equal installments of principal and interest at a rate of 9.5% per annum. An additional 4% of the principal or approximately $85,000 will be due as the final payment at the end of the loan term. The Company recorded $8,528 and $28,785 as additional interest expense during the nine months ended September 30, 2014 and 2013, respectively, related to the $85,000 payment. The Company will continue to accrue the balance of the $85,000 cash payment over the remaining term of the loan using the effective interest rate method. As of September 30, 2014 and December 31, 2013, $85,000 and $76,472 was recorded in accrued liabilities on the condensed consolidated balance sheets relating to this payment. All borrowings under the agreement are collateralized by substantially all of the Company’s assets, including intellectual property. As of September 30, 2014 and December 31, 2013, the note payable had an outstanding balance of $1,471,799 and $1,462,244, respectively. The term loan has a maturity date of October 1, 2014 and was repaid on that date as discussed in Note 13. | In December 2008, the Company entered into a loan and security agreement with a financial institution for $1,500,000. In connection with the agreement, the Company issued a warrant to the lender to purchase a total of 196,721 shares of the Company’s Series A convertible preferred stock at $0.61 per share (Note 9). The borrowings were repayable over 27 months at a rate of 8.5% per annum. An additional $75,000 was due as final payment at the end of the loan term. All borrowings under the agreement were collateralized by substantially all of the Company’s assets, excluding intellectual property. | |||||||||
In February 2013, the Company and lender amended the loan and security agreement to defer up to 3 months of principal payments contingent upon the receipt of bridge loan proceeds in increments of $500,000, up to $1,500,000 on or before April 30, 2013, beginning March 1, 2013. This amendment also included a $15,000 restructuring fee that would be due upon the maturity date of the loan. | The agreement contained a material adverse change clause, as defined in the agreement, which would result in an event of default if the bank deems a material adverse change to have occurred to the Company’s business. The Company was also required to comply with certain affirmative and negative covenants, including obtaining additional equity financing of at least $6,000,000 on or before March 31, 2009. The Company did not meet this covenant and subsequently obtained a forbearance agreement from the bank extending the equity financing requirement to July 31, 2009. In November 2010, the Company paid off the outstanding principal amount, interest accrued and final payment and paid a prepayment penalty. | |||||||||
In May 2013, the Company and lender amended the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more, on or before September 30, 2013. The principal payments were to be deferred and payable on August 1, 2013. This amendment also included a $10,000 restructuring fee that would be due upon the maturity date of the loan. | In November 2010, the Company entered into a loan and security agreement with a financial institution for $2,000,000. The borrowings were repayable over 36 months at a rate of 9.5% per annum. An additional $80,000 was due as final payment at the end of the loan term. In connection with the agreement, the Company issued a warrant to the lender to purchase a total of 163,934 shares of the Company’s Series A convertible preferred stock at $0.61 per share (Note 9). All borrowings under the agreement are collateralized by substantially all of the Company’s assets, excluding intellectual property. The Company used a portion of the proceeds received to repay, in full, amounts outstanding under the December 2008 loan agreement. As of December 31, 2012 and 2013, the note payable had an outstanding balance of $0. | |||||||||
In July 2013, the Company and lender agreed to further amend the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more, on or before August 28, 2013, and an additional month deferral provided a 2013 equity event was completed resulting in net cash proceeds of not less than $10 million from the sale of the Company’s equity securities consummated by September 27, 2013. Principal payments would be deferred and payable on October 1, 2013, provided both of these conditions were met. This amendment also included a $10,000 restructuring fee that would be due upon the maturity date of the loan. | In April 2012, the Company entered into a loan and security agreement for up to $2,135,159 in term loans. The full amount was drawn down in April 2012. In connection with the agreement, the Company issued a warrant to the lender to purchase a total of 73,770 shares of the Company’s Series A convertible preferred stock at $0.61 per share (Note 9). The borrowings were repayable in interest only payments until May 1, 2012 and then 30 equal installments of principal and interest at a rate of 9.5% per annum. An additional 4% of the principal or approximately $85,000 will be due as final payment at the end of the loan term. The Company recorded $41,127, $35,345 and $76,472 as additional interest expense during the years ended December 31, 2012 and 2013 and, cumulatively, for the period from September 21, 2005 (date of inception) to December 31, 2013, respectively, related to the $85,000 payment. The Company will continue to accrue the balance of the $85,000 cash payment over the remaining term of the loan using the effective interest rate method. The Company will continue to accrue the balance of the $85,000 cash payment over the remaining term of the loan using the effective interest rate method. As of December 31, 2012, $41,172 was recorded as accrued liabilities, noncurrent on the balance sheet relating to this payment. As of December 31, 2013, $76,472 was recorded as accrued liabilities on the balance sheet relating to this payment. The Company used the proceeds from these term loans to pay off an existing loan with the financial institution. All borrowings under the agreement are collateralized by substantially all of the Company’s assets, including intellectual property. As of December 31, 2012 and 2013, the note payable had an outstanding balance of $1,606,612 and $1,471,798, respectively. | |||||||||
In September 2013, the Company and lender agreed to further amend the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more on or before August 28, 2013 and another $500,000 or more on or before October 28, 2013. Principal payments would be deferred until December 1, 2013. This amendment also included a $10,000 restructuring fee that would be due upon the maturity date of the loan. | In February 2013, the Company and lender amended the loan and security agreement to defer up to 3 months of principal payments contingent upon the receipt of bridge loan proceeds in increments of $500,000, up to $1,500,000 on or before April 30, 2013, beginning March 1, 2013. This amendment also includes a $15,000 restructuring fee that will be due upon loan maturity currently scheduled for October 1, 2014. | |||||||||
In November 2013, the Company and lender agreed to further amend the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more on or before December 27, 2013 and upon the consummation of a 2014 equity event requiring the receipt of not less than $7 million in net cash proceeds by no later than January 24, 2014. Principal payments would be deferred until February 1, 2014. This amendment also included a $10,000 restructuring fee that would be due upon the maturity date of the loan. | In May 2013, the Company and lender amended the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more, on or before June 30, 2013. The principal payments was to be deferred and payable on August 1, 2013. This amendment also included a $10,000 restructuring fee that would be due upon loan maturity currently scheduled for October 1, 2014. | |||||||||
In January 2014, the Company and lender agreed to further amend the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more on or before February 25, 2014 and consummation of an equity event by April 25, 2014. This amendment included an additional $5,000 restructuring fee for each month principal payments are deferred beginning February 1, 2014 through April 1, 2014, provided restructuring fees in this amendment shall not exceed $15,000 in total that would also be due upon the maturity date of the loan. | In July 2013, the Company and lender agreed to further amend the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more, on or before August 28, 2013, and an additional month deferral provided a 2013 equity event was completed resulting in net cash proceeds of not less than $10 million from the sale of the Company’s equity securities consummated by September 27, 2013. Principal payments would be deferred and payable on October 1, 2013, provided both of these conditions were met. This amendment also included an additional restructuring fee of $10,000 that would be due upon loan maturity currently scheduled for October 1, 2014. | |||||||||
In February 2014, the Company and lender agreed to further amend the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more on or before April 25, 2014 and consummation of an equity event by June 27, 2014. This amendment included an additional $5,000 restructuring fee for each month principal payments are deferred beginning March 1, 2014 through June 1, 2014, provided restructuring fees in this amendment shall not exceed $20,000. This amendment also amended the January 2014 restructuring fee such that the January 2014 restructuring fee shall not exceed $5,000 in total that would also be due upon the maturity date of the loan. | In September 2013, the Company and lender agreed to further amend the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more on or before August 28, 2013 and another $500,000 or more on or before October 28, 2013. Principal payments would be deferred until December 1, 2013. This amendment also includes an additional $10,000 in restructuring fees that would be due upon maturity currently scheduled for October 1, 2014. | |||||||||
In June 2014, the Company and lender agreed to further amend the loan and security agreement such that the remaining 3 months of principal payments would be deferred until the maturity date of the term loan when all unpaid principal and interest will be immediately due. This amendment also includes an additional $5,000 restructuring fee for each month principal payments are deferred beginning July 1, 2014 through September 1, 2014, provided restructuring fees in this amendment do not exceed $15,000 in total that would also be due upon the maturity date of the loan. | In November 2013, the Company and lender agreed to further amend the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more on or before December 27, 2013 and upon the consummation of a 2014 equity event requiring the receipt of not less than $7 million in net cash proceeds by no later than January 24, 2014. Principal payments would be deferred until February 1, 2014. This amendment also includes an additional $10,000 in restructuring fees or $55,000 in total as of December 31, 2013 that will be due upon loan maturity currently scheduled for October 1, 2014. The Company recorded $27,288 as additional interest expense during the year ended December 31, 2013 related to the $55,000 restructuring payment. The Company will continue to accrue the balance of the $55,000 cash restructuring payment over the remaining term of the loan using the effective interest rate method. As of December 31, 2013, $27,288 was recorded as accrued liabilities on the balance sheets relating to this payment. | |||||||||
In September 2014, the lender agreed to reduce the total restructuring fees to $47,500. The Company recorded $20,212, net of the reduction in fees, and $45,000 as additional interest expense during the nine months ended September 30, 2014 and 2013, respectively, related to these restructuring fees. The Company has been accruing the balance of the cash restructuring payment over the term of the loan using the effective interest rate method. As of September 30, 2014 and December 31, 2013, $47,500 and $27,288 was recorded as an accrued liability on the condensed consolidated balance sheets relating to this restructuring payment. | The Agreement contains a material adverse change clause, as defined in the agreement, which would result in an event of default if the bank deems a material adverse change to have occurred to the Company’s business. The continuing liquidity issues the Company faces could be construed by note holder as a material adverse change which could trigger an acceleration of all of the outstanding debt. As such, the Company has classified all of its outstanding debt balance as a current liability as of December 31, 2013. | |||||||||
The loan and security agreement contains a material adverse change clause, as defined in the agreement, which would result in an event of default if the lender deems a material adverse change to have occurred to the Company’s business. The continuing liquidity issues the Company faces could be construed by the note holder as a material adverse change which could trigger an acceleration of all of the outstanding debt. As such, the Company has classified all of its outstanding debt balance as a current liability as of September 30, 2014 and December 31, 2013. | As of December 31, 2013, future minimum payments under the note payable are as follows: | |||||||||
As of September 30, 2014, future minimum payments under the note payable are as follows: | Year ending December 31, 2014 | $ | 1,597,196 | |||||||
Year Ending December 31, 2014 | $ | 1,618,091 | Less: Amount representing interest | (125,398 | ) | |||||
1,618,091 | Present value of obligations | 1,471,798 | ||||||||
Less: Amount representing interest | (146,292 | ) | Less: Unamortized debt discount | (8,554 | ) | |||||
Present value of obligations | 1,471,799 | 1,463,244 | ||||||||
Less: Unamortized debt discount | - | Less: Notes payable, current portion | 1,463,244 | |||||||
1,471,799 | Notes payable, noncurrent portion | $ | - | |||||||
Less: Notes payable, current portion | 1,471,799 | |||||||||
Notes payable, noncurrent portion | $ | - | ||||||||
On September 30, 2014, the Company entered into a Loan and Security Agreement pursuant to which we received a term loan in the amount of $5 million, which will be funded in three tranches. The first tranche of $2.5 million was provided to the Company on October 1, 2014. The proceeds from the first tranche were used to repay the existing loan (including interest and restructuring fees) with a financial institution which totaled $1,630,925. Before the second and third tranches of the term loan will be funded, we must meet certain enrollment milestones and achieve certain positive results relating to our OUS Clinical Trials, among other things. In connection with the loan agreement, the Company issued a 10-year warrant to the lender for the purchase of 471,698 shares of the Company’s common stock at $0.53 per share (Note 8). |
Note_6_Related_Party_Convertib
Note 6 - Related Party Convertible Bridge Notes (Related Party Convertible Bridge Notes [Member]) | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2014 | Dec. 31, 2013 | |||
Related Party Convertible Bridge Notes [Member] | ||||
Note 6 - Related Party Convertible Bridge Notes [Line Items] | ||||
Long-term Debt [Text Block] | 6 | Related Party Convertible Bridge Notes | 6 | Related Party Convertible Bridge Notes |
In November 2012, the Company issued $1,000,000 in convertible promissory notes to related parties. The notes accrue interest at 8% per annum and mature at the earlier of i) the date upon which the majority note holders demand repayment after May 15, 2013 or ii) the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000. As of September 30, 2014 and December 31, 2013, the outstanding principal balance was $0 and $1,000,000. Because the holders had the ability to demand repayment after May 15, 2013, the Company classified all of the outstanding debt balance and related accrued interest of $88,986 as a current liability as of December 31, 2013. In connection with the Merger, these convertible promissory notes were extinguished. | In May 2011 (“May 2011 note”), the Company issued a convertible promissory note in the amount of $1,000,000. The note bears an interest rate of 8% per annum. The May 2011 note was amended in June 2011 and September 2011 to issue another $1,000,000 on each amendment date, for an aggregate of $3,000,000. In conjunction with the notes, the Company issued a warrant to the investor to purchase Series B convertible preferred stock with a warrant coverage amount equal to 10% and 20% of the principal amount of the notes for the initial and subsequent closings, respectively. In April 2012, the principal and accrued interest of $3,188,494 on these notes were converted to 63,769,863 shares of Series B convertible preferred stock at a conversion price of $0.05 per share. | |||
On February 13, 2013, the Company entered into a note purchase agreement (“2013 Note Purchase Agreement”) with related parties to which it was authorized to issue and sell convertible promissory notes up to $1,500,000 in the aggregate, of which $1,000,000 was issued. These notes were intended as bridge financing to a planned alternative public offering in the second quarter of 2013. The notes accrue interest at 8% per annum and mature at the earlier of the date upon which the majority note holders demand repayment after August 13, 2013 or the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000 excluding the conversion of these notes and the November 2012 notes. The notes convert into the number of shares equal to the principal and unpaid accrued interest divided by the conversion price, which is defined as 80% of the purchase price in the qualified financing. If the Company does not execute a qualified financing, the holders may elect conversion of the notes prior to the maturity date of August 13, 2013. Under the elective conversion, the notes convert into the number of the next equity financing shares or shares of Series B convertible preferred stock that are equal to the principal and the unpaid accrued interest divided by the conversion price. The conversion price is defined as 80% of the price paid by the investors in the next equity financing series or $0.05, if the notes are converted into the Series B convertible preferred stock. In April 2013, the Company completed another closing of the 2013 Note Purchase Agreement for $500,000. On June 3, 2013, the Company entered into an amendment to the 2013 Note Purchase Agreement to increase the total amount of the convertible promissory notes up to $2,000,000 in the aggregate if issued before June 30, 2013. In June 2013, the Company completed another closing of the 2013 Note Purchase Agreement for $500,000. On August 7, 2013, the Company entered into an amendment to the 2013 Note Purchase Agreement to increase the total amount of the convertible promissory notes up to $2,500,000 in the aggregate if issued before August 28, 2013. In August 2013, the Company completed another closing of the 2013 Note Purchase Agreement for $500,000. As of September 30, 2014 and December 31, 2013, the outstanding principal balance was $0 and $2,500,000. Because the holders had the ability to demand repayment after August 13, 2013, the Company classified all of the outstanding debt balance and related accrued interest of $130,466 as a current liability as of December 31, 2013. In connection with the Merger, these convertible promissory notes were extinguished. | In November 2011 (“November 2011 note”), the Company issued a convertible promissory note for $250,000 in two closings during November 2011 and December 2011 for an aggregate of $500,000. The note bears an interest rate of 8%. In conjunction with the notes, the Company issued a warrant to investors to purchase Series B convertible preferred stock with a warrant coverage amount equal to 20% of the principal amount of the notes for each of the closings, respectively. | |||
On September 27, 2013, the Company entered into a note purchase agreement (“September 2013 Note Purchase Agreement”) with related parties to which it was authorized to issue and sell convertible promissory notes up to $500,000 in the aggregate. These notes were intended as bridge financing to a planned APO in the third quarter of 2013. The notes accrue interest at 8% per annum and mature at the earlier of the date upon which the majority note holders demand repayment after March 31, 2014 or the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000 excluding the conversion of these notes, the November 2012 notes and the 2013 Note Purchase Agreement. The notes convert into the number of shares equal to the principal and unpaid accrued interest divided by the conversion price, which is defined as 70% of the purchase price in the qualified financing. If the Company does not execute a qualified financing, the holders may elect conversion of the notes prior to the maturity date of March 31, 2014. Under the elective conversion, the notes convert into the number of the next equity financing shares or shares of Series B convertible preferred stock that are equal to the principal and the unpaid accrued interest divided by the conversion price. The conversion price is defined as 70% of the price paid by the investors in the next equity financing series or $0.05, if the notes are converted into the Series B convertible preferred stock. As of September 30, 2014 and December 31, 2013, the outstanding principal balance was $0 and $500,000. Because the holders had the ability to demand repayment after March 31, 2014, the Company classified all of the outstanding debt balance and related accrued interest of $10,411 as a current liability as of December 31, 2013. In connection with the Merger, these convertible promissory notes were extinguished. | In January 2012 and March 2012, the Company amended the November 2011 notes to provide the sale and issuance of up to $500,000 of convertible promissory notes and warrants under the same terms as the original agreement. In three separate closings during January 2012, February 2012 and April 2012, convertible promissory notes totaling $1,000,000 were issued. In conjunction with the notes, the Company issued a warrant to investors to purchase Series B convertible preferred stock with a warrant coverage amount equal to 20% of the principal amount of the notes for each of the closings, respectively. The aggregate principal amount of the November 2011 notes including the January and March amendments was $1,500,000, prior to the conversion. In April, 2012, the principal and accrued interest of $1,521,474 on these notes were converted to 30,429,485 shares of Series B convertible preferred stock at a conversion price of $0.05 per share. | |||
On November 12, 2013, the Company entered into a note purchase agreement (“November 2013 Note Purchase Agreement”) with related parties to which it was authorized to issue and sell convertible promissory notes up to $500,000 in the aggregate. These notes were intended as bridge financing to a planned APO in the fourth quarter of 2013. The notes accrue interest at 8% per annum and mature at the earlier of the date upon which the majority note holders demand repayment after March 31, 2014 or the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000 excluding the conversion of these notes, the November 2012 notes and the 2013 Note Purchase Agreement. The notes convert into the number of shares equal to the principal and unpaid accrued interest divided by the conversion price, which is defined as 70% of the purchase price in the qualified financing. If the Company does not execute a qualified financing, the holders may elect conversion of the notes prior to the maturity date of March 31, 2014. Under the elective conversion, the notes convert into the number of the next equity financing shares or shares of Series B convertible preferred stock that are equal to the principal and the unpaid accrued interest divided by the conversion price. The conversion price is defined as 70% of the price paid by the investors in the next equity financing series or $0.05, if the notes are converted into the Series B convertible preferred stock. As of September 30, 2014 and December 31, 2013, the outstanding principal balance was $0 and $500,000. Because the holders had the ability to demand repayment after March 31, 2014, the Company classified all of the outstanding debt balance and related accrued interest of $5,370 as a current liability as of December 31, 2013. In connection with the Merger, these convertible promissory notes were extinguished. | In April 2012, June 2012 and July 2012, the Company issued an aggregate of 171,199,348 shares of Series B convertible preferred stock at a purchase price of $0.05 per share, which included 94,199,348 shares being issued upon the conversion of principal and accrued interest of $4,709,968 on the May 2011 notes and November 2011 notes. | |||
On December 27, 2013, the Company entered into a note purchase agreement (“December 2013 Note Purchase Agreement”) with related parties to which it was authorized to issue and sell convertible promissory notes up to $375,000 in the aggregate. These notes were intended as bridge financing to a planned APO in the first quarter of 2014. The notes accrue interest at 9% per annum and mature at the earlier of the date upon which the majority note holders demand repayment after March 31, 2014 or the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000 excluding the conversion of these notes, the November 2012 notes and the 2013 Note Purchase Agreement. The notes convert into the number of shares equal to the principal and unpaid accrued interest divided by the conversion price, which is defined as 70% of the purchase price in the qualified financing. If the Company does not execute a qualified financing, the holders may elect conversion of the notes prior to the maturity date of March 31, 2014. Under the elective conversion, the notes convert into the number of the next equity financing shares or shares of Series B convertible preferred stock that are equal to the principal and the unpaid accrued interest divided by the conversion price. The conversion price is defined as 70% of the price paid by the investors in the next equity financing series or $0.05, if the notes are converted into the Series B convertible preferred stock. As of September 30, 2014 and December 31, 2013, the outstanding principal balance was $0 and $375,000. Because the holders had the ability to demand repayment after March 31, 2014, the Company classified all of the outstanding debt balance and related accrued interest of $370 as a current liability as of December 31, 2013. In connection with the Merger, these convertible promissory notes were extinguished. | In November 2012, the Company issued $1,000,000 in convertible promissory notes to related parties. The notes accrue interest at 8% per annum and mature at the earlier of the date upon which the majority note holders demand repayment after May 15, 2013 or the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000. As of December 31, 2012 and 2013, the outstanding principal balance was $1,000,000. Because the holders have the ability to demand repayment after May 15, 2013, the Company has classified all of the outstanding debt balance and related accrued interest of $8,987 and $88,986 as a current liability as of December 31, 2012 and 2013, respectively. | |||
On March 5, 2014, the Company entered into a note purchase agreement in which it was authorized to issue and sell up to $1,250,000 in aggregate principal amount of convertible promissory notes of which $200,000 was issued. In May 2014, the Company completed another sale of convertible promissory notes in the aggregate principal amount of $1,050,000. The notes accrued interest at 9% per annum and converted into common stock in connection with the private placement. | On February 13, 2013, the Company entered into a note purchase agreement (“2013 Note Purchase Agreement”) with related parties to which it was authorized to issue and sell convertible promissory notes up to $1,500,000 in the aggregate, of which $1,000,000 was issued. These notes were intended as bridge financing to a planned alternative public offering (“APO”) in the second quarter of 2013. The notes accrue interest at 8% per annum and mature at the earlier of the date upon which the majority note holders demand repayment after August 13, 2013 or the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000 excluding the conversion of these notes and the November 2012 notes. The notes convert into the number of shares equal to the principal and unpaid accrued interest divided by the conversion price, which is defined as 80% of the purchase price in the qualified financing. If the Company does not execute a qualified financing, the holders may elect conversion of the notes prior to the maturity date of August 13, 2013. Under the elective conversion, the notes convert into the number of the next equity financing shares or shares of Series B convertible preferred stock that are equal to the principal and the unpaid accrued interest divided by the conversion price. The conversion price is defined as 80% of the price paid by the investors in the next equity financing series or $0.05, if the notes are converted into the Series B convertible preferred stock. In April 2013, the Company completed another closing of the 2013 Note Purchase Agreement for $500,000. On June 3, 2013, the Company entered into an amendment to the 2013 Note Purchase Agreement to increase the total amount of the convertible promissory notes up to $2,000,000 in the aggregate if issued before June 30, 2013. In June 2013, the Company completed another closing of the 2013 Note Purchase Agreement for $500,000. On August 7, 2013, the Company entered into an amendment to the 2013 Note Purchase Agreement to increase the total amount of the convertible promissory notes up to $2,500,000 in the aggregate if issued before August 28, 2013. In August 2013, the Company completed another closing of the 2013 Note Purchase Agreement for $500,000. As of December 31, 2013, the outstanding principal balance was $2,500,000. Because the holders have the ability to demand repayment after August 13, 2013, the Company has classified all of the outstanding debt balance and related accrued interest of $130,466 as a current liability as of December 31, 2013. | |||
On July 7, 2014, the Company entered into a note purchase agreement in which it was authorized to issue convertible promissory notes up to $250,000 in the aggregate. The notes accrue interest at 9% per annum and converted into common stock in connection with the private placement. | On September 27, 2013, the Company entered into a note purchase agreement (“September 2013 Note Purchase Agreement”) with related parties to which it was authorized to issue and sell convertible promissory notes up to $500,000 in the aggregate. These notes were intended as bridge financing to a planned alternative public offering (“APO”) in the third quarter of 2013. The notes accrue interest at 8% per annum and mature at the earlier of the date upon which the majority note holders demand repayment after March 31, 2014 or the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000 excluding the conversion of these notes, the November 2012 notes and the 2013 Note Purchase Agreement. The notes convert into the number of shares equal to the principal and unpaid accrued interest divided by the conversion price, which is defined as 70% of the purchase price in the qualified financing. If the Company does not execute a qualified financing, the holders may elect conversion of the notes prior to the maturity date of March 31, 2014. Under the elective conversion, the notes convert into the number of the next equity financing shares or shares of Series B convertible preferred stock that are equal to the principal and the unpaid accrued interest divided by the conversion price. The conversion price is defined as 70% of the price paid by the investors in the next equity financing series or $0.05, if the notes are converted into the Series B convertible preferred stock. As of December 31, 2013, the outstanding principal balance was $500,000. Because the holders have the ability to demand repayment after March 31, 2014, the Company has classified all of the outstanding debt balance and related accrued interest of $10,411 as a current liability as of December 31, 2013. | |||
Pursuant to the Company’s amendment to the note purchase agreement dated November 20, 2012, effective February 13, 2013, the above notes payable would be redeemable upon a change of control of the Company at an amount equal to 300% of the outstanding principal amount and accrued and unpaid interest on the notes as of the time of a change of control. A change of control will occur in the event the Company enters into a transaction where the holders of the voting securities no longer own a majority of the total outstanding voting securities once the transaction is completed or a disposition of substantially all assets occurs. The sale of stock for capital raising purposes or an alternative public offering involving a reverse merger into a public shell company for capital raising purposes is excluded from the Company’s definition of a change of control. The Company has determined that the value of this provision is not material and as such did not record a liability on the Company’s condensed consolidated financial statements as of December 31, 2013. All of these notes were extinguished as part of the Merger Agreement. | On November 12, 2013, the Company entered into a note purchase agreement (“November 2013 Note Purchase Agreement”) with related parties to which it was authorized to issue and sell convertible promissory notes up to $500,000 in the aggregate. These notes were intended as bridge financing to a planned alternative public offering (“APO”) in the forth quarter of 2013. The notes accrue interest at 8% per annum and mature at the earlier of the date upon which the majority note holders demand repayment after March 31, 2014 or the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000 excluding the conversion of these notes, the November 2012 notes and the 2013 Note Purchase Agreement. The notes convert into the number of shares equal to the principal and unpaid accrued interest divided by the conversion price, which is defined as 70% of the purchase price in the qualified financing. If the Company does not execute a qualified financing, the holders may elect conversion of the notes prior to the maturity date of March 31, 2014. Under the elective conversion, the notes convert into the number of the next equity financing shares or shares of Series B convertible preferred stock that are equal to the principal and the unpaid accrued interest divided by the conversion price. The conversion price is defined as 70% of the price paid by the investors in the next equity financing series or $0.05, if the notes are converted into the Series B convertible preferred stock. As of December 31, 2013, the outstanding principal balance was $500,000. Because the holders have the ability to demand repayment after March 31, 2014, the Company has classified all of the outstanding debt balance and related accrued interest of $5,370 as a current liability as of December 31, 2013. | |||
On December 27, 2013, the Company entered into a note purchase agreement (“December 2013 Note Purchase Agreement”) with related parties to which it was authorized to issue and sell convertible promissory notes up to $375,000 in the aggregate. These notes were intended as bridge financing to a planned alternative public offering (“APO”) in the first quarter of 2014. The notes accrue interest at 9% per annum and mature at the earlier of the date upon which the majority note holders demand repayment after March 31, 2014 or the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000 excluding the conversion of these notes, the November 2012 notes and the 2013 Note Purchase Agreement. The notes convert into the number of shares equal to the principal and unpaid accrued interest divided by the conversion price, which is defined as 70% of the purchase price in the qualified financing. If the Company does not execute a qualified financing, the holders may elect conversion of the notes prior to the maturity date of March 31, 2014. Under the elective conversion, the notes convert into the number of the next equity financing shares or shares of Series B convertible preferred stock that are equal to the principal and the unpaid accrued interest divided by the conversion price. The conversion price is defined as 70% of the price paid by the investors in the next equity financing series or $0.05, if the notes are converted into the Series B convertible preferred stock. As of December 31, 2013, the outstanding principal balance was $375,000. Because the holders have the ability to demand repayment after March 31, 2014, the Company has classified all of the outstanding debt balance and related accrued interest of $370 as a current liability as of December 31, 2013. | ||||
Pursuant to the Company’s amendment to the note purchase agreement dated November 20, 2012, effective February 13, 2013, the above notes payable would be redeemable upon a change of control of the Company at an amount equal to 300% of the outstanding principal amount and accrued and unpaid interest on the notes as of the time of a change of control. A change of control will occur in the event the Company enters into a transaction where the holders of the voting securities no longer own a majority of the total outstanding voting securities once the transaction is completed or a disposition of substantially all assets occurs. The sale of stock for capital raising purposes or an alternative public offering involving a reverse merger into a public shell company for capital raising purposes is excluded from the Company’s definition of a change of control. The Company has determined that the value of this provision is not material and as such has not recorded a liability on the Company’s financial statements as of December 31, 2012 and 2013. |
Note_7_Commitments_and_Conting
Note 7 - Commitments and Contingencies | 9 Months Ended | 12 Months Ended | ||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||
Commitments and Contingencies Disclosure [Abstract] | ||||||||||
Commitments and Contingencies Disclosure [Text Block] | 7 | Commitments and Contingencies | 7 | Commitments and Contingencies | ||||||
Operating Lease | Operating Lease | |||||||||
In January 2012, the Company relocated and entered into a lease agreement for a new facility. The new lease commenced in March 2012 and will terminate in February 2015. Rent expense for the nine months ended September 30, 2014 and 2013 was $128,359 and $128,359, respectively. | In January 2012, the Company relocated and entered into a lease agreement for a new facility. The new lease commenced in March 2012 and will terminate in February 2015. Rent expense for the years ended December 31, 2012 and 2013 and, cumulatively, for the period from September 21, 2005 (date of inception) to December 31, 2013 was $166,398, $173,896, and $744,602, respectively. | |||||||||
As of September 30, 2014, future minimum payments under the lease are as follows: | At December 31, 2013, future minimum payments under the lease are as follows: | |||||||||
Year Ending December 31, | Year Ending December 31, | |||||||||
2014 | $ | 46,428 | 2014 | $ | 184,002 | |||||
2015 | 30,952 | 2015 | 30,952 | |||||||
Total minimum lease payments | $ | 77,380 | $ | 214,954 | ||||||
Indemnification Agreements | Indemnification Agreements | |||||||||
The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not breached the agreement and/or the loss is not attributable to the indemnified party’s negligence or willful malfeasance. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal. | The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not breached the agreement and/or the loss is not attributable to the indemnified party’s negligence or willful malfeasance. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal. | |||||||||
Contingencies | Contingencies | |||||||||
From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. | From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. |
Note_8_Common_Stock
Note 8 - Common Stock | 9 Months Ended | 12 Months Ended | |||||
Sep. 30, 2014 | Dec. 31, 2013 | ||||||
Stockholders' Equity Note [Abstract] | |||||||
Stockholders' Equity Note Disclosure [Text Block] | 8 | Common Stock | 8 | Common Stock | |||
In connection with the Merger, all shares of Viveve Series A convertible preferred stock and Series B convertible preferred stock were converted to common stock and the Company exchanged shares of common stock with the former stockholders of Viveve. The total common shares issued for these transactions was 3,743,282 shares based on the exchange ratio of 0.0080497. | In April 2012, the Company amended and restated its Certificate of Incorporation to increase the number of authorized common stock to 612,000,000 shares. The common stockholders, voting as a separate class, are entitled to elect one member of the Company’s Board of Directors. The preferred stockholders also have rights to elect two members of the Board of Directors. Pursuant to these rights, both classes of stock will vote together as one class to elect all remaining directors. The holders of common stock are also entitled to receive dividends whenever funds are legally available, as, when, and if declared by the Board of Directors. As of December 31, 2013, no dividends have been declared to date. Additionally, shares of common stock were issued under restricted stock purchase agreements. These shares are subject to a right of repurchase by the Company, which typically lapses over a four year period. In June 2009, the Company repurchased 565,833 shares of common stock. As of December 31, 2012 and 2013, the Company had 194,441 and 666 shares of common stock, respectively, subject to repurchase. | ||||||
In connection with the proposed Merger, on May 9, 2014, Viveve issued to GBS Venture Partners Limited (“GBS”), a convertible debenture holder, a warrant to purchase shares of our common stock equal to approximately 5% of the outstanding shares of common stock on a post-Merger basis in consideration for the cancellation of convertible promissory notes in the aggregate principal amount of $1,750,000 and accrued interest of approximately $211,000 held by GBS. As part of the closing of the Merger, the Company issued 943,596 shares of common stock to GBS upon the automatic exercise of the warrant. | As of December 31, 2013, the Company had reserved common stock for future issuance as follows: | ||||||
Concurrent with the Merger, the Company completed a separate private placement of 11,305,567 shares of our common stock, together with warrants for the purchase of 940,189 shares of common stock, for gross proceeds of approximately $6,000,000, which included the conversion of $1,545,678 of convertible promissory notes and related accrued interest. The price per unit was $0.53. | Conversion of Series A convertible preferred stock | 291,132,255 | |||||
Conversion of Series B convertible preferred stock | 171,199,348 | ||||||
Warrants for Common Stock | Exercise of options under stock plan | 45,146,118 | |||||
Issuance of options under stock plan | 36,449,336 | ||||||
In connection with the private placement, the Company issued warrants to purchase a total of 940,189 shares of common stock at an exercise price of $0.53 per share. The warrants have a contractual life of five years and are exercisable immediately in whole or in part, on or before five years from the issuance date. | Exercise and conversion of convertible preferred stock warrants | 24,299,963 | |||||
568,227,020 | |||||||
In connection with the Loan and Security Agreement entered into on September 30, 2014, the Company issued a warrant to purchase a total of 471,698 shares of common stock at an exercise price of $0.53 per share. The warrant has a contractual life of ten years and is exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrant on the date of issuance to be $622,170 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 77%, risk free interest rate of 2.5% and a contractual life of ten years. The warrant will expire on September 30, 2024. The fair value of the warrant was recorded as a deferred financing cost in other assets and will be amortized to interest expense over the loan term. | |||||||
As of Septemeber 30, 2014, all of these warrants remain outstanding. |
Note_9_Convertible_Preferred_S
Note 9 - Convertible Preferred Stock | 9 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | ||||||||||||||||||||||||||||||||||
Disclosure Text Block Supplement [Abstract] | |||||||||||||||||||||||||||||||||||
Preferred Stock [Text Block] | 9 | Convertible Preferred Stock | 9 | Convertible Preferred Stock | |||||||||||||||||||||||||||||||
As part of the Merger Agreement, all shares of the Series A convertible preferred stock and Series B convertible preferred stock converted to common stock, pursuant to the conversion rights. | In April 2012, the Company amended and restated its Certificate of Incorporation to decrease the number of authorized Series A convertible preferred stock (“Series A”) to 24,543,626 and create a new series of preferred stock, to be designated Series B convertible preferred stock (“Series B”), consisting of 227,000,000 authorized shares. | ||||||||||||||||||||||||||||||||||
The holders of preferred stock had various rights and preferences as follows: | The holders of preferred stock have various rights and preferences as follows: | ||||||||||||||||||||||||||||||||||
Dividends | Dividends | ||||||||||||||||||||||||||||||||||
The preferred stockholders were entitled to receive, when and as declared by the Board of Directors, out of funds legally available, cash dividends in the amount of $0.0488 and $0.004, respectively, per share, per year for each share of Series A and Series B outstanding in preference and priority to any declaration or payment of any distribution on common stock in such calendar year. These dividends are noncumulative. No distributions could be made to common stock unless all declared dividends on preferred stock have been paid or set aside for payment. No dividends have been declared to date. | The preferred stockholders are entitled to receive, when and as declared by the Board of Directors, out of funds legally available, cash dividends in the amount of $0.0488 and $0.004, respectively, per share, per year for each share of Series A and Series B outstanding in preference and priority to any declaration or payment of any distribution on common stock in such calendar year. These dividends are noncumulative. No distributions shall be made to common stock unless all declared dividends on preferred stock have been paid or set aside for payment. No dividends have been declared to date. | ||||||||||||||||||||||||||||||||||
Liquidation | Liquidation | ||||||||||||||||||||||||||||||||||
Upon liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the holders of the Series A and Series B were entitled to receive an amount per share equal to the original issuance price for the preferred stock (as adjusted for any stock dividends, stock splits or recapitalization and similar events), plus all declared and unpaid dividends thereon to the date fixed for such distribution. If upon the liquidation event, there were insufficient funds to permit the payment to stockholders of the full preferential amounts, then the entire assets and funds of the Company would be distributed ratably among the holders of preferred stock. | Upon liquidation, dissolution or winding up of the Corporation, either voluntary or involuntary, the holders of the Series A and Series B are entitled to receive an amount per share equal to the original issuance price for the preferred stock (as adjusted for any stock dividends, stock splits or recapitalization and similar events), plus all declared and unpaid dividends thereon to the date fixed for such distribution. If upon the liquidation event, there are insufficient funds to permit the payment to stockholders of the full preferential amounts, then the entire assets and funds of the Company will be distributed ratably among the holders of preferred stock. | ||||||||||||||||||||||||||||||||||
Conversion | Conversion | ||||||||||||||||||||||||||||||||||
At the option of the holder thereof, each share of preferred stock was convertible, at the option of the holder at any time after the date of issuance into fully paid and non-assessable shares of common stock as determined by dividing the applicable original issue price for such series by the conversion price for such series. The conversion price was $0.05 for Series A and Series B. | At the option of the holder thereof, each share of preferred stock shall be convertible, at the option of the holder at any time after the date of issuance into fully paid and non-assessable shares of common stock as determined by dividing the applicable original issue price for such series by the conversion price for such series. The conversion price is $0.05 for Series A and Series B. | ||||||||||||||||||||||||||||||||||
Each share of preferred stock was to automatically be converted into shares of common stock at their respective conversion price immediately upon the earlier of (A) immediately prior to the closing of a firm commitment underwritten initial public offering pursuant to a registration statement under the Securities Act of 1933 covering the offering and sale of the Company’s common stock provided the aggregate gross proceeds to the Company and/or selling stockholders was not less than $30,000,000 prior to underwriters’ commissions and expenses, or (B) upon receipt of a written request for conversion from the holders of a majority of the voting power of the outstanding shares of preferred stock. | Each share of preferred stock shall automatically be converted into shares of common stock at their respective conversion price immediately upon the earlier of (A) immediately prior to the closing of a firm commitment underwritten initial public offering pursuant to a registration statement under the Securities Act of 1933 covering the offering and sale of the Company’s common stock provided the aggregate gross proceeds to the Company and/or selling stockholders are not less than $30,000,000 prior to underwriters’ commissions and expenses, or (B) upon receipt of a written request for conversion from the holders of a majority of the voting power of the outstanding shares of preferred stock. | ||||||||||||||||||||||||||||||||||
Voting | Voting | ||||||||||||||||||||||||||||||||||
Each holder of preferred stock was entitled to the number of votes equal to the number of shares of common stock into which such holder’s shares of preferred stock could be converted as of the record date. The holders of shares of the preferred stock were entitled to vote on all matters on which the common stock was entitled to vote. The holders of preferred stock, voting as a separate class, were entitled to elect two members of the Board of Directors. The holders of common stock, voting as a separate class, were entitled to elect one member of the Board of Directors. Any additional members of the Board of Directors were to be elected by the holders of common stock and preferred stock, voting together as a single class. | Each holder of preferred stock shall be entitled to the number of votes equal to the number of shares of common stock into which such holder’s shares of preferred stock could be converted as of the record date. The holders of shares of the preferred stock shall be entitled to vote on all matters on which the common stock shall be entitled to vote. The holders of preferred stock, voting as a separate class, shall be entitled to elect two members of the Board of Directors. The holders of common stock, voting as a separate class, shall be entitled to elect one member of the Board of Directors. Any additional members of the Board of Directors shall be elected by the holders of common stock and preferred stock, voting together as a single class. | ||||||||||||||||||||||||||||||||||
Warrants for Convertible Preferred Stock | Warrants for Convertible Preferred Stock | ||||||||||||||||||||||||||||||||||
In connection with the loan and security agreement entered into in December 2008, the Company issued a warrant to purchase a total of 196,721 shares of Series A at an exercise price of $0.61 per share. The warrant had a contractual life of ten years and was exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrant on the date of issuance to be $53,863 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 79%, risk free interest rate of 2.7% and a contractual life of ten years. The warrant was to expire on December 2, 2018. The fair value of the warrant was recorded as a debt issuance cost in other assets and was amortized to interest expense over the draw down term of the loan. The entire amount of the warrant was amortized to interest expense in the year ended December 31, 2008. The fair value of the warrant was re-measured as of the date of the Merger, September 23, 2014, and September 30, 2013 and $9,639 and $(2,361) were recorded to other income (expense), net, respectively, for the nine months ended September 30, 2014 and 2013. The warrants were extinguished in connection with the Merger. | In connection with the issuance of Series A in August 2007, the investors acquired the rights to purchase additional shares of Series A at $0.61 per share. Such rights lapsed upon the achievement of certain milestones which occurred in April 2009. The Company calculated the fair value of these rights to be $357,829 using the Black-Scholes option pricing model with the following assumptions: dividend yield of 0%, expected volatility of 46%, risk free interest rate of 3.9% and a contractual life of 1.4 years. This amount was revalued as of December 31, 2007 and 2008 and $23,143 and $266,293 was recorded to other income (expense), net, respectively. The warrant was revalued upon the achievement of the milestones and $68,393 was recorded to other income (expense), net, during the year ended December 31, 2009. | ||||||||||||||||||||||||||||||||||
In connection with the Series A offering in 2009, the Company issued warrants to purchase 245,900 shares of Series A for $0.61 per share in April 2009. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the fair value of the warrants on the date of issuance to be $70,082 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 79%, risk free interest rate of 2.8% and a contractual life of ten years. The warrants were to expire on April 2, 2019. The fair value of the warrants was recorded as an equity issuance cost. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and September 30, 2013 and $11,803 and $(984) were recorded to other income (expense), net, respectively, for the nine months ended September 30, 2014 and 2013. The warrants were extinguished in connection with the Merger. | In connection with the loan and security agreement entered into in December 2008, the Company issued a warrant to purchase a total of 196,721 shares of Series A at an exercise price of $0.61 per share. The warrant has a contractual life of ten years and is exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrant on the date of issuance to be $53,863 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 79%, risk free interest rate of 2.7% and a contractual life of ten years. The warrant expires on December 2, 2018. The fair value of the warrant was recorded as a debt issuance cost in other assets and was amortized to interest expense over the draw down term of the loan. The entire amount of the warrant was amortized to interest expense in the year ended December 31, 2008. The fair value of the warrant was re-measured as of December 31, 2012 and 2013 and ($4,131) and $6,885 were recorded to other income (expense), net, respectively, and $9,797 was recorded for the cumulative period from September 21, 2005 (date of inception) to December 31, 2013. | ||||||||||||||||||||||||||||||||||
In connection with the loan and security agreement entered into in November 2010, the Company issued a warrant to purchase a total of 163,934 shares of Series A at an exercise price of $0.61 per share. The warrant had a contractual life of ten years and was exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrant on the date of issuance to be $46,721 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 79%, risk free interest rate of 2.9% and a contractual life of ten years. The warrant was to expire on November 19, 2020. The fair value of the warrant was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrant was re-measured as of the date of the Merger, September 23, 2014, and September 30, 2013 and $2,295 and $(1,311) were recorded to other income (expense), net, respectively, for the nine months ended September 30, 2014 and 2013. The warrants were extinguished in connection with the Merger. | In connection with the Series A offering in 2009, the Company issued warrants to purchase 245,900 shares of Series A for $0.61 per share in April 2009. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the fair value of the warrants on the date of issuance to be $70,082 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 79%, risk free interest rate of 2.8% and a contractual life of ten years. The warrants expire on April 2, 2019. The fair value of the warrants was recorded as an equity issuance cost. The fair value of the warrants was re-measured as of December 31, 2012 and 2013 and ($5,900) and $8,607 were recorded to other income (expense), net, respectively, and $11,804 was recorded for the cumulative period from September 21, 2005 (date of inception) to December 31, 2013. | ||||||||||||||||||||||||||||||||||
In connection with the loan and security agreement entered into in April 2012, the Company issued a warrant to purchase a total of 73,770 shares of Series A at an exercise price of $0.61 per share. The warrant had a contractual life of ten years and was exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrant on the date of issuance to be $27,443 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 92%, risk free interest rate of 1.98% and a contractual life of ten years. The warrant was to expire on April 19, 2022. The fair value of the warrant was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrant was re-measured as of the date of the Merger, September 23, 2014, and September 30, 2013 and $3,025 and $885 was recorded to other income (expense), net, respectively, for the nine months ended September 30, 2014 and 2013. The warrants were extinguished in connection with the Merger. | In connection with the loan and security agreement entered into in November 2010, the Company issued a warrant to purchase a total of 163,934 shares of Series A at an exercise price of $0.61 per share. The warrant has a contractual life of ten years and is exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrant on the date of issuance to be $46,721 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 79%, risk free interest rate of 2.9% and a contractual life of ten years. The warrant expires on November 19, 2020. The fair value of the warrant was recorded as a debt discount and will be amortized to interest expense over the life of the loan. The fair value of the warrant was re-measured as of December 31, 2012 and 2013 and ($6,485) and $2,131 were recorded to other income (expense), net, respectively, and $328 was recorded for the cumulative period from September 21, 2005 (date of inception) to December 31, 2013. | ||||||||||||||||||||||||||||||||||
In May 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 2,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $84,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 3.2% and a contractual life of ten years. The warrants were to expire on May 9, 2021. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and September 30, 2013 and $2,000 and $2,000 were recorded to other income (expense), net, respectively, for the nine months ended September 30, 2014 and 2013. The warrants were extinguished in connection with the Merger. | In connection with the loan and security agreement entered into in April 2012, the Company issued a warrant to purchase a total of 73,770 shares of Series A at an exercise price of $0.61 per share. The warrant has a contractual life of ten years and is exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrant on the date of issuance to be $27,443 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 92%, risk free interest rate of 1.98% and a contractual life of ten years. The warrant expires on April 19, 2022. The fair value of the warrant was recorded as a debt discount and will be amortized to interest expense over the life of the loan. The fair value of the warrant was re-measured as of December 31, 2012 and 2013 and $591 and $1,918 was recorded to other income (expense), net, respectively, and $2,509 was recorded for the cumulative period from September 21, 2005 (date of inception) to December 31, 2013. | ||||||||||||||||||||||||||||||||||
In June 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 4,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $168,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 3.2% and a contractual life of ten years. The warrants were to expire on June 30, 2021. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and September 30, 2013 and $4,000 and $4,000 were recorded to other income (expense), net, respectively, for the nine months ended September 30, 2014 and 2013. The warrants were extinguished in connection with the Merger. | In May 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 2,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $84,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 3.2% and a contractual life of ten years. The warrants expire on May 9, 2021. The fair value of the warrants was recorded as a debt discount and will be amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of December 31, 2012 and 2013 and $23,000 and $6,000 were recorded to other income (expense), net, respectively, and $30,000 was recorded for the cumulative period from September 21, 2005 (date of inception) to December 31, 2013. | ||||||||||||||||||||||||||||||||||
In September 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 4,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $168,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 2.0% and a contractual life of ten years. The warrants were to expire on September 9, 2021. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and September 30, 2013 and $0 and $4,000 was recorded to other income (expense), net, respectively, for the nine months ended September 30, 2014 and 2013. The warrants were extinguished in connection with the Merger. | In June 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 4,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $168,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 3.2% and a contractual life of ten years. The warrants expire on June 30, 2021. The fair value of the warrants was recorded as a debt discount and will be amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of December 31, 2012 and 2013 and $46,000 and $12,000 were recorded to other income (expense), net, respectively, and $60,000 was recorded for the cumulative period from September 21, 2005 (date of inception) to December 31, 2013. | ||||||||||||||||||||||||||||||||||
In November 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 1,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $42,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 2.1% and a contractual life of ten years. The warrants were to expire on November 30, 2021. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and September 30, 2013 and $1,000 and $1,000 were recorded to other income (expense), net, respectively, for the nine months ended September 30, 2014 and 2013. The warrants were extinguished in connection with the Merger. | In September 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 4,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $168,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 2.0% and a contractual life of ten years. The warrants expire on September 9, 2021. The fair value of the warrants was recorded as a debt discount and will be amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of December 31, 2012 and 2013 and $46,000 and $12,000 was recorded to other income (expense), net, respectively, and $60,000 was recorded for the cumulative period from September 21, 2005 (date of inception) to December 31, 2013. | ||||||||||||||||||||||||||||||||||
In December 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 1,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $41,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 1.8% and a contractual life of ten years. The warrants were to expire on December 19, 2021. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and September 30, 2013 and $1,000 and $0 were recorded to other income (expense), net, respectively, for the nine months ended September 30, 2014 and 2013. The warrants were extinguished in connection with the Merger. | In November 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 1,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $42,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 2.1% and a contractual life of ten years. The warrants expire on November 30, 2021. The fair value of the warrants was recorded as a debt discount and will be amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of December 31, 2012 and 2013 and $11,000 and $2,000 were recorded to other income (expense), net, respectively, and $14,000 was recorded for the cumulative period from September 21, 2005 (date of inception) to December 31, 2013. | ||||||||||||||||||||||||||||||||||
In January 2012, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 910,445 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $37,328 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 1.8% and a contractual life of ten years. The warrants were to expire on January 31, 2022. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and September 30, 2013 and $3,642 and $910 were recorded to other income (expense), net, respectively, for the nine months ended September 30, 2014 and 2013. The warrants were extinguished in connection with the Merger. | In December 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 1,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $41,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 1.8% and a contractual life of ten years. The warrants expire on December 19, 2021. The fair value of the warrants was recorded as a debt discount and will be amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of December 31, 2012 and 2013 and $11,000 and $2,000 were recorded to other income (expense), net, respectively, and $13,000 was recorded for the cumulative period from September 21, 2005 (date of inception) to December 31, 2013. | ||||||||||||||||||||||||||||||||||
In February 2012, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 738,535 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $31,018 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 1.98% and a contractual life of ten years. The warrants were to expire on February 27, 2022. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and September 30, 2013 and $2,954 and $740 were recorded to other income (expense), net, respectively, for the nine months ended September 30 2014 and 2013. The warrants were extinguished in connection with the Merger. | In January 2012, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 910,445 shares of Series B at an exercise price of $0.05 per share. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $37,328 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 1.8% and a contractual life of ten years. The warrants expire on January 1, 2022. The fair value of the warrants was recorded as a debt discount and will be amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of December 31, 2012 and 2013 and $7,283 and $1,821 was recorded to other income (expense), net, respectively, and $9,104 was recorded for the cumulative period from September 21, 2005 (date of inception) to December 31, 2013. | ||||||||||||||||||||||||||||||||||
In April 2012, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 2,351,019 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $98,743 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 2.0% and a contractual life of ten years. The warrants were to expire on April 16, 2022. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and September 30, 2013 and $9,404 and $2,351 were recorded to other income (expense), net, respectively, for the nine months ended September 30, 2014 and 2013. The warrants were extinguished in connection with the Merger. | In February 2012, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 738,535 shares of Series B at an exercise price of $0.05 per share. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $31,018 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 1.98% and a contractual life of ten years. The warrants expire on February 27, 2022. The fair value of the warrants was recorded as a debt discount and will be amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of December 31, 2012 and 2013 and $6,646 and $1,477 was recorded to other income (expense), net, respectively, and $8,123 was recorded for the cumulative period from September 21, 2005 (date of inception) to December 31, 2013. | ||||||||||||||||||||||||||||||||||
Convertible preferred stock warrants outstanding as of December 31, 2013 were as follows: | In April 2012, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 2,351,019 shares of Series B at an exercise price of $0.05 per share. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $98,743 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 2.0% and a contractual life of ten years. The warrants expire on April 16, 2022. The fair value of the warrants was recorded as a debt discount and will be amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of December 31, 2012 and 2013 and $21,159 and $4,702 was recorded to other income (expense), net, respectively, and $25,861 was recorded for the cumulative period from September 21, 2005 (date of inception) to December 31, 2013. | ||||||||||||||||||||||||||||||||||
Number of | Convertible preferred stock warrants outstanding as of December 31, 2012 were as follows: | ||||||||||||||||||||||||||||||||||
Shares | |||||||||||||||||||||||||||||||||||
Series | Outstanding | Fair Value | Series | Number of | Fair Value as of | ||||||||||||||||||||||||||||||
Exercisable | Expiration | Exercise | Under | December 31, | Exercisable | Expiration | Exercise | Warrants | December 31, | ||||||||||||||||||||||||||
Issuance Date | for | Date | Price | Warrants | 2013 | Issuance Date | for | Date | Price | Outstanding | 2012 | ||||||||||||||||||||||||
Dec-08 | Series A | 2-Dec-18 | $ | 0.61 | 196,721 | $ | 44,066 | Dec-08 | Series A | 2-Dec-18 | $ | 0.61 | 196,721 | $ | 50,951 | ||||||||||||||||||||
Apr-09 | Series A | 2-Apr-19 | 0.61 | 245,900 | 58,278 | Apr-09 | Series A | 2-Apr-19 | 0.61 | 245,900 | 66,885 | ||||||||||||||||||||||||
Nov-10 | Series A | 19-Nov-20 | 0.61 | 163,934 | 46,393 | Nov-10 | Series A | 19-Nov-20 | 0.61 | 163,934 | 48,524 | ||||||||||||||||||||||||
May-11 | Series B | 6-May-21 | 0.05 | 2,000,000 | 54,000 | May-11 | Series B | 6-May-21 | 0.05 | 2,000,000 | 60,000 | ||||||||||||||||||||||||
Jun-11 | Series B | 30-Jun-21 | 0.05 | 4,000,000 | 108,000 | Jun-11 | Series B | 30-Jun-21 | 0.05 | 4,000,000 | 120,000 | ||||||||||||||||||||||||
Sep-11 | Series B | 9-Sep-21 | 0.05 | 4,000,000 | 108,000 | Sep-11 | Series B | 9-Sep-21 | 0.05 | 4,000,000 | 120,000 | ||||||||||||||||||||||||
Nov-11 | Series B | 30-Nov-21 | 0.05 | 1,000,000 | 28,000 | Nov-11 | Series B | 30-Nov-21 | 0.05 | 1,000,000 | 30,000 | ||||||||||||||||||||||||
Dec-11 | Series B | 19-Dec-21 | 0.05 | 1,000,000 | 28,000 | Dec-11 | Series B | 19-Dec-21 | 0.05 | 1,000,000 | 30,000 | ||||||||||||||||||||||||
Jan-12 | Series B | 31-Jan-22 | 0.05 | 910,445 | 28,224 | Jan-12 | Series B | 31-Jan-22 | 0.05 | 910,445 | 30,045 | ||||||||||||||||||||||||
Feb-12 | Series B | 28-Feb-22 | 0.05 | 738,535 | 22,895 | Feb-12 | Series B | 28-Feb-22 | 0.05 | 738,535 | 24,372 | ||||||||||||||||||||||||
Apr-12 | Series B | 16-Apr-22 | 0.05 | 2,351,019 | 72,882 | Apr-12 | Series B | 16-Apr-22 | 0.05 | 2,351,019 | 77,584 | ||||||||||||||||||||||||
Apr-12 | Series A | 19-Apr-22 | 0.61 | 73,770 | 24,934 | Apr-12 | Series A | 19-Apr-22 | 0.61 | 73,770 | 26,852 | ||||||||||||||||||||||||
16,680,324 | $ | 623,672 | 16,680,324 | $ | 685,213 | ||||||||||||||||||||||||||||||
Convertible preferred stock warrants outstanding as of December 31, 2013 were as follows: | |||||||||||||||||||||||||||||||||||
Series | Number of | Fair Value as of | |||||||||||||||||||||||||||||||||
Exercisable | Expiration | Exercise | Warrants | December 31, | |||||||||||||||||||||||||||||||
Issuance Date | for | Date | Price | Outstanding | 2013 | ||||||||||||||||||||||||||||||
Dec-08 | Series A | 2-Dec-18 | $ | 0.61 | 196,721 | $ | 44,066 | ||||||||||||||||||||||||||||
Apr-09 | Series A | 2-Apr-19 | 0.61 | 245,900 | 58,278 | ||||||||||||||||||||||||||||||
Nov-10 | Series A | 19-Nov-20 | 0.61 | 163,934 | 46,393 | ||||||||||||||||||||||||||||||
May-11 | Series B | 6-May-21 | 0.05 | 2,000,000 | 54,000 | ||||||||||||||||||||||||||||||
Jun-11 | Series B | 30-Jun-21 | 0.05 | 4,000,000 | 108,000 | ||||||||||||||||||||||||||||||
Sep-11 | Series B | 9-Sep-21 | 0.05 | 4,000,000 | 108,000 | ||||||||||||||||||||||||||||||
Nov-11 | Series B | 30-Nov-21 | 0.05 | 1,000,000 | 28,000 | ||||||||||||||||||||||||||||||
Dec-11 | Series B | 19-Dec-21 | 0.05 | 1,000,000 | 28,000 | ||||||||||||||||||||||||||||||
Jan-12 | Series B | 31-Jan-22 | 0.05 | 910,445 | 28,224 | ||||||||||||||||||||||||||||||
Feb-12 | Series B | 28-Feb-22 | 0.05 | 738,535 | 22,895 | ||||||||||||||||||||||||||||||
Apr-12 | Series B | 16-Apr-22 | 0.05 | 2,351,019 | 72,882 | ||||||||||||||||||||||||||||||
Apr-12 | Series A | 19-Apr-22 | 0.61 | 73,770 | 24,934 | ||||||||||||||||||||||||||||||
16,680,324 | $ | 623,672 | |||||||||||||||||||||||||||||||||
Note_10_Summary_of_Stock_Optio
Note 10 - Summary of Stock Options | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | 10 | Summary of Stock Options | 10 | Stock Option Plan | ||||||||||||||||||||||||||||||||||||||||||||
Stock Option Plans | In February 2006, the Company adopted the 2006 Stock Option Plan (the “Plan”) under which the Board of Directors may issue incentive and nonqualified stock options to employees, directors, and consultants. The Board of Directors has the authority to determine to whom options will be granted, the number of options, the term and the exercise price. If an individual owns stock representing more than 10% of the outstanding shares, the price of each option shall be at least 110% of the fair market value, as determined by the Board of Directors. The exercise price of an incentive stock option and a nonqualified stock option shall not be less than 100% and 85%, respectively, of the fair market value of the common stock on the date of grant. All options granted have a term of ten years, other than options granted to individuals holding more than 10% of the total outstanding shares which have a term of five years. Options granted generally vest over four years. | |||||||||||||||||||||||||||||||||||||||||||||||
The Company has issued equity awards in the form of stock options from three employee benefit plans. The plans include the PLC 2005 Stock Incentive Plan (the “2005 Plan”), the Viveve Amended and Restated 2006 Stock Plan (the “2006 Plan”) and the PLC 2013 Stock Option and Incentive Plan (the “2013 Plan”). | Activity under the Plan is as follows: | |||||||||||||||||||||||||||||||||||||||||||||||
The 2005 Plan was adopted by PLC's Board of Directors and approved by its stockholders. 22,095 shares of common stock remain reserved for issuance under the 2005 Plan. The Company does not intend to grant further awards from the 2005 Plan, however, it will continue to administer the 2005 Plan until all outstanding awards are exercised, expire, terminate or are forfeited. There are currently outstanding stock option awards issued from the 2005 Plan covering a total of 22,095 shares of the Company’s common stock. The weighted average exercise price of the outstanding stock options is $12.83 per share and the weighted average remaining contractual term is 8.80 years. | Outstanding Options | |||||||||||||||||||||||||||||||||||||||||||||||
Weighted | ||||||||||||||||||||||||||||||||||||||||||||||||
The 2006 Plan was adopted by the Board of Directors of Viveve and was terminated in conjunction with the Merger. Outstanding stock option awards have been assumed by the Company and will continue to be administered in accordance with the terms of the 2006 Plan until such awards are exercised, expire, terminate or are forfeited. There are currently outstanding stock option awards issued from the 2006 Plan covering a total of 324,820 shares of the Company’s common stock and no shares available for future awards. The weighted average exercise price of the outstanding stock options is $1.55 per share and the weighted average remaining contractual term is 8.06 years. Additionally, prior to the Merger, the Board of Directors voted to accelerate the vesting of all unvested options that were outstanding as of the date of the Merger such that all options would be immediately vested and exercisable by the holders. Furthermore, at the Merger, outstanding options to purchase shares of Viveve, Inc. common stock issued from the 2006 Plan were converted into options to purchase shares of the Company’s Common Stock (rounded down to the nearest whole share). The number of shares of the Company’s common stock into which the 2006 Plan options were converted was determined by multiplying the number of shares covered by each 2006 Plan option by the exchange ratio of 0.0080497. The exercise price of each 2006 Plan option was determined by dividing the exercise price of each 2006 Plan option immediately prior to the Merger by the exchange ratio of 0.0080497 (rounded up to the nearest cent). | Shares | Weighted | Average | |||||||||||||||||||||||||||||||||||||||||||||
Available | Number | Average | Remaining | |||||||||||||||||||||||||||||||||||||||||||||
The 2013 Plan was also adopted by PLC's Board of Directors and approved by its stockholders. The 2013 Plan is administered by the Compensation Committee of the Company’s Board of Directors (the “Administrator”). Under the 2013 Plan, the Company may grant to eligible participants awards of equity which may take the form of stock options (both incentive stock options and non-qualified stock options), stock appreciation rights, restricted, deferred or unrestricted stock awards, performance based awards or dividend equivalent rights. Awards may be granted to officers, employees, non-employee Directors (as defined in the 2013 Plan) and other key persons (including consultants and prospective employees). The term of any stock option award may not exceed 10 years and may be subject to vesting conditions, as determined by the Administrator. Options granted generally vest over four years. Incentive stock options may be granted only to employees of the Company or any subsidiary that is a “subsidiary corporation” within the meaning of Section 424(f) of the Internal Revenue Code. The exercise price of any stock option award cannot be less than the fair market value of the Company’s common stock, provided, however, that an incentive stock option granted to an employee who owns more than 10% of the Company’s outstanding voting power must have an exercise price of no less than 110% of the fair market value of the Company’s common stock and a term that does not exceed five years. There are currently outstanding stock option awards issued from the 2013 Plan covering a total of 1,947,619 shares of the Company’s common stock and there remain reserved for future awards 839,148 shares of the Company’s common stock. The weighted average exercise price of the outstanding stock options is $0.80 per share. Concurrent with the Merger, the stockholders approved an amendment to the 2013 Plan to increase the number of shares reserved under the 2013 Plan from 113,826 to 3,111,587. | for | of | Exercise | Contractual | ||||||||||||||||||||||||||||||||||||||||||||
Grant | Shares | Price | Term (years) | |||||||||||||||||||||||||||||||||||||||||||||
Activity under the 2005 Plan, the 2006 Plan and the 2013 Plan is as follows: | ||||||||||||||||||||||||||||||||||||||||||||||||
Shares reserved at plan inception | 1,000,000 | - | $ | - | ||||||||||||||||||||||||||||||||||||||||||||
Outstanding Options | Options granted | (51,500 | ) | 51,500 | 0.001 | |||||||||||||||||||||||||||||||||||||||||||
Weighted | Balances as of December 31, 2006 | 948,500 | 51,500 | 0.001 | 9.96 | |||||||||||||||||||||||||||||||||||||||||||
Weighted | Average | Additional shares reserved | 2,000,000 | - | - | |||||||||||||||||||||||||||||||||||||||||||
Number | Average | Remaining | Options granted | (867,000 | ) | 867,000 | 0.06 | |||||||||||||||||||||||||||||||||||||||||
of | Exercise | Contractual | Options forfeited | 5,000 | (5,000 | ) | 0.001 | |||||||||||||||||||||||||||||||||||||||||
Shares | Price | Term (years) | Balances as of December 31, 2007 | 2,086,500 | 913,500 | 0.06 | 9.82 | |||||||||||||||||||||||||||||||||||||||||
Options granted | (72,500 | ) | 72,500 | 0.06 | ||||||||||||||||||||||||||||||||||||||||||||
Options outstanding as of December 31, 2013 | 363,413 | $ | 2.94 | 8.8 | Balances as of December 31, 2008 | 2,014,000 | 986,000 | 0.06 | 8.87 | |||||||||||||||||||||||||||||||||||||||
Options granted | 1,901,476 | $ | 0.6 | Options granted | (1,892,029 | ) | 1,892,029 | 0.06 | ||||||||||||||||||||||||||||||||||||||||
Options assumed from PLC | 68,238 | $ | 10.24 | Options exercised | - | (322,395 | ) | 0.06 | ||||||||||||||||||||||||||||||||||||||||
Options canceled | (38,593 | ) | $ | 1.75 | Options forfeited | 377,605 | (377,605 | ) | 0.06 | |||||||||||||||||||||||||||||||||||||||
Options outstanding as of September 30, 2014 | 2,294,534 | $ | 1.02 | 9.67 | Balances as of December 31, 2009 | 499,576 | 2,178,029 | 0.06 | 9 | |||||||||||||||||||||||||||||||||||||||
Additional shares reserved | 461,957 | - | - | |||||||||||||||||||||||||||||||||||||||||||||
As of September 30, 2014, the Company had 839,148 shares available for grant. | Options granted | (771,412 | ) | 771,412 | 0.05 | |||||||||||||||||||||||||||||||||||||||||||
Options exercised | - | (173,455 | ) | 0.001 | ||||||||||||||||||||||||||||||||||||||||||||
The options outstanding and exercisable as of September 30, 2014 are as follows: | Options forfeited | 12,500 | (12,500 | ) | 0.06 | |||||||||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2010 | 202,621 | 2,763,486 | 0.06 | 8.4 | ||||||||||||||||||||||||||||||||||||||||||||
Options Outstanding | Options Exercisable | Additional shares reserved | 500,000 | - | - | |||||||||||||||||||||||||||||||||||||||||||
Weighted | Options granted | (345,000 | ) | 345,000 | 0.12 | |||||||||||||||||||||||||||||||||||||||||||
Number | Weighted | Average | Number | Weighted | Options exercised | - | (9,000 | ) | 0.001 | |||||||||||||||||||||||||||||||||||||||
Outstanding | Average | Remaining | Exercisable | Average | Options forfeited | 139,000 | (139,000 | ) | 0.06 | |||||||||||||||||||||||||||||||||||||||
Range of | as of | Exercise | Contractual | as of | Exercise | Repurchase of restricted stock options | 5,250 | - | ||||||||||||||||||||||||||||||||||||||||
Exercise Prices | 30-Sep-14 | Price | Term (Years) | September 30, 2014 | Price | Balances as of December 31, 2011 | 501,871 | 2,960,486 | 0.07 | 7.7 | ||||||||||||||||||||||||||||||||||||||
Additional shares reserved | 80,000,000 | - | - | |||||||||||||||||||||||||||||||||||||||||||||
$0.12 | 320 | $ | 0.12 | 2.21 | 320 | $ | 0.12 | Options granted | (43,694,521 | ) | 43,694,521 | 0.01 | ||||||||||||||||||||||||||||||||||||
$0.60 | 1,901,476 | $ | 0.6 | 10 | 20,000 | $ | 0.6 | Options exercised | - | (1,866,903 | ) | 0.07 | ||||||||||||||||||||||||||||||||||||
$1.24 | 314,036 | $ | 1.24 | 8.15 | 314,036 | $ | 1.24 | Balances as of December 31, 2012 | 36,807,350 | 44,788,104 | 0.01 | 9.74 | ||||||||||||||||||||||||||||||||||||
$7.00 | - | $9.00 | 59,372 | $ | 8.63 | 8.28 | 59,372 | $ | 8.63 | Options granted | (11,873,890 | ) | 11,873,890 | 0.01 | ||||||||||||||||||||||||||||||||||
$12.00 | - | $18.63 | 19,081 | $ | 15.29 | 6.79 | 19,081 | $ | 15.29 | Options cancelled | 11,515,876 | (11,515,876 | ) | 0.01 | ||||||||||||||||||||||||||||||||||
$37.00 | 250 | $ | 37 | 3.72 | 250 | $ | 37 | Balances as of December 31, 2013 | 36,449,336 | 45,146,118 | $ | 0.01 | 8.8 | |||||||||||||||||||||||||||||||||||
2,294,535 | $ | 1.02 | 9.67 | 413,059 | $ | 2.94 | ||||||||||||||||||||||||||||||||||||||||||
Options vested and expected to vest as of December 31, 2013 | 43,338,910 | $ | 0.01 | 8.8 | ||||||||||||||||||||||||||||||||||||||||||||
Stock-Based Compensation | Options vested as of December 31, 2013 | 15,025,985 | $ | 0.02 | 8.6 | |||||||||||||||||||||||||||||||||||||||||||
During the three and nine months ended September 30, 2014, the Company granted stock options to employees to purchase 1,901,476 shares of common stock with a weighted average grant date fair value of $0.32 per share. Stock-based compensation expense recognized during the three months ended September 30, 2014 and 2013 was $113,345 and $16,284 respectively. Stock-based compensation expense recognized during the nine months ended September 30, 2014 and 2013 was $143,643 and $66,001, respectively. As of September 30, 2014, the total unrecognized compensation cost in connection with unvested stock options was approximately $567,000. These costs are expected to be recognized over a period of approximately 3.26 years. The aggregate intrinsic value of options outstanding as of September 30, 2014 was approximately $1.7 million. There were no options exercised during the nine months ended September 30, 2014 and 2013. | The options outstanding and exercisable as of December 31, 2013 are as follows: | |||||||||||||||||||||||||||||||||||||||||||||||
The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following assumptions: | Options Outstanding | Options Vested | ||||||||||||||||||||||||||||||||||||||||||||||
Weighted | ||||||||||||||||||||||||||||||||||||||||||||||||
Nine Months Ended | Average | Weighted | ||||||||||||||||||||||||||||||||||||||||||||||
September 30, | Remaining | Average | ||||||||||||||||||||||||||||||||||||||||||||||
2014 | 2013 | Exercise | Number | Contractual | Number | Exercise | ||||||||||||||||||||||||||||||||||||||||||
Price | Outstanding | Life (Years) | of Options | Price | ||||||||||||||||||||||||||||||||||||||||||||
Expected term (in years) | 5 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||
Average volatility | 61% | 67% | $ | 0.001 | 40,000 | 2.95 | 40,000 | $ | 0.001 | |||||||||||||||||||||||||||||||||||||||
Risk-free interest rate | 1.80% | 0.87% | 0.06 | 980,250 | 5.68 | 921,104 | 0.06 | |||||||||||||||||||||||||||||||||||||||||
Dividend yield | 0% | 0% | 0.15 | 514,833 | 7.94 | 447,055 | 0.15 | |||||||||||||||||||||||||||||||||||||||||
0.01 | 43,611,035 | 8.89 | 13,617,826 | 0.01 | ||||||||||||||||||||||||||||||||||||||||||||
Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No dividend yield is included as the Company has not issued any dividends and does not anticipate issuing any dividends in the future. | 45,146,118 | 8.8 | 15,025,985 | $ | 0.02 | |||||||||||||||||||||||||||||||||||||||||||
The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three and nine months ended September 30, 2014 and 2013: | Stock-Based Compensation Associated with Awards to Employees | |||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended | Nine Months Ended | During the years ended December 31, 2012 and 2013, the Company granted stock options to employees to purchase 38,996,262 and 11,788,890 shares of common stock with a weighted average grant date fair value of $0.03262 and $0.00559 per share, respectively. Stock-based compensation expense recognized during the years ended December 31, 2012 and 2013 and, cumulatively, for the period from September 21, 2005 (date of inception) to December 31, 2013, includes compensation expense for stock-based awards granted to employees of $102,511, $94,021 and $282,032 respectively. As of December 31, 2013, there was total unrecognized compensation costs of $129,937 related to these stock options. These costs are expected to be recognized over a period of approximately 1.74 years. The total fair value of employee options vested during the years ended December 31, 2012 and 2013 was $54,199 and $139,914, respectively. The aggregate intrinsic value of options outstanding and exercisable as of December 31, 2012 and 2013 was $2,322 and $322, respectively. The aggregate intrinsic value of options exercised during the years ended December 31, 2012 and 2013 was $0. | ||||||||||||||||||||||||||||||||||||||||||||||
September 30, | September 30, | |||||||||||||||||||||||||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following assumptions: | ||||||||||||||||||||||||||||||||||||||||||||
Research and development | $ | 101 | $ | 976 | $ | 667 | $ | (7,016 | ) | Cumulative for the Period | ||||||||||||||||||||||||||||||||||||||
General and administrative | 113,245 | 15,308 | 142,976 | 73,017 | 21-Sep-05 | |||||||||||||||||||||||||||||||||||||||||||
Total | $ | 113,346 | $ | 16,284 | $ | 143,643 | $ | 66,001 | (Date of Inception) to | |||||||||||||||||||||||||||||||||||||||
2012 | 2013 | 31-Dec-13 | ||||||||||||||||||||||||||||||||||||||||||||||
Expected term (in years) | 5 | 5 | 5.00 - 6.25 | |||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 68 | % | 67 | % | 60% - 79 | % | ||||||||||||||||||||||||||||||||||||||||||
Risk-free interest rate | 0.76% - 0.84 | % | 0.84 | % | 0.76% - 4.7 | % | ||||||||||||||||||||||||||||||||||||||||||
Dividend yield | 0 | % | 0 | % | 0 | % | ||||||||||||||||||||||||||||||||||||||||||
Expected Term | ||||||||||||||||||||||||||||||||||||||||||||||||
The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding. The Company derived the expected term based on expected terms for similar entities, referred to as “guideline” companies, as the Company did not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. In evaluating similarity, the Company considered factors such as industry, stage of life cycle and size. | ||||||||||||||||||||||||||||||||||||||||||||||||
Volatility | ||||||||||||||||||||||||||||||||||||||||||||||||
Since the Company is a private entity with no historical data regarding the volatility of its common stock, the expected volatility used is based on volatility of similar entities, referred to as “guideline” companies. In evaluating similarity, the Company considered factors such as industry, stage of life cycle and size. | ||||||||||||||||||||||||||||||||||||||||||||||||
Risk-Free Interest Rate | ||||||||||||||||||||||||||||||||||||||||||||||||
The risk-free rate is based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options. | ||||||||||||||||||||||||||||||||||||||||||||||||
Dividend Yield | ||||||||||||||||||||||||||||||||||||||||||||||||
The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future and, therefore, used an expected dividend yield of zero in the valuation model. | ||||||||||||||||||||||||||||||||||||||||||||||||
Forfeitures | ||||||||||||||||||||||||||||||||||||||||||||||||
The Company estimates forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. All stock-based payment awards are amortized on a straight-line basis over the requisite service periods of the awards, which are generally the vesting periods. If the Company’s actual forfeiture rate is materially different from its estimate, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period. | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock-Based Compensation for Nonemployees | ||||||||||||||||||||||||||||||||||||||||||||||||
During the years ended December 31, 2012 and 2013, the Company granted options to purchase 4,698,259 and 85,000 shares of common stock to nonemployees, respectively. Stock-based compensation expense related to stock options granted to nonemployees is recognized as the stock options are earned. The Company believes that the fair value of the stock options is more reliably measurable than the fair value of the services received. The stock-based compensation expense will fluctuate as the estimated fair value of the common stock fluctuates. During the years ended December 31, 2012 and 2013 and, cumulatively, for the period from September 21, 2005 (date of inception) to December 31, 2013, the Company recorded $6,686, ($6,593) and $9,183, respectively, of stock-based compensation expense related to nonemployees. The fair value of nonemployee stock options granted was estimated using the following assumptions: | ||||||||||||||||||||||||||||||||||||||||||||||||
Cumulative for the Period | ||||||||||||||||||||||||||||||||||||||||||||||||
21-Sep-05 | ||||||||||||||||||||||||||||||||||||||||||||||||
(Date of Inception) to | ||||||||||||||||||||||||||||||||||||||||||||||||
2012 | 2013 | 31-Dec-13 | ||||||||||||||||||||||||||||||||||||||||||||||
Contractual term (in years) | 10-Apr | 10-Mar | 10-Mar | |||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 68% | 67% | 60% - 79% | |||||||||||||||||||||||||||||||||||||||||||||
Risk-free interest rate | 0.72% - 1.78% | 0.78% - 3.04% | 0.56% - 4.7% | |||||||||||||||||||||||||||||||||||||||||||||
Dividend yield | 0% | 0% | 0% | |||||||||||||||||||||||||||||||||||||||||||||
Note_11_Income_Taxes
Note 11 - Income Taxes | 9 Months Ended | 12 Months Ended | |||||||||
Sep. 30, 2014 | Dec. 31, 2013 | ||||||||||
Income Tax Disclosure [Abstract] | |||||||||||
Income Tax Disclosure [Text Block] | 11 | Income Taxes | 11 | Income Taxes | |||||||
Provision for Income Tax | The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows: | ||||||||||
The Company’s effective tax rate is 0% for the three and nine months ended September 30, 2014 and the Company expects that its effective tax rate for the full year 2014 will be 0%. Based on the weight of available evidence, including cumulative losses since inception and expected future losses, the Company has determined that it is more likely than not that the deferred tax asset amount will not be realized and therefore a full valuation allowance has been provided on net deferred tax assets. | 2012 | 2013 | |||||||||
As of September 30, 2014, the Company had net operating loss carryforwards of approximately $11,188,000 and $11,176,000 available to offset future taxable income, if any, for both federal and California state income tax purposes, respectively. The Company’s federal and state net operating loss carry-forwards begin to expire in 2027 and 2016, respectively, and valuation allowances have been provided, where necessary. | Net operating loss carryforwards | $ | 3,951,000 | $ | 4,203,000 | ||||||
Research and development credits | 162,000 | 162,000 | |||||||||
Utilization of the net operating loss carry-forward may be subject to an annual limitation due to the ownership percentage change limitations provided by the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of the net operating loss before utilization. | Start-up expenses capitalized | 5,726,000 | 7,156,000 | ||||||||
Accruals and reserves | 150,000 | 99,000 | |||||||||
All of the Company’s tax years will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss or credits. | Property and equipment | (22,000 | ) | (11,000 | ) | ||||||
9,967,000 | 11,609,000 | ||||||||||
Uncertain Tax Positions | Less: Valuation allowance | (9,967,000 | ) | (11,609,000 | ) | ||||||
$ | - | $ | - | ||||||||
The gross amount of unrecognized tax benefits as of September 30, 2014 is approximately $78 thousand related to reserves on research and development credits, none of which will affect the effective tax rate if recognized due to the valuation allowance. The Company does not expect any material changes in the next 12 months in unrecognized tax benefits. | |||||||||||
Based on a number of factors, including the lack of history of profits and the fact that the Company competes in a developing market that is characterized by rapidly changing technology, management believes that there is sufficient uncertainty regarding the realization of deferred tax assets such that a full valuation allowance has been provided. The valuation allowance increased by $1,789,000 and $1,642,000 during the years ended December 31, 2012 and 2013, respectively. | |||||||||||
The Company recognizes interest and/or penalties related to uncertain tax positions as other expense and not tax expense. The Company currently has no interest and penalties related to uncertain tax positions. | |||||||||||
As of December 31, 2013, the Company had net operating loss carryforwards of approximately $10,554,000 and $10,543,000 available to offset future taxable income, if any, for both federal and California state income tax purposes, respectively. The Company’s federal and state net operating loss carryforwards begin to expire in 2027 and 2017, respectively, and valuation allowances have been provided, where necessary. | |||||||||||
As of December 31, 2013, the Company also had federal and state research and development credit carryforwards of approximately $142,000 and $136,000, respectively, available to reduce future taxable income. The federal credit carryforward begins to expire in 2027, the California credit will carryforward indefinitely and valuation allowances have been provided, where necessary. | |||||||||||
Utilization of the net operating loss carryforward may be subject to an annual limitation due to the ownership percentage change limitations provided by the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of the net operating loss before utilization. | |||||||||||
No liability related to uncertain tax positions is recorded on the financial statements. As of December 31, 2013, the Company had an unrecognized tax benefit of $70,000. It is the Company’s policy to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary. | |||||||||||
All of the Company’s tax years will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss or credits. |
Note_12_Related_Party_Transact
Note 12 - Related Party Transactions | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2014 | Dec. 31, 2013 | |||
Related Party Transactions [Abstract] | ||||
Related Party Transactions Disclosure [Text Block] | 12 | Related Party Transactions | 12 | Related Party Transactions |
In June 2006, the Company entered into a Development and Manufacturing Agreement with Stellartech Research Corporation (the “Agreement”). The Agreement was amended on October 4, 2007. Under the Agreement, the Company agreed to purchase 300 units of generators manufactured by Stellartech. In conjunction with the Agreement, Stellartech purchased 300,000 shares of common stock at par value. These shares are subject to a right of repurchase by the Company, which lapse over a four-year period. As of December 31, 2012, none of the shares of common stock were subject to repurchase. Under the Agreement, the Company paid Stellartech $345,472 and $33,000 for goods and services in the nine months ended September 30, 2014 and 2013, respectively. | From March 2006 through March 2008, the Company leased office space from the Company’s then Chief Executive Officer. Rent payments made to the Chief Executive Officer for the year ended December 31, 2008 and, cumulatively, for the period from September 21, 2005 (date of inception) to December 31, 2008 were $12,000 and $72,391, respectively. There were no rental payments made to the Chief Executive Officer after March 2008. | |||
In June 2006, the Company entered into a Development and Manufacturing Agreement with Stellartech Research Corporation (the “Agreement”). The Agreement was amended on October 4, 2007. Under the Agreement, Viveve agreed to purchase 300 units of generators manufactured by Stellartech. In conjunction with the Agreement, Stellartech purchased 300,000 shares of common stock at par value. These shares were subject to a right of repurchase by the Company, which lapsed over a four-year period. As of December 31, 2012, none of the shares of common stock were subject to repurchase. Under the Agreement, the Company has paid Stellartech $325,936, $33,000 and $6,920,619 for goods and services in the years ended December 31, 2012 and 2013 and, cumulatively, for the period from September 21, 2005 (date of inception) to December 31, 2013, respectively. | ||||
In April 2012, the Viveve-Parmer Arbitration (a dispute between the Company and its original Chief Executive Officer) was settled and resulted in the award and judgment in favor of Dr. Parmer. In accordance with the Settlement Agreement and General Release, the Company paid Dr. Parmer $1,000,000, less applicable withholdings (payment executed April 20, 2012), issued a subordinated unsecured note of $150,000 payable in three equal installments on March 31, 2013, June 30, 2013 and September 30, 2013, all of which were paid, and issued 754,635 shares of restricted common stock. In addition, if the Company closes an equity financing, the Company shall issue Dr. Parmer a number of shares equal to $150,000 divided by the price per share. | ||||
In June 2012, the Company entered into a Supply and Purchase Agreement with Donna Bella International, Limited (“Donna Bella”). Under the agreement, Donna Bella will have exclusivity to purchase the Company’s products in Hong Kong, provided Donna Bella purchases $1,000,000 of the Company’s Series B. In addition, Donna Bella will have exclusivity to purchase the Company’s products in China, provided that (a) Donna Bella purchases $1,000,000 of the Company’s Series B and (b) the Company obtains registration with the State Food and Drug Administration (“SFDA”) for its products with the assistance of Donna Bella. The parties agree to negotiate minimum purchases for the China market upon receipt of SFDA clearance. Donna Bella agrees to designate a subsidiary of Donna Bella in China with legal independent legal standing, to assist the Company in obtaining the registration with SFDA at Donna Bella’s subsidiary’s cost. Such designated subsidiary of Donna Bella shall start the registration process on behalf of the Company immediately after the signing of this agreement, subject to the request of and approval by the Company. In July 2012, Donna Bella purchased $1,000,000 of the Company’s Series B. | ||||
On March 14, 2013, the Company entered into a Separation and Release Agreement with a former executive officer (the “Separation Agreement”). In accordance with the terms and conditions of the Separation Agreement, the employee resigned as an officer of the Company and observer to the Company’s Board of Directors. The Company agreed to pay a severance payment equal to an aggregate of $271,346 (the “Severance Payment”) payable as follows: (1) $25,000 for each month for the ten months following April 15, 2013 (the “Separation Date”) and (2) $21,346 for the 11th month following the Separation Date. In the event that the employee engages in any activities that compete with the Company anytime during the eleven months following the Separation Date, the Company’s obligation to pay any further amounts in connection with the Severance Payment shall cease. | ||||
In addition to the above, an aggregate of 5,278,330 options of the 11,015,646 options previously granted to the former executive officer vested effective as of the Separation Date. The former executive officer agreed to release and discharge the Company from any and all claims, debts, obligations or liabilities, known and unknown, which relate to employment with the Company or the termination of that employment. |
Note_13_Subsequent_Events
Note 13 - Subsequent Events | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2014 | Dec. 31, 2013 | |||
Subsequent Events [Abstract] | ||||
Subsequent Events [Text Block] | 13 | Subsequent Events | 13 | Subsequent Events |
On September 30, 2014, the Company entered into a Loan and Security Agreement pursuant to which we received a term loan in the amount of $5 million, which will be funded in 3 tranches. The first tranch of $2.5 million was provided to the Company on October 1, 2014. The proceeds from the first tranche were used to repay the existing loan with a financial institution which totaled $1,630,925. Before the second and the third tranches of the term loan will be funded, we must meet certain enrollment milestones and achieve certain positive results relating to our OUS Clinical Trials, among other things. | On January 31, 2014, the Company and lender agreed to further amend the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more on or before February 25, 2014 and consummation of an equity event by April 25, 2014. On February 25, 2014, a further extension to defer principal payments through March 31, 2014 was verbally agreed upon. | |||
On March 5, 2014, the Company entered into a note purchase agreement in which it was authorized to issue and sell convertible promissory notes up to $500,000 in the aggregate of which $100,000 was issued on March 5, 2014. The notes accrue interest at 9% per annum and will convert into a subsequent equity financing, which the Company expects to complete by June 30, 2014. | ||||
The Company has evaluated all events occurring subsequent to December 31, 2013 through March 18, 2014, the date these accompanying financials were available to be issued and did not identify any additional material recognizable subsequent events. |
Note_4_Balance_Sheet_Component
Note 4 - Balance Sheet Components | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Disclosure Text Block Supplement [Abstract] | |||||||||
Supplemental Balance Sheet Disclosures [Text Block] | 4 | Balance Sheet Components | |||||||
Property and Equipment, Net | |||||||||
2012 | 2013 | ||||||||
Medical equipment | $ | 215,639 | $ | 276,443 | |||||
Computer equipment | 30,871 | 32,143 | |||||||
Furniture and fixtures | 13,293 | 13,293 | |||||||
259,803 | 321,879 | ||||||||
Less: Accumulated depreciation and amortization | (131,176 | ) | (194,355 | ) | |||||
Net property and equipment | $ | 128,627 | $ | 127,524 | |||||
Depreciation and amortization expense for the years ended December 31, 2012 and 2013 and for the cumulative period from September 21, 2005 (date of inception) to December 31, 2013 was $57,173, $66,120 and $239,475, respectively. | |||||||||
Accrued Liabilities | |||||||||
2012 | 2013 | ||||||||
Accrued settlement related costs | $ | 263,560 | $ | - | |||||
Accrued interest | 8,987 | 312,075 | |||||||
Accrued severence pay | - | 58,846 | |||||||
Accrued vacation | 54,153 | 81,499 | |||||||
Accrued loan restructuring fees | - | 27,288 | |||||||
Deferred rent | 18,034 | 15,284 | |||||||
Other accruals | 910 | 21,160 | |||||||
Total accrued liabilities | $ | 345,644 | $ | 516,152 | |||||
Accounting_Policies_by_Policy_
Accounting Policies, by Policy (Policies) | 9 Months Ended | ||||||||||||||||
Sep. 30, 2014 | |||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||
Use of Estimates, Policy [Policy Text Block] | Use of Estimates | ||||||||||||||||
The preparation of condensed consolidated financial statements in conformity with US GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect on our operating results. | |||||||||||||||||
Reclassification, Policy [Policy Text Block] | Reclassifications | ||||||||||||||||
Certain prior year financial statement amounts have been reclassified to conform to the current year’s presentation. These reclassifications had no impact on previously reported total assets, stockholders’ deficit or net loss. | |||||||||||||||||
Revenue Recognition, Policy [Policy Text Block] | Revenue Recognition | ||||||||||||||||
The Company recognizes revenue from the sale of its product, the Viveve® System, and single-use treatment tips. Revenue is recognized upon delivery, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of Viveve’s products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance outside the U.S. and currently sells the Viveve System in Canada, Hong Kong and Japan. | |||||||||||||||||
The Company does not provide its customers with a contractual right of return. | |||||||||||||||||
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Issued and Adopted Accounting Standards | ||||||||||||||||
In May 2014, as part of its ongoing efforts to assist in the convergence of US GAAP and International Financial Reporting Standards (“IFRS”), the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The ASU provides alternative methods of initial adoption and is effective for annual and interim periods beginning after December 15, 2016. We are currently evaluating the impact that this standard will have on our condensed consolidated financial statements. | |||||||||||||||||
In June 2014, the FASB issued ASU No. 2014-12, “Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could be Achieved After a Requisite Service Period” (“ASU 2014-12”). Companies commonly issue share-based payment awards that require a specific performance target to be achieved in order for employees to become eligible to vest in the awards. ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period should be treated as a performance condition. The performance target should not be reflected in estimating the grant date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved. ASU 2014-12 will be effective for the Company’s fiscal years beginning fiscal 2016 and interim reporting periods within that year, using either the retrospective or prospective transition method. Early adoption is permitted. We are currently evaluating the effect of the adoption of this guidance on our condensed consolidated financial statements. | |||||||||||||||||
In June 2014, the FASB issued ASU 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in topic 810, Consolidation” (“ASU 2014-10”). ASU 2014-10 removes the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. ASU 2014-10 also eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. The amendments in ASU 2014-10 will be effective retrospectively except for the clarification to Topic 275, which shall be applied prospectively for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued. We elected to early adopt the provisions of ASU 2014-10 in the second quarter of 2014. | |||||||||||||||||
In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 310-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”), to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Since ASU 2014-15 only impacts financial statement disclosure requirements regarding whether there is substantial doubt about an entity’s ability to continue as a going concern, we do not expect its adoption to have an impact on our condensed consolidated financial statements. | |||||||||||||||||
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Credit Risk and Other Risks and Uncertainties | ||||||||||||||||
To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows. | |||||||||||||||||
The Company’s future products may require approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no assurance that the Company’s future products will receive any of these required approvals. If the Company was denied such approvals or such approvals were delayed, it would have a material adverse impact on the Company’s financial results, financial position and future cash flows. | |||||||||||||||||
The Company is subject to risks common to companies in the medical device industry including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products. | |||||||||||||||||
During the nine months ended September 30, 2014, three customers accounted for 94% of the Company’s revenue. | |||||||||||||||||
During the nine months ended September 30, 2013, one customer accounted for 100% of the Company’s revenue. | |||||||||||||||||
During the three months ended September 30, 2014, two customers accounted for 79% of the Company’s revenue. | |||||||||||||||||
During the three months ended September 30, 2013, one customer accounted for 100% of the Company’s revenue. | |||||||||||||||||
Sales outside the U.S. accounted for 100% of the Company's revenue for all periods presented. | |||||||||||||||||
Inventory, Policy [Policy Text Block] | Inventory | ||||||||||||||||
Inventory is stated at the lower of cost or market, cost being determined on an actual cost basis on a first-in, first-out basis and market being determined as the lower of replacement cost or net realizable value. | |||||||||||||||||
Standard Product Warranty, Policy [Policy Text Block] | Product Warranty | ||||||||||||||||
The Company’s products are generally subject to a one year warranty, which provides for the repair, rework or replacement of products (at its option) that fail to perform within stated specification. The Company has assessed the historical claims and, to date, product warranty claims have not been significant. The Company will continue to assess if there should be a warranty accrual. | |||||||||||||||||
Comprehensive Income, Policy [Policy Text Block] | Comprehensive Loss | ||||||||||||||||
Comprehensive loss represents the changes in equity of an enterprise, except those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and nine months ended September 31, 2014 and 2013, the Company’s comprehensive loss is the same as its net loss. There were no components of comprehensive loss for any of the periods presented. | |||||||||||||||||
Earnings Per Share, Policy [Policy Text Block] | Net Loss per Share Attributable to Common Stockholders | ||||||||||||||||
The Company’s basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, options and warrants to purchase common stock are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Potential common shares will always be anti-dilutive for periods in which the Company has reported a net loss. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders for the three and nine months ended September 30, 2014 and 2013. | |||||||||||||||||
For the three and nine months ended September 30, 2014 and 2013, the following weighted average common stock equivalent shares were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. | |||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||
September 30, | September 30, | ||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||
Stock options to purchase common stock | 476,671 | 409,488 | 445,804 | 491,609 | |||||||||||||
Warrants to purchase convertible preferred stock | 72,322 | - | 24,107 | - |
Note_2_Summary_of_Significant_1
Note 2 - Summary of Significant Accounting Policies (Tables) | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||||||||||
Accounting Policies [Abstract] | ||||||||||||||||||||||||||
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended | Nine Months Ended | Decemeber 31, | |||||||||||||||||||||||
September 30, | September 30, | 2012 | 2013 | |||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | Convertible preferred stock | 462,331,603 | 462,331,603 | ||||||||||||||||||||
Stock options to purchase common stock | 476,671 | 409,488 | 445,804 | 491,609 | Stock options to purchase common stock | 44,788,104 | 45,146,118 | |||||||||||||||||||
Warrants to purchase convertible preferred stock | 72,322 | - | 24,107 | - | Warrants to purchase convertible preferred stock | 24,299,963 | 24,299,963 |
Note_3_Fair_Value_Measurements1
Note 3 - Fair Value Measurements (Tables) | 9 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | ||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | Assets and Liabilities at Fair Value as of | Assets and Liabilities at Fair Value as of December 31, 2012 | |||||||||||||||||||||||||||||||||
30-Sep-14 | Quoted prices in active markets for identical assets | Significant | Significant unobservable | ||||||||||||||||||||||||||||||||
Quoted | Significant | Significant | other observable inputs | inputs | |||||||||||||||||||||||||||||||
prices in | other | unobservable | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||||||||
active | observable | inputs | Assets | ||||||||||||||||||||||||||||||||
markets for | inputs | Money market fund | $ | 503 | $ | - | $ | - | $ | 503 | |||||||||||||||||||||||||
identical | Total assets | $ | 503 | $ | - | $ | - | $ | 503 | ||||||||||||||||||||||||||
assets | Liabilities | ||||||||||||||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | Preferred stock warrant liabilities | $ | - | $ | - | $ | 685,213 | $ | 685,213 | |||||||||||||||||||||||
Assets | Total liabilities | $ | - | $ | - | $ | 685,213 | $ | 685,213 | ||||||||||||||||||||||||||
Money market fund | $ | 190 | $ | - | $ | - | $ | 190 | Assets and Liabilities at Fair Value as of December 31, 2013 | ||||||||||||||||||||||||||
Total assets | $ | 190 | $ | - | $ | - | $ | 190 | Quoted prices in active markets for identical assets | Significant | Significant unobservable | ||||||||||||||||||||||||
Liabilities | other observable inputs | inputs | |||||||||||||||||||||||||||||||||
Preferred stock warrant liabilities | $ | - | $ | - | $ | - | $ | - | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||
Total liabilities | $ | - | $ | - | $ | - | $ | - | Assets | ||||||||||||||||||||||||||
Assets and Liabilities at Fair Value as of | Money market fund | $ | 324 | $ | - | $ | - | $ | 324 | ||||||||||||||||||||||||||
31-Dec-13 | Total assets | $ | 324 | $ | - | $ | - | $ | 324 | ||||||||||||||||||||||||||
Quoted | Significant | Significant | Liabilities | ||||||||||||||||||||||||||||||||
prices in | other | unobservable | Preferred stock warrant liabilities | $ | - | $ | - | $ | 623,672 | $ | 623,672 | ||||||||||||||||||||||||
active | observable | inputs | Total liabilities | $ | - | $ | - | $ | 623,672 | $ | 623,672 | ||||||||||||||||||||||||
markets for | inputs | ||||||||||||||||||||||||||||||||||
identical | |||||||||||||||||||||||||||||||||||
assets | |||||||||||||||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||||||||||||||
Assets | |||||||||||||||||||||||||||||||||||
Money market fund | $ | 324 | $ | - | $ | - | $ | 324 | |||||||||||||||||||||||||||
Total assets | $ | 324 | $ | - | $ | - | $ | 324 | |||||||||||||||||||||||||||
Liabilities | |||||||||||||||||||||||||||||||||||
Preferred stock warrant liabilities | $ | - | $ | - | $ | 623,672 | $ | 623,672 | |||||||||||||||||||||||||||
Total liabilities | $ | - | $ | - | $ | 623,672 | $ | 623,672 | |||||||||||||||||||||||||||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Fair value as of December 31, 2013 | $ | 623,672 | Fair value as of December 31, 2011 | $ | 646,844 | |||||||||||||||||||||||||||||
Change in fair value recorded in other income (expense), net | (21,484 | ) | Fair value of warrants issued | 194,532 | |||||||||||||||||||||||||||||||
Fair value as of March 31, 2014 | 602,188 | Change in fair value recorded in other income (expense), net | (156,163 | ) | |||||||||||||||||||||||||||||||
Change in fair value recorded in other income (expense), net | (22,001 | ) | Fair value as of December 31, 2012 | 685,213 | |||||||||||||||||||||||||||||||
Fair value as of June 30, 2014 | 580,187 | Fair value of warrants issued | - | ||||||||||||||||||||||||||||||||
Change in fair value recorded in other income (expense), net, as of September 23, 2014, date of the Merger Agreement | (7,277 | ) | Change in fair value recorded in other income (expense), net | (61,541 | ) | ||||||||||||||||||||||||||||||
Extinguishment of warrant liabilities pursuant to the Merger Agreement (reclassified to equity) | (572,910 | ) | Fair value as of December 31, 2013 | $ | 623,672 | ||||||||||||||||||||||||||||||
Fair value as of September 30, 2014 | $ | - | |||||||||||||||||||||||||||||||||
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] | Fair Value as of | Valuation | Unobservable | Range | Fair Value as of | Range | |||||||||||||||||||||||||||||
31-Dec-13 | Techniques | Input | (Weighted Average) | 31-Dec-12 | Valuation | Unobservable | (Weighted Average) | ||||||||||||||||||||||||||||
Preferred stock warrant liabilities | $ | 623,672 | Black-Scholes | Preferred series | Preferred stock warrant liabilities | $ | 685,213 | Black-Scholes option pricing model | Preferred series prices | $0.04 | - | 0.44 | (- | $0.06 | -) | ||||||||||||||||||||
option pricing model | prices | $0.04 | - | $0.44 | (- | $0.06 | -) | Volatility | 74.20% | - | 91.60% | (- | 83% | -) | |||||||||||||||||||||
Volatility | 70.62% | - | 84.23% | (- | 76% | -) | Fair Value as of | Range | |||||||||||||||||||||||||||
31-Dec-13 | Valuation | Unobservable | (Weighted Average) | ||||||||||||||||||||||||||||||||
Preferred stock warrant liabilities | $ | 623,672 | Black-Scholes option pricing model | Preferred series prices | $ | 0.04 | - | 0.44 | (- | $0.06 | -) | ||||||||||||||||||||||||
Volatility | 70.60% | - | 84.20% | (- | 76% | -) |
Note_4_Accrued_Liabilities_Tab
Note 4 - Accrued Liabilities (Tables) | 9 Months Ended | 12 Months Ended | ||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||
Payables and Accruals [Abstract] | ||||||||||||||||||
Schedule of Accrued Liabilities [Table Text Block] | September 30, | December 31, | 2012 | 2013 | ||||||||||||||
2014 | 2013 | |||||||||||||||||
Accrued settlement related costs | $ | 263,560 | $ | - | ||||||||||||||
Accrued interest | $ | 13,792 | $ | 235,603 | Accrued interest | 8,987 | 312,075 | |||||||||||
Accrued professional fees | 125,671 | 15,000 | Accrued severence pay | - | 58,846 | |||||||||||||
Accrued loan balloon payment | 85,000 | 76,472 | Accrued vacation | 54,153 | 81,499 | |||||||||||||
Accrued vacation | 73,809 | 81,499 | Accrued loan restructuring fees | - | 27,288 | |||||||||||||
Accrued loan restructuring fees | 47,500 | 27,288 | Deferred rent | 18,034 | 15,284 | |||||||||||||
Accrued severence pay | - | 58,846 | Other accruals | 910 | 21,160 | |||||||||||||
Other accruals | 41,766 | 21,444 | Total accrued liabilities | $ | 345,644 | $ | 516,152 | |||||||||||
Total accrued liabilities | $ | 387,538 | $ | 516,152 |
Note_5_Note_Payable_Tables
Note 5 - Note Payable (Tables) | 9 Months Ended | 12 Months Ended | ||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||
Debt Disclosure [Abstract] | ||||||||||
Schedule of Debt [Table Text Block] | Year Ending December 31, 2014 | $ | 1,618,091 | Year ending December 31, 2014 | $ | 1,597,196 | ||||
1,618,091 | ||||||||||
Less: Amount representing interest | (146,292 | ) | Less: Amount representing interest | (125,398 | ) | |||||
Present value of obligations | 1,471,799 | Present value of obligations | 1,471,798 | |||||||
Less: Unamortized debt discount | - | Less: Unamortized debt discount | (8,554 | ) | ||||||
1,471,799 | 1,463,244 | |||||||||
Less: Notes payable, current portion | 1,471,799 | Less: Notes payable, current portion | 1,463,244 | |||||||
Notes payable, noncurrent portion | $ | - | Notes payable, noncurrent portion | $ | - |
Note_7_Commitments_and_Conting1
Note 7 - Commitments and Contingencies (Tables) | 9 Months Ended | 12 Months Ended | ||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||
Commitments and Contingencies Disclosure [Abstract] | ||||||||||
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | Year Ending December 31, | Year Ending December 31, | ||||||||
2014 | $ | 46,428 | 2014 | $ | 184,002 | |||||
2015 | 30,952 | 2015 | 30,952 | |||||||
Total minimum lease payments | $ | 77,380 | $ | 214,954 |
Note_9_Convertible_Preferred_S1
Note 9 - Convertible Preferred Stock (Tables) | 9 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | ||||||||||||||||||||||||||||||||||
Disclosure Text Block Supplement [Abstract] | |||||||||||||||||||||||||||||||||||
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Number of | Series | Number of | Fair Value as of | |||||||||||||||||||||||||||||||
Shares | Exercisable | Expiration | Exercise | Warrants | December 31, | ||||||||||||||||||||||||||||||
Series | Outstanding | Fair Value | Issuance Date | for | Date | Price | Outstanding | 2012 | |||||||||||||||||||||||||||
Exercisable | Expiration | Exercise | Under | December 31, | |||||||||||||||||||||||||||||||
Issuance Date | for | Date | Price | Warrants | 2013 | Dec-08 | Series A | 2-Dec-18 | $ | 0.61 | 196,721 | $ | 50,951 | ||||||||||||||||||||||
Apr-09 | Series A | 2-Apr-19 | 0.61 | 245,900 | 66,885 | ||||||||||||||||||||||||||||||
Dec-08 | Series A | 2-Dec-18 | $ | 0.61 | 196,721 | $ | 44,066 | Nov-10 | Series A | 19-Nov-20 | 0.61 | 163,934 | 48,524 | ||||||||||||||||||||||
Apr-09 | Series A | 2-Apr-19 | 0.61 | 245,900 | 58,278 | May-11 | Series B | 6-May-21 | 0.05 | 2,000,000 | 60,000 | ||||||||||||||||||||||||
Nov-10 | Series A | 19-Nov-20 | 0.61 | 163,934 | 46,393 | Jun-11 | Series B | 30-Jun-21 | 0.05 | 4,000,000 | 120,000 | ||||||||||||||||||||||||
May-11 | Series B | 6-May-21 | 0.05 | 2,000,000 | 54,000 | Sep-11 | Series B | 9-Sep-21 | 0.05 | 4,000,000 | 120,000 | ||||||||||||||||||||||||
Jun-11 | Series B | 30-Jun-21 | 0.05 | 4,000,000 | 108,000 | Nov-11 | Series B | 30-Nov-21 | 0.05 | 1,000,000 | 30,000 | ||||||||||||||||||||||||
Sep-11 | Series B | 9-Sep-21 | 0.05 | 4,000,000 | 108,000 | Dec-11 | Series B | 19-Dec-21 | 0.05 | 1,000,000 | 30,000 | ||||||||||||||||||||||||
Nov-11 | Series B | 30-Nov-21 | 0.05 | 1,000,000 | 28,000 | Jan-12 | Series B | 31-Jan-22 | 0.05 | 910,445 | 30,045 | ||||||||||||||||||||||||
Dec-11 | Series B | 19-Dec-21 | 0.05 | 1,000,000 | 28,000 | Feb-12 | Series B | 28-Feb-22 | 0.05 | 738,535 | 24,372 | ||||||||||||||||||||||||
Jan-12 | Series B | 31-Jan-22 | 0.05 | 910,445 | 28,224 | Apr-12 | Series B | 16-Apr-22 | 0.05 | 2,351,019 | 77,584 | ||||||||||||||||||||||||
Feb-12 | Series B | 28-Feb-22 | 0.05 | 738,535 | 22,895 | Apr-12 | Series A | 19-Apr-22 | 0.61 | 73,770 | 26,852 | ||||||||||||||||||||||||
Apr-12 | Series B | 16-Apr-22 | 0.05 | 2,351,019 | 72,882 | 16,680,324 | $ | 685,213 | |||||||||||||||||||||||||||
Apr-12 | Series A | 19-Apr-22 | 0.61 | 73,770 | 24,934 | Series | Number of | Fair Value as of | |||||||||||||||||||||||||||
16,680,324 | $ | 623,672 | Exercisable | Expiration | Exercise | Warrants | December 31, | ||||||||||||||||||||||||||||
Issuance Date | for | Date | Price | Outstanding | 2013 | ||||||||||||||||||||||||||||||
Dec-08 | Series A | 2-Dec-18 | $ | 0.61 | 196,721 | $ | 44,066 | ||||||||||||||||||||||||||||
Apr-09 | Series A | 2-Apr-19 | 0.61 | 245,900 | 58,278 | ||||||||||||||||||||||||||||||
Nov-10 | Series A | 19-Nov-20 | 0.61 | 163,934 | 46,393 | ||||||||||||||||||||||||||||||
May-11 | Series B | 6-May-21 | 0.05 | 2,000,000 | 54,000 | ||||||||||||||||||||||||||||||
Jun-11 | Series B | 30-Jun-21 | 0.05 | 4,000,000 | 108,000 | ||||||||||||||||||||||||||||||
Sep-11 | Series B | 9-Sep-21 | 0.05 | 4,000,000 | 108,000 | ||||||||||||||||||||||||||||||
Nov-11 | Series B | 30-Nov-21 | 0.05 | 1,000,000 | 28,000 | ||||||||||||||||||||||||||||||
Dec-11 | Series B | 19-Dec-21 | 0.05 | 1,000,000 | 28,000 | ||||||||||||||||||||||||||||||
Jan-12 | Series B | 31-Jan-22 | 0.05 | 910,445 | 28,224 | ||||||||||||||||||||||||||||||
Feb-12 | Series B | 28-Feb-22 | 0.05 | 738,535 | 22,895 | ||||||||||||||||||||||||||||||
Apr-12 | Series B | 16-Apr-22 | 0.05 | 2,351,019 | 72,882 | ||||||||||||||||||||||||||||||
Apr-12 | Series A | 19-Apr-22 | 0.61 | 73,770 | 24,934 | ||||||||||||||||||||||||||||||
16,680,324 | $ | 623,672 |
Note_10_Summary_of_Stock_Optio1
Note 10 - Summary of Stock Options (Tables) | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||||||||||||||||||||||||||||||||
Note 10 - Summary of Stock Options (Tables) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | Outstanding Options | Outstanding Options | ||||||||||||||||||||||||||||||||||||||||||||||
Weighted | Weighted | |||||||||||||||||||||||||||||||||||||||||||||||
Weighted | Average | Shares | Weighted | Average | ||||||||||||||||||||||||||||||||||||||||||||
Number | Average | Remaining | Available | Number | Average | Remaining | ||||||||||||||||||||||||||||||||||||||||||
of | Exercise | Contractual | for | of | Exercise | Contractual | ||||||||||||||||||||||||||||||||||||||||||
Shares | Price | Term (years) | Grant | Shares | Price | Term (years) | ||||||||||||||||||||||||||||||||||||||||||
Options outstanding as of December 31, 2013 | 363,413 | $ | 2.94 | 8.8 | Shares reserved at plan inception | 1,000,000 | - | $ | - | |||||||||||||||||||||||||||||||||||||||
Options granted | 1,901,476 | $ | 0.6 | Options granted | (51,500 | ) | 51,500 | 0.001 | ||||||||||||||||||||||||||||||||||||||||
Options assumed from PLC | 68,238 | $ | 10.24 | Balances as of December 31, 2006 | 948,500 | 51,500 | 0.001 | 9.96 | ||||||||||||||||||||||||||||||||||||||||
Options canceled | (38,593 | ) | $ | 1.75 | Additional shares reserved | 2,000,000 | - | - | ||||||||||||||||||||||||||||||||||||||||
Options outstanding as of September 30, 2014 | 2,294,534 | $ | 1.02 | 9.67 | Options granted | (867,000 | ) | 867,000 | 0.06 | |||||||||||||||||||||||||||||||||||||||
Options forfeited | 5,000 | (5,000 | ) | 0.001 | ||||||||||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2007 | 2,086,500 | 913,500 | 0.06 | 9.82 | ||||||||||||||||||||||||||||||||||||||||||||
Options granted | (72,500 | ) | 72,500 | 0.06 | ||||||||||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2008 | 2,014,000 | 986,000 | 0.06 | 8.87 | ||||||||||||||||||||||||||||||||||||||||||||
Options granted | (1,892,029 | ) | 1,892,029 | 0.06 | ||||||||||||||||||||||||||||||||||||||||||||
Options exercised | - | (322,395 | ) | 0.06 | ||||||||||||||||||||||||||||||||||||||||||||
Options forfeited | 377,605 | (377,605 | ) | 0.06 | ||||||||||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2009 | 499,576 | 2,178,029 | 0.06 | 9 | ||||||||||||||||||||||||||||||||||||||||||||
Additional shares reserved | 461,957 | - | - | |||||||||||||||||||||||||||||||||||||||||||||
Options granted | (771,412 | ) | 771,412 | 0.05 | ||||||||||||||||||||||||||||||||||||||||||||
Options exercised | - | (173,455 | ) | 0.001 | ||||||||||||||||||||||||||||||||||||||||||||
Options forfeited | 12,500 | (12,500 | ) | 0.06 | ||||||||||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2010 | 202,621 | 2,763,486 | 0.06 | 8.4 | ||||||||||||||||||||||||||||||||||||||||||||
Additional shares reserved | 500,000 | - | - | |||||||||||||||||||||||||||||||||||||||||||||
Options granted | (345,000 | ) | 345,000 | 0.12 | ||||||||||||||||||||||||||||||||||||||||||||
Options exercised | - | (9,000 | ) | 0.001 | ||||||||||||||||||||||||||||||||||||||||||||
Options forfeited | 139,000 | (139,000 | ) | 0.06 | ||||||||||||||||||||||||||||||||||||||||||||
Repurchase of restricted stock options | 5,250 | - | ||||||||||||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2011 | 501,871 | 2,960,486 | 0.07 | 7.7 | ||||||||||||||||||||||||||||||||||||||||||||
Additional shares reserved | 80,000,000 | - | - | |||||||||||||||||||||||||||||||||||||||||||||
Options granted | (43,694,521 | ) | 43,694,521 | 0.01 | ||||||||||||||||||||||||||||||||||||||||||||
Options exercised | - | (1,866,903 | ) | 0.07 | ||||||||||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2012 | 36,807,350 | 44,788,104 | 0.01 | 9.74 | ||||||||||||||||||||||||||||||||||||||||||||
Options granted | (11,873,890 | ) | 11,873,890 | 0.01 | ||||||||||||||||||||||||||||||||||||||||||||
Options cancelled | 11,515,876 | (11,515,876 | ) | 0.01 | ||||||||||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2013 | 36,449,336 | 45,146,118 | $ | 0.01 | 8.8 | |||||||||||||||||||||||||||||||||||||||||||
Options vested and expected to vest as of December 31, 2013 | 43,338,910 | $ | 0.01 | 8.8 | ||||||||||||||||||||||||||||||||||||||||||||
Options vested as of December 31, 2013 | 15,025,985 | $ | 0.02 | 8.6 | ||||||||||||||||||||||||||||||||||||||||||||
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] | Options Outstanding | Options Exercisable | Options Outstanding | Options Vested | ||||||||||||||||||||||||||||||||||||||||||||
Weighted | Weighted | |||||||||||||||||||||||||||||||||||||||||||||||
Number | Weighted | Average | Number | Weighted | Average | Weighted | ||||||||||||||||||||||||||||||||||||||||||
Outstanding | Average | Remaining | Exercisable | Average | Remaining | Average | ||||||||||||||||||||||||||||||||||||||||||
Range of | as of | Exercise | Contractual | as of | Exercise | Exercise | Number | Contractual | Number | Exercise | ||||||||||||||||||||||||||||||||||||||
Exercise Prices | 30-Sep-14 | Price | Term (Years) | September 30, 2014 | Price | Price | Outstanding | Life (Years) | of Options | Price | ||||||||||||||||||||||||||||||||||||||
$0.12 | 320 | $ | 0.12 | 2.21 | 320 | $ | 0.12 | $ | 0.001 | 40,000 | 2.95 | 40,000 | $ | 0.001 | ||||||||||||||||||||||||||||||||||
$0.60 | 1,901,476 | $ | 0.6 | 10 | 20,000 | $ | 0.6 | 0.06 | 980,250 | 5.68 | 921,104 | 0.06 | ||||||||||||||||||||||||||||||||||||
$1.24 | 314,036 | $ | 1.24 | 8.15 | 314,036 | $ | 1.24 | 0.15 | 514,833 | 7.94 | 447,055 | 0.15 | ||||||||||||||||||||||||||||||||||||
$7.00 | - | $9.00 | 59,372 | $ | 8.63 | 8.28 | 59,372 | $ | 8.63 | 0.01 | 43,611,035 | 8.89 | 13,617,826 | 0.01 | ||||||||||||||||||||||||||||||||||
$12.00 | - | $18.63 | 19,081 | $ | 15.29 | 6.79 | 19,081 | $ | 15.29 | 45,146,118 | 8.8 | 15,025,985 | $ | 0.02 | ||||||||||||||||||||||||||||||||||
$37.00 | 250 | $ | 37 | 3.72 | 250 | $ | 37 | |||||||||||||||||||||||||||||||||||||||||
2,294,535 | $ | 1.02 | 9.67 | 413,059 | $ | 2.94 | ||||||||||||||||||||||||||||||||||||||||||
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Nine Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||
September 30, | ||||||||||||||||||||||||||||||||||||||||||||||||
2014 | 2013 | |||||||||||||||||||||||||||||||||||||||||||||||
Expected term (in years) | 5 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||
Average volatility | 61% | 67% | ||||||||||||||||||||||||||||||||||||||||||||||
Risk-free interest rate | 1.80% | 0.87% | ||||||||||||||||||||||||||||||||||||||||||||||
Dividend yield | 0% | 0% | ||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||
September 30, | September 30, | |||||||||||||||||||||||||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||||||||||||||||||||||||||||||||||
Research and development | $ | 101 | $ | 976 | $ | 667 | $ | (7,016 | ) | |||||||||||||||||||||||||||||||||||||||
General and administrative | 113,245 | 15,308 | 142,976 | 73,017 | ||||||||||||||||||||||||||||||||||||||||||||
Total | $ | 113,346 | $ | 16,284 | $ | 143,643 | $ | 66,001 | ||||||||||||||||||||||||||||||||||||||||
Employee Stock Option [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Note 10 - Summary of Stock Options (Tables) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Cumulative for the Period | |||||||||||||||||||||||||||||||||||||||||||||||
21-Sep-05 | ||||||||||||||||||||||||||||||||||||||||||||||||
(Date of Inception) to | ||||||||||||||||||||||||||||||||||||||||||||||||
2012 | 2013 | 31-Dec-13 | ||||||||||||||||||||||||||||||||||||||||||||||
Expected term (in years) | 5 | 5 | 5.00 - 6.25 | |||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 68 | % | 67 | % | 60% - 79 | % | ||||||||||||||||||||||||||||||||||||||||||
Risk-free interest rate | 0.76% - 0.84 | % | 0.84 | % | 0.76% - 4.7 | % | ||||||||||||||||||||||||||||||||||||||||||
Dividend yield | 0 | % | 0 | % | 0 | % | ||||||||||||||||||||||||||||||||||||||||||
Nonemployee Stock Option [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Note 10 - Summary of Stock Options (Tables) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Cumulative for the Period | |||||||||||||||||||||||||||||||||||||||||||||||
21-Sep-05 | ||||||||||||||||||||||||||||||||||||||||||||||||
(Date of Inception) to | ||||||||||||||||||||||||||||||||||||||||||||||||
2012 | 2013 | 31-Dec-13 | ||||||||||||||||||||||||||||||||||||||||||||||
Contractual term (in years) | 10-Apr | 10-Mar | 10-Mar | |||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 68% | 67% | 60% - 79% | |||||||||||||||||||||||||||||||||||||||||||||
Risk-free interest rate | 0.72% - 1.78% | 0.78% - 3.04% | 0.56% - 4.7% | |||||||||||||||||||||||||||||||||||||||||||||
Dividend yield | 0% | 0% | 0% |
Note_4_Balance_Sheet_Component1
Note 4 - Balance Sheet Components (Tables) | 9 Months Ended | 12 Months Ended | ||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||
Disclosure Text Block Supplement [Abstract] | ||||||||||||||||||
Property, Plant and Equipment [Table Text Block] | 2012 | 2013 | ||||||||||||||||
Medical equipment | $ | 215,639 | $ | 276,443 | ||||||||||||||
Computer equipment | 30,871 | 32,143 | ||||||||||||||||
Furniture and fixtures | 13,293 | 13,293 | ||||||||||||||||
259,803 | 321,879 | |||||||||||||||||
Less: Accumulated depreciation and amortization | (131,176 | ) | (194,355 | ) | ||||||||||||||
Net property and equipment | $ | 128,627 | $ | 127,524 | ||||||||||||||
Schedule of Accrued Liabilities [Table Text Block] | September 30, | December 31, | 2012 | 2013 | ||||||||||||||
2014 | 2013 | |||||||||||||||||
Accrued settlement related costs | $ | 263,560 | $ | - | ||||||||||||||
Accrued interest | $ | 13,792 | $ | 235,603 | Accrued interest | 8,987 | 312,075 | |||||||||||
Accrued professional fees | 125,671 | 15,000 | Accrued severence pay | - | 58,846 | |||||||||||||
Accrued loan balloon payment | 85,000 | 76,472 | Accrued vacation | 54,153 | 81,499 | |||||||||||||
Accrued vacation | 73,809 | 81,499 | Accrued loan restructuring fees | - | 27,288 | |||||||||||||
Accrued loan restructuring fees | 47,500 | 27,288 | Deferred rent | 18,034 | 15,284 | |||||||||||||
Accrued severence pay | - | 58,846 | Other accruals | 910 | 21,160 | |||||||||||||
Other accruals | 41,766 | 21,444 | Total accrued liabilities | $ | 345,644 | $ | 516,152 | |||||||||||
Total accrued liabilities | $ | 387,538 | $ | 516,152 |
Note_8_Common_Stock_Tables
Note 8 - Common Stock (Tables) | 12 Months Ended | ||||
Dec. 31, 2013 | |||||
Stockholders' Equity Note [Abstract] | |||||
Schedule of Common Stock Reserved for Future Issuance [Table Text Block] | Conversion of Series A convertible preferred stock | 291,132,255 | |||
Conversion of Series B convertible preferred stock | 171,199,348 | ||||
Exercise of options under stock plan | 45,146,118 | ||||
Issuance of options under stock plan | 36,449,336 | ||||
Exercise and conversion of convertible preferred stock warrants | 24,299,963 | ||||
568,227,020 |
Note_11_Income_Taxes_Tables
Note 11 - Income Taxes (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Income Tax Disclosure [Abstract] | |||||||||
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | 2012 | 2013 | |||||||
Net operating loss carryforwards | $ | 3,951,000 | $ | 4,203,000 | |||||
Research and development credits | 162,000 | 162,000 | |||||||
Start-up expenses capitalized | 5,726,000 | 7,156,000 | |||||||
Accruals and reserves | 150,000 | 99,000 | |||||||
Property and equipment | (22,000 | ) | (11,000 | ) | |||||
9,967,000 | 11,609,000 | ||||||||
Less: Valuation allowance | (9,967,000 | ) | (11,609,000 | ) | |||||
$ | - | $ | - |
Note_1_The_Company_and_Basis_o1
Note 1 - The Company and Basis of Presentation (Details) (USD $) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended | |||
Sep. 23, 2014 | Sep. 30, 2014 | Sep. 30, 2014 | Dec. 31, 2007 | 9-May-14 | Dec. 31, 2013 | Dec. 30, 2013 | Dec. 31, 2012 | |
Note 1 - The Company and Basis of Presentation (Details) [Line Items] | ||||||||
Extinguishment of Debt, Amount | $5,397,278 | |||||||
573,000 | 572,910 | 572,910 | ||||||
Conversion of Stock, Shares Issued (in Shares) | 3,743,282 | |||||||
Proceeds from Issuance of Private Placement | 6,000,000 | 4,204,220 | ||||||
Debt Conversion, Original Debt, Amount | 1,545,678 | 1,545,678 | 501,873 | |||||
Stock Issued During Period, Shares, New Issues (in Shares) | 11,305,567 | |||||||
Warrant Term | 5 years | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 940,189 | 16,680,324 | 16,680,324 | 16,680,324 | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.53 | $0.06 | ||||||
Accrued Interest [Member] | Convertible Debt [Member] | ||||||||
Note 1 - The Company and Basis of Presentation (Details) [Line Items] | ||||||||
Extinguishment of Debt, Amount | 522,000 | |||||||
Accrued Interest [Member] | GBS [Member] | ||||||||
Note 1 - The Company and Basis of Presentation (Details) [Line Items] | ||||||||
Debt Conversion, Original Debt, Amount | 211,000 | |||||||
Convertible Debt [Member] | ||||||||
Note 1 - The Company and Basis of Presentation (Details) [Line Items] | ||||||||
Extinguishment of Debt, Amount | 4,875,000 | |||||||
Viveve [Member] | ||||||||
Note 1 - The Company and Basis of Presentation (Details) [Line Items] | ||||||||
Conversion of Stock, Shares Issued (in Shares) | 3,743,282 | |||||||
Percentage of Total Common Stock Attributable to Viveve Capital Stock Converted | 62.00% | |||||||
Payment to Each Non-Accredited Investors For Converted Shares Upon Merger | 16,500 | |||||||
GBS [Member] | ||||||||
Note 1 - The Company and Basis of Presentation (Details) [Line Items] | ||||||||
Stock Issued During Period, Shares, Other (in Shares) | 943,596 | |||||||
Debt Conversion, Original Debt, Amount | $1,750,000 |
Note_2_Summary_of_Significant_2
Note 2 - Summary of Significant Accounting Policies (Details) (USD $) | 12 Months Ended | 99 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2014 | |
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | |||||||
Advertising Expense (in Dollars) | $264,834 | $7,812 | $918,013 | ||||
Three Customers [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | |||||||
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | |||||||
Concentration Risk, Percentage | 100.00% | 100.00% | 94.00% | ||||
One Customer [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | |||||||
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | |||||||
Concentration Risk, Percentage | 100.00% | 100.00% | |||||
Two Customers [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | |||||||
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | |||||||
Concentration Risk, Percentage | 79.00% | ||||||
Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | Non US [Member] | |||||||
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | |||||||
Concentration Risk, Percentage | 100.00% | ||||||
Minimum [Member] | |||||||
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | |||||||
Property, Plant and Equipment, Estimated Useful Lives | three | ||||||
Maximum [Member] | |||||||
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | |||||||
Property, Plant and Equipment, Estimated Useful Lives | five |
Note_2_Summary_of_Significant_3
Note 2 - Summary of Significant Accounting Policies (Details) - Antidilutive Securities | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | |
Equity Option [Member] | ||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||||
Antidilutive shares | 476,671 | 409,488 | 445,804 | 491,609 | 45,146,118 | 44,788,104 |
Common Stock Warrants [Member] | ||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||||
Antidilutive shares | 72,322 | 24,107 |
Note_3_Fair_Value_Measurements2
Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value [Line Items] | |||
Total assets | $190 | $324 | $503 |
Preferred stock warrant liabilities | 623,672 | 685,213 | |
Total liabilities | 623,672 | 685,213 | |
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member] | |||
Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value [Line Items] | |||
Money market fund | 190 | 324 | 503 |
Fair Value, Inputs, Level 1 [Member] | |||
Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value [Line Items] | |||
Total assets | 190 | 324 | 503 |
Fair Value, Inputs, Level 3 [Member] | |||
Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value [Line Items] | |||
Preferred stock warrant liabilities | 623,672 | 685,213 | |
Total liabilities | 623,672 | 685,213 | |
Money Market Funds [Member] | |||
Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value [Line Items] | |||
Money market fund | $190 | $324 | $503 |
Note_3_Fair_Value_Measurements3
Note 3 - Fair Value Measurements (Details) - Summary of Changes in Fair Value of Preferred Stock Warrant Liabilities (USD $) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 99 Months Ended | ||||||
Sep. 23, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 30, 2013 | Dec. 31, 2011 | |
Summary of Changes in Fair Value of Preferred Stock Warrant Liabilities [Abstract] | |||||||||||
Fair value | $580,187 | $602,188 | $623,672 | $685,213 | $623,672 | $623,672 | $646,844 | ||||
Change in fair value recorded in other income (expense), net | -7,277 | -22,001 | -21,484 | 50,762 | 11,230 | 61,541 | 156,163 | 622,824 | |||
Extinguishment of warrant liabilities pursuant to the Merger Agreement (reclassified to equity) | ($573,000) | ($572,910) | ($572,910) |
Note_3_Fair_Value_Measurements4
Note 3 - Fair Value Measurements (Details) - Summary of the Valuation Techniques for Fair Value of Preferred Stock Warrant Liabilities (USD $) | 12 Months Ended | |||||||
Dec. 31, 2013 | Dec. 31, 2012 | Sep. 23, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 30, 2013 | Dec. 31, 2011 | Jan. 01, 2013 | |
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||||||||
Preferred stock warrant liabilities | $623,672 | $685,213 | $580,187 | $602,188 | $623,672 | $646,844 | ||
$0.06 | $0.53 | |||||||
76.00% | 83.00% | |||||||
Preferred Stock Warrant Liabilities [Member] | Minimum [Member] | ||||||||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||||||||
$0.04 | $0.04 | |||||||
Preferred Stock Warrant Liabilities [Member] | Maximum [Member] | ||||||||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||||||||
$0.44 | $0.44 | |||||||
Preferred Stock Warrant Liabilities [Member] | ||||||||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||||||||
Preferred stock warrant liabilities | $623,672 | $685,213 | $623,672 | |||||
$0.06 | $0.06 | |||||||
Minimum [Member] | ||||||||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||||||||
$0.04 | ||||||||
70.62% | 74.20% | |||||||
Maximum [Member] | ||||||||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||||||||
$0.44 | ||||||||
84.23% | 91.60% |
Note_4_Accrued_Liabilities_Det
Note 4 - Accrued Liabilities (Details) - Accrued Liabilities (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Accrued Liabilities [Abstract] | |||
Accrued interest | $13,792 | $235,603 | $8,987 |
Accrued professional fees | 125,671 | 15,000 | |
Accrued loan balloon payment | 85,000 | 76,472 | |
Accrued vacation | 73,809 | 81,499 | 54,153 |
Accrued loan restructuring fees | 47,500 | 27,288 | |
Accrued severence pay | 58,846 | ||
Other accruals | 41,766 | 21,444 | 910 |
Total accrued liabilities | $387,538 | $516,152 | $345,644 |
Note_5_Note_Payable_Details
Note 5 - Note Payable (Details) (USD $) | 1 Months Ended | 9 Months Ended | 12 Months Ended | 51 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | |||||||||||||
Sep. 23, 2014 | Apr. 30, 2012 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Feb. 28, 2013 | 31-May-13 | Sep. 30, 2013 | Jul. 31, 2013 | Nov. 30, 2013 | Jan. 31, 2014 | Feb. 28, 2014 | 30-May-13 | Oct. 01, 2014 | Jun. 30, 2014 | Sep. 30, 2014 | Sep. 30, 2014 | Dec. 31, 2008 | Nov. 30, 2010 | Dec. 30, 2013 | |
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 940,189 | 16,680,324 | 16,680,324 | 16,680,324 | 16,680,324 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.53 | $0.06 | $0.06 | |||||||||||||||||||
Debt Instrument, Repayment of Principal and Interest, Number of Installments | 30 | |||||||||||||||||||||
Accrued Loan Balloon Payment | $85,000 | $76,472 | $76,472 | $85,000 | $85,000 | |||||||||||||||||
Notes Payable, Current | 1,471,799 | 1,463,244 | 1,581,390 | 1,463,244 | 1,471,799 | 1,471,799 | 1,462,244 | |||||||||||||||
Accrued Debt Restructuring Costs | 47,500 | 27,288 | 27,288 | 47,500 | 47,500 | |||||||||||||||||
Warrant Term | 5 years | |||||||||||||||||||||
Notes Payable | 1,471,799 | 1,463,244 | 1,463,244 | 1,471,799 | 1,471,799 | |||||||||||||||||
Accrued Liabilities, Current | 387,538 | 516,152 | 345,644 | 516,152 | 387,538 | 387,538 | ||||||||||||||||
April 2012 Warrants [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 73,770 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | 0.61 | |||||||||||||||||||||
December 2008 Warrants [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 196,721 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.61 | |||||||||||||||||||||
November 2010 Warrants [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 163,934 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.61 | |||||||||||||||||||||
Related to Final Payment [Member] | April 2012 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Interest Expense, Debt | 8,528 | 28,785 | 35,345 | 41,127 | 76,472 | |||||||||||||||||
Bridge Loans on or before April 30, 2013 [Member] | April 2012 Term Loan [Member] | Minimum [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Contingent Bridge Loan Proceeds | 500,000 | |||||||||||||||||||||
Bridge Loans on or before April 30, 2013 [Member] | April 2012 Term Loan [Member] | Maximum [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Contingent Bridge Loan Proceeds | 1,500,000 | |||||||||||||||||||||
Bridge Loans on or before September, 2013 [Member] | April 2012 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Contingent Bridge Loan Proceeds | 500,000 | |||||||||||||||||||||
Bridge Loans on or before August 28, 2103 [Member] | April 2012 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Contingent Bridge Loan Proceeds | 500,000 | 500,000 | ||||||||||||||||||||
Bridge Loans on or before August 28, 2103 [Member] | November 2010 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Contingent Bridge Loan Proceeds | 500,000 | |||||||||||||||||||||
Bridge Loans on or before October 28, 2013 [Member] | April 2012 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Contingent Bridge Loan Proceeds | 500,000 | |||||||||||||||||||||
Bridge Loans on or before October 28, 2013 [Member] | November 2010 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Contingent Bridge Loan Proceeds | 500,000 | |||||||||||||||||||||
Bridge Loan on or before December 27, 2013 [Member] | April 2012 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Contingent Bridge Loan Proceeds | 500,000 | |||||||||||||||||||||
Bridge Loans on or before February 25, 2014 [Member] | April 2012 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Contingent Bridge Loan Proceeds | 500,000 | |||||||||||||||||||||
Bridge Loans on or before April 25, 2014 [Member] | April 2012 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Contingent Bridge Loan Proceeds | 500,000 | |||||||||||||||||||||
Amendment to the January 2014 Amendment [Member] | April 2012 Term Loan [Member] | Maximum [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Restructuring Fee | 5,000 | |||||||||||||||||||||
Related to the Restructuring Payment [Member] | April 2012 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Interest Expense, Debt | 20,212 | |||||||||||||||||||||
Bridge Loans on or Before June 30, 2013 [Member] | April 2012 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Contingent Bridge Loan Proceeds | 500,000 | |||||||||||||||||||||
First Tranche [Member] | September 2014 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Proceeds from Issuance of Debt | 2,500,000 | |||||||||||||||||||||
Repayments of Debt | 1,630,925 | |||||||||||||||||||||
April 2012 Term Loan [Member] | Maximum [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Restructuring Fee | 15,000 | 20,000 | 15,000 | |||||||||||||||||||
April 2012 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Face Amount | 2,135,159 | |||||||||||||||||||||
Debt Instrument, Repayment of Principal and Interest, Number of Installments | 30 | |||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.50% | |||||||||||||||||||||
Additional Percentage of Principal Owed Upon Final Payment | 4.00% | |||||||||||||||||||||
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid | 85,000 | |||||||||||||||||||||
Interest Expense, Debt | 27,288 | |||||||||||||||||||||
Accrued Loan Balloon Payment | 85,000 | 76,472 | 41,172 | 76,472 | 85,000 | 85,000 | 76,472 | |||||||||||||||
Debt Instrument, Restructuring Fee | 45,000 | 15,000 | 10,000 | 10,000 | 10,000 | 10,000 | 5,000 | 5,000 | 10,000 | 5,000 | 47,500 | |||||||||||
Contingent Equity Event Proceeds | 10,000,000 | 7,000,000 | ||||||||||||||||||||
Accrued Debt Restructuring Costs | 47,500 | 55,000 | 55,000 | 47,500 | 47,500 | 27,288 | ||||||||||||||||
Notes Payable | 1,471,798 | 1,606,612 | 1,471,798 | |||||||||||||||||||
Accrued Liabilities, Current | 27,288 | 27,288 | ||||||||||||||||||||
September 2014 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Face Amount | 5,000,000 | 5,000,000 | 5,000,000 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 471,698 | 471,698 | 471,698 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.53 | $0.53 | $0.53 | |||||||||||||||||||
Warrant Term | 10 years | 10 years | ||||||||||||||||||||
December 2008 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Face Amount | 1,500,000 | |||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.50% | |||||||||||||||||||||
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid | 75,000 | |||||||||||||||||||||
Debt Instrument, Term | 27 months | |||||||||||||||||||||
Debt Instrument, Covenant Terms, Additional Equity Financing | 6,000,000 | |||||||||||||||||||||
November 2010 Term Loan [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Face Amount | 2,000,000 | |||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.50% | |||||||||||||||||||||
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid | 80,000 | |||||||||||||||||||||
Debt Instrument, Term | 36 months | |||||||||||||||||||||
Notes Payable | $0 | $0 | $0 | |||||||||||||||||||
Minimum [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.04 | $0.04 | ||||||||||||||||||||
Maximum [Member] | ||||||||||||||||||||||
Note 5 - Note Payable (Details) [Line Items] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.44 | $0.44 |
Note_5_Note_Payable_Details_Su
Note 5 - Note Payable (Details) - Summary of Note Payble (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 30, 2013 | Dec. 31, 2012 |
Summary of Note Payble [Abstract] | ||||
$1,618,091 | ||||
Less: Amount representing interest | -146,292 | -125,398 | ||
Present value of obligations | 1,471,799 | 1,471,798 | ||
1,471,799 | 1,463,244 | |||
Less: Notes payable, current portion | 1,471,799 | 1,463,244 | 1,462,244 | 1,581,390 |
Notes payable, noncurrent portion | $0 |
Note_6_Related_Party_Convertib1
Note 6 - Related Party Convertible Bridge Notes (Details) (USD $) | 1 Months Ended | 4 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 9 Months Ended | 0 Months Ended | 1 Months Ended | 5 Months Ended | 2 Months Ended | 4 Months Ended | 25 Months Ended | 12 Months Ended | ||||||||||||||
Apr. 30, 2012 | Jul. 30, 2012 | Nov. 30, 2012 | Feb. 13, 2013 | Aug. 31, 2013 | Jun. 30, 2013 | Apr. 30, 2013 | Sep. 30, 2014 | Sep. 27, 2013 | Nov. 12, 2013 | Dec. 27, 2013 | Mar. 05, 2014 | Jun. 30, 2014 | Sep. 30, 2011 | Dec. 31, 2011 | Apr. 30, 2012 | Apr. 30, 2014 | Dec. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Aug. 07, 2013 | Jul. 07, 2014 | 31-May-11 | Jun. 30, 2011 | Nov. 30, 2011 | Jan. 31, 2012 | Mar. 31, 2012 | |
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Interest Payable, Current | $13,792 | $235,603 | $8,987 | ||||||||||||||||||||||||
Series B Preferred Stock [Member] | Related Party Convertible Bridge Notes [Member] | Aggregate of the May 2011 Notes, Including June and September 2011 Amendments [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $0.05 | $0.05 | |||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 63,769,863 | ||||||||||||||||||||||||||
Series B Preferred Stock [Member] | Related Party Convertible Bridge Notes [Member] | Aggregate of the November 2011 Notes, Including January and March Amendments [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $0.05 | $0.05 | |||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 30,429,485 | ||||||||||||||||||||||||||
Series B Preferred Stock [Member] | Related Party Convertible Bridge Notes [Member] | May 2011 Notes and November 2011 Notes [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | 4,709,968 | ||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 94,199,348 | ||||||||||||||||||||||||||
Series B Preferred Stock [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 171,199,348 | ||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $0.05 | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | November 2012 Convertible Promissory Note [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Face Amount | 1,000,000 | ||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||||||||||||||||||
Minimum Gross Proceeds from Issuance of Common or Preferred Stock | 5,000,000 | ||||||||||||||||||||||||||
Convertible Debt | 0 | 1,000,000 | 1,000,000 | 1,000,000 | |||||||||||||||||||||||
Interest Payable, Current | 88,986 | 88,986 | 8,987 | ||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | 2013 Note Purchase Agreement [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||||||||||||||||||
Minimum Gross Proceeds from Issuance of Common or Preferred Stock | 5,000,000 | ||||||||||||||||||||||||||
Convertible Debt | 0 | 2,500,000 | 2,500,000 | ||||||||||||||||||||||||
Interest Payable, Current | 130,466 | 130,466 | |||||||||||||||||||||||||
Maximum Authorized Convertible Promissory Notes Issuable | 1,500,000 | 2,000,000 | 2,500,000 | ||||||||||||||||||||||||
Proceeds from Convertible Debt | 1,000,000 | 500,000 | 500,000 | 500,000 | |||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price as a Percentage of Purchase Price | 80.00% | ||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $0.05 | ||||||||||||||||||||||||||
Debt Instrument, Redemption Price, Percentage of Principal Amount and Accrued and Unpaid Interest Redeemed | 300.00% | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | September 2013 Note Purchase Agreement [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||||||||||||||||||
Minimum Gross Proceeds from Issuance of Common or Preferred Stock | 5,000,000 | ||||||||||||||||||||||||||
Convertible Debt | 0 | 500,000 | |||||||||||||||||||||||||
Interest Payable, Current | 10,411 | ||||||||||||||||||||||||||
Maximum Authorized Convertible Promissory Notes Issuable | 500,000 | ||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price as a Percentage of Purchase Price | 70.00% | ||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $0.05 | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | November 2013 Note Purchase Agreement [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||||||||||||||||||
Minimum Gross Proceeds from Issuance of Common or Preferred Stock | 5,000,000 | ||||||||||||||||||||||||||
Convertible Debt | 0 | 500,000 | |||||||||||||||||||||||||
Interest Payable, Current | 5,370 | ||||||||||||||||||||||||||
Maximum Authorized Convertible Promissory Notes Issuable | 500,000 | ||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price as a Percentage of Purchase Price | 70.00% | ||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $0.05 | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | December 2013 Note Purchase Agreement [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.00% | ||||||||||||||||||||||||||
Minimum Gross Proceeds from Issuance of Common or Preferred Stock | 5,000,000 | ||||||||||||||||||||||||||
Convertible Debt | 0 | 375,000 | 375,000 | ||||||||||||||||||||||||
Interest Payable, Current | 370 | ||||||||||||||||||||||||||
Maximum Authorized Convertible Promissory Notes Issuable | 375,000 | ||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price as a Percentage of Purchase Price | 70.00% | ||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $0.05 | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | March 2014 Note Purchase Agreement [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.00% | ||||||||||||||||||||||||||
Maximum Authorized Convertible Promissory Notes Issuable | 1,250,000 | ||||||||||||||||||||||||||
Proceeds from Convertible Debt | 200,000 | 1,050,000 | |||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | July 2013 Note Purchase Agreement [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.00% | ||||||||||||||||||||||||||
Maximum Authorized Convertible Promissory Notes Issuable | 250,000 | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | May 2011 Convertible Promissory Note [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Face Amount | 1,000,000 | ||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||||||||||||||||||
Warrant to Purchase Series B Convertible Preferred Stock, Coverage Amount, Percentage | 10.00% | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | June 2011 Amendment of May 2011 Convertible Promissory Note [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Face Amount | 1,000,000 | ||||||||||||||||||||||||||
Warrant to Purchase Series B Convertible Preferred Stock, Coverage Amount, Percentage | 20.00% | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | September 2011 Amendment of May 2011 Convertible Promissory Note [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Face Amount | 1,000,000 | ||||||||||||||||||||||||||
Warrant to Purchase Series B Convertible Preferred Stock, Coverage Amount, Percentage | 20.00% | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | Aggregate of the May 2011 Notes, Including June and September 2011 Amendments [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Face Amount | 3,000,000 | ||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | 3,188,494 | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | November 2011 Closing of November 2011 Note [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Face Amount | 250,000 | ||||||||||||||||||||||||||
Warrant to Purchase Series B Convertible Preferred Stock, Coverage Amount, Percentage | 20.00% | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | December 2011 Closing of November 2011 Note [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Face Amount | 250,000 | ||||||||||||||||||||||||||
Warrant to Purchase Series B Convertible Preferred Stock, Coverage Amount, Percentage | 20.00% | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | November 2011 Convertible Promissory Note [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Face Amount | 500,000 | ||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | January 2012 Amendment to November 2011 Note [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Maximum Authorized Convertible Promissory Notes Issuable | 500,000 | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | March 2012 Amendment to November 2011 Note [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Maximum Authorized Convertible Promissory Notes Issuable | 500,000 | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | Three Separate Closings of the January/March 2012 Amendments to November 2011 Note [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Face Amount | 1,000,000 | 1,000,000 | |||||||||||||||||||||||||
Warrant to Purchase Series B Convertible Preferred Stock, Coverage Amount, Percentage | 20.00% | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | Aggregate of the November 2011 Notes, Including January and March Amendments [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Face Amount | 1,500,000 | 1,500,000 | |||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | 1,521,474 | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | 2013 Note Purchase Agreement [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Maximum Authorized Convertible Promissory Notes Issuable | 2,000,000 | ||||||||||||||||||||||||||
Proceeds from Convertible Debt | $500,000 | ||||||||||||||||||||||||||
Related Party Convertible Bridge Notes [Member] | |||||||||||||||||||||||||||
Note 6 - Related Party Convertible Bridge Notes (Details) [Line Items] | |||||||||||||||||||||||||||
Debt Instrument, Redemption Price, Percentage of Principal Amount and Accrued and Unpaid Interest Redeemed | 300.00% |
Note_7_Commitments_and_Conting2
Note 7 - Commitments and Contingencies (Details) (USD $) | 9 Months Ended | 12 Months Ended | 15 Months Ended | 99 Months Ended | |
Sep. 30, 2014 | Sep. 30, 2013 | Dec. 30, 2013 | Sep. 30, 2012 | Dec. 30, 2013 | |
Commitments and Contingencies Disclosure [Abstract] | |||||
Operating Leases, Rent Expense | $128,359 | $128,359 | $173,896 | $166,398 | $744,602 |
Note_7_Commitments_and_Conting3
Note 7 - Commitments and Contingencies (Details) - Future Minimum Lease Payments (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
Future Minimum Lease Payments [Abstract] | ||
2014 | $46,428 | $184,002 |
2015 | 30,952 | 30,952 |
Total minimum lease payments | $77,380 | $214,954 |
Note_8_Common_Stock_Details
Note 8 - Common Stock (Details) (USD $) | 1 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | |||||
Sep. 23, 2014 | Jun. 30, 2009 | Sep. 30, 2014 | Dec. 30, 2013 | Dec. 31, 2007 | 9-May-14 | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Apr. 30, 2012 | |
Note 8 - Common Stock (Details) [Line Items] | ||||||||||
Conversion of Stock, Shares Issued | 3,743,282 | |||||||||
Conversion of Stock, Exchange Ratio | 0.0080497 | |||||||||
Debt Conversion, Original Debt, Amount (in Dollars) | $1,545,678 | $1,545,678 | $501,873 | |||||||
Stock Issued During Period, Shares, New Issues | 11,305,567 | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 940,189 | 16,680,324 | 16,680,324 | 16,680,324 | ||||||
Proceeds from Issuance of Private Placement (in Dollars) | 6,000,000 | 4,204,220 | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.53 | $0.06 | ||||||||
Warrant Term | 5 years | |||||||||
Common Stock, Shares Authorized | 612,000,000 | 612,000,000 | 612,000,000 | |||||||
Dividends (in Dollars) | 0 | 0 | ||||||||
Shares Subject to Repurchase, Lapse Period | 4 years | |||||||||
Treasury Stock, Shares, Acquired | 565,833 | |||||||||
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased | 666 | 194,441 | ||||||||
Accrued Interest [Member] | GBS [Member] | ||||||||||
Note 8 - Common Stock (Details) [Line Items] | ||||||||||
Debt Conversion, Original Debt, Amount (in Dollars) | 211,000 | |||||||||
September 2014 Term Loan [Member] | ||||||||||
Note 8 - Common Stock (Details) [Line Items] | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 471,698 | 471,698 | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.53 | $0.53 | ||||||||
Warrant Term | 10 years | 10 years | ||||||||
Warrants and Rights Outstanding (in Dollars) | 622,170 | 622,170 | ||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | |||||||||
Fair Value Assumptions, Expected Volatility Rate | 77.00% | |||||||||
Fair Value Assumptions, Risk Free Interest Rate | 2.50% | |||||||||
GBS [Member] | ||||||||||
Note 8 - Common Stock (Details) [Line Items] | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants as Percentage of Outstanding Shares of Common Stock | 5.00% | |||||||||
Debt Conversion, Original Debt, Amount (in Dollars) | $1,750,000 | |||||||||
Stock Issued During Period, Shares, Other | 943,596 |
Note_9_Convertible_Preferred_S2
Note 9 - Convertible Preferred Stock (Details) (USD $) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 99 Months Ended | 12 Months Ended | 99 Months Ended | 1 Months Ended | 13 Months Ended | 1 Months Ended | |||||||||||||||||||
Sep. 23, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 30, 2013 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2007 | Dec. 30, 2012 | Dec. 30, 2013 | Dec. 31, 2008 | Apr. 30, 2009 | Nov. 30, 2010 | Nov. 30, 2011 | Apr. 30, 2012 | Aug. 31, 2007 | 31-May-11 | Jun. 30, 2011 | Sep. 30, 2011 | Nov. 30, 2011 | Dec. 31, 2011 | Jan. 31, 2012 | Feb. 28, 2012 | Feb. 29, 2012 | |
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 940,189 | 16,680,324 | 16,680,324 | 16,680,324 | 16,680,324 | 16,680,324 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.53 | $0.06 | $0.06 | ||||||||||||||||||||||||||
Warrant Term | 5 years | ||||||||||||||||||||||||||||
Warrant Liabilities Noncurrent | $580,187 | $602,188 | $623,672 | $685,213 | $623,672 | $623,672 | $623,672 | $646,844 | |||||||||||||||||||||
Fair Value Adjustment of Warrants | 7,277 | 22,001 | 21,484 | -50,762 | -11,230 | -61,541 | -156,163 | -622,824 | |||||||||||||||||||||
Other Nonoperating Income (Expense) [Member] | Series A Preferred Stock [Member] | December 2008 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 9,639 | 6,885 | -4,131 | 9,797 | -2,361 | ||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Member] | Series A Preferred Stock [Member] | April 2009 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 11,803 | -984 | |||||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Member] | Series A Preferred Stock [Member] | November 2010 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 2,295 | -1,311 | |||||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Member] | Series A Preferred Stock [Member] | April 2012 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 3,025 | 885 | |||||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Member] | Series A Preferred Stock [Member] | August 2007 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 68,393 | 266,293 | 23,143 | ||||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | April 2012 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 9,404 | 2,351 | 4,702 | 21,159 | 25,861 | ||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | May 2011 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 2,000 | 2,000 | |||||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | June 2011 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 4,000 | 4,000 | |||||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | September 2011 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 0 | 4,000 | 12,000 | 46,000 | 60,000 | ||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | November 2011 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 1,000 | 1,000 | 2,000 | 11,000 | 14,000 | ||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | December 2011 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 1,000 | 0 | 2,000 | 11,000 | 13,000 | ||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | January 2012 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 3,642 | 910 | 1,821 | 7,283 | 9,104 | ||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | February 2012 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 2,954 | 740 | 1,477 | 6,646 | 8,123 | ||||||||||||||||||||||||
Series A Preferred Stock [Member] | December 2008 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 196,721 | 196,721 | 196,721 | 196,721 | 196,721 | 196,721 | 196,721 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.61 | $0.61 | $0.61 | $0.61 | $0.61 | $0.61 | $0.61 | ||||||||||||||||||||||
Warrant Term | 10 years | ||||||||||||||||||||||||||||
Warrant Liabilities Noncurrent | 44,066 | 50,951 | 44,066 | 44,066 | 53,863 | 44,066 | 53,863 | ||||||||||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 79.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 2.70% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Term | 10 years | ||||||||||||||||||||||||||||
Series A Preferred Stock [Member] | April 2009 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 245,900 | 245,900 | 245,900 | 245,900 | 245,900 | 245,900 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.61 | $0.61 | $0.61 | $0.61 | $0.61 | $0.61 | |||||||||||||||||||||||
Warrant Term | 10 years | ||||||||||||||||||||||||||||
Warrant Liabilities Noncurrent | 58,278 | 66,885 | 58,278 | 58,278 | 58,278 | 70,082 | |||||||||||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 79.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 2.80% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Term | 10 years | ||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 8,607 | -5,900 | 11,804 | ||||||||||||||||||||||||||
Series A Preferred Stock [Member] | November 2010 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 163,934 | 163,934 | 163,934 | 163,934 | 163,934 | 163,934 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.61 | $0.61 | $0.61 | $0.61 | $0.61 | $0.61 | |||||||||||||||||||||||
Warrant Term | 10 years | ||||||||||||||||||||||||||||
Warrant Liabilities Noncurrent | 46,393 | 48,524 | 46,393 | 46,393 | 46,393 | 46,721 | |||||||||||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | |||||||||||||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 79.00% | 79.00% | |||||||||||||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 2.90% | 2.90% | |||||||||||||||||||||||||||
Fair Value Assumptions, Expected Term | 10 years | 10 years | |||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 2,131 | -6,485 | 328 | ||||||||||||||||||||||||||
Series A Preferred Stock [Member] | April 2012 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 73,770 | 73,770 | 73,770 | 73,770 | 73,770 | 73,770 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.61 | $0.61 | $0.61 | $0.61 | $0.61 | $0.61 | |||||||||||||||||||||||
Warrant Term | 10 years | ||||||||||||||||||||||||||||
Warrant Liabilities Noncurrent | 24,934 | 26,852 | 24,934 | 24,934 | 24,934 | 27,443 | |||||||||||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 92.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 1.98% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Term | 10 years | ||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 1,918 | 591 | 2,509 | ||||||||||||||||||||||||||
Series A Preferred Stock [Member] | August 2007 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.61 | ||||||||||||||||||||||||||||
Warrant Liabilities Noncurrent | 357,829 | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 46.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 3.90% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Term | 1 year 146 days | ||||||||||||||||||||||||||||
Series A Preferred Stock [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Preferred Stock, Dividend Rate, Per-Dollar-Amount (in Dollars per share) | $0.05 | $0.05 | |||||||||||||||||||||||||||
Preferred Stock, Dividends Per Share, Declared (in Dollars per share) | $0 | $0 | |||||||||||||||||||||||||||
Preferred Stock, Conversion Price (in Dollars per share) | $0.05 | $0.05 | $0.05 | $0.05 | |||||||||||||||||||||||||
Convertible Preferred Stock, Terms of Conversion, Minimum Aggregate Gross Proceeds Required for Automatic Conversion | 30,000,000 | 30,000,000 | |||||||||||||||||||||||||||
Preferred Stock, Shares Authorized (in Shares) | 24,543,626 | 24,543,626 | 24,543,626 | 24,543,626 | 24,543,626 | 24,543,626 | |||||||||||||||||||||||
Series B Preferred Stock [Member] | April 2012 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 2,351,019 | 2,351,019 | 2,351,019 | 2,351,019 | 2,351,019 | 2,351,019 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | |||||||||||||||||||||||
Warrant Term | 10 years | ||||||||||||||||||||||||||||
Warrant Liabilities Noncurrent | 72,882 | 77,584 | 72,882 | 72,882 | 72,882 | 98,743 | |||||||||||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 84.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 2.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Term | 10 years | ||||||||||||||||||||||||||||
Series B Preferred Stock [Member] | May 2011 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | |||||||||||||||||||||||
Warrant Term | 10 years | ||||||||||||||||||||||||||||
Warrant Liabilities Noncurrent | 54,000 | 60,000 | 54,000 | 54,000 | 54,000 | 84,000 | |||||||||||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 84.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 3.20% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Term | 10 years | ||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 6,000 | 23,000 | 30,000 | ||||||||||||||||||||||||||
Series B Preferred Stock [Member] | June 2011 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 4,000,000 | 4,000,000 | 4,000,000 | 4,000,000 | 4,000,000 | 4,000,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | |||||||||||||||||||||||
Warrant Term | 10 years | ||||||||||||||||||||||||||||
Warrant Liabilities Noncurrent | 108,000 | 120,000 | 108,000 | 108,000 | 108,000 | 168,000 | |||||||||||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 84.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 3.20% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Term | 10 years | ||||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | 12,000 | 46,000 | 60,000 | ||||||||||||||||||||||||||
Series B Preferred Stock [Member] | September 2011 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 4,000,000 | 4,000,000 | 4,000,000 | 4,000,000 | 4,000,000 | 4,000,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | |||||||||||||||||||||||
Warrant Term | 10 years | ||||||||||||||||||||||||||||
Warrant Liabilities Noncurrent | 108,000 | 120,000 | 108,000 | 108,000 | 108,000 | 168,000 | |||||||||||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 84.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 2.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Term | 10 years | ||||||||||||||||||||||||||||
Series B Preferred Stock [Member] | November 2011 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 0.05 | $0.05 | ||||||||||||||||||||||
Warrant Term | 10 years | ||||||||||||||||||||||||||||
Warrant Liabilities Noncurrent | 28,000 | 30,000 | 28,000 | 28,000 | 28,000 | 42,000 | 42,000 | ||||||||||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 84.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 2.10% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Term | 10 years | ||||||||||||||||||||||||||||
Series B Preferred Stock [Member] | December 2011 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | |||||||||||||||||||||||
Warrant Term | 10 years | ||||||||||||||||||||||||||||
Warrant Liabilities Noncurrent | 28,000 | 30,000 | 28,000 | 28,000 | 28,000 | 41,000 | |||||||||||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 84.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 1.80% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Term | 10 years | ||||||||||||||||||||||||||||
Series B Preferred Stock [Member] | January 2012 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 910,445 | 910,445 | 910,445 | 910,445 | 910,445 | 910,445 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | |||||||||||||||||||||||
Warrant Term | 10 years | ||||||||||||||||||||||||||||
Warrant Liabilities Noncurrent | 28,224 | 30,045 | 28,224 | 28,224 | 28,224 | 37,328 | |||||||||||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 84.00% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 1.80% | ||||||||||||||||||||||||||||
Fair Value Assumptions, Expected Term | 10 years | ||||||||||||||||||||||||||||
Series B Preferred Stock [Member] | February 2012 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 738,535 | 738,535 | 738,535 | 738,535 | 738,535 | 738,535 | 738,535 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||||||||||
Warrant Term | 10 years | 10 years | |||||||||||||||||||||||||||
Warrant Liabilities Noncurrent | 22,895 | 24,372 | 22,895 | 22,895 | 22,895 | 31,018 | 31,018 | ||||||||||||||||||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | |||||||||||||||||||||||||||
Fair Value Assumptions, Expected Volatility Rate | 84.00% | 84.00% | |||||||||||||||||||||||||||
Fair Value Assumptions, Risk Free Interest Rate | 1.98% | 1.98% | |||||||||||||||||||||||||||
Fair Value Assumptions, Expected Term | 10 years | 10 years | |||||||||||||||||||||||||||
Series B Preferred Stock [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Preferred Stock, Dividend Rate, Per-Dollar-Amount (in Dollars per share) | $0.00 | $0.00 | |||||||||||||||||||||||||||
Preferred Stock, Dividends Per Share, Declared (in Dollars per share) | $0 | $0 | |||||||||||||||||||||||||||
Preferred Stock, Conversion Price (in Dollars per share) | $0.05 | $0.05 | $0.05 | $0.05 | |||||||||||||||||||||||||
Convertible Preferred Stock, Terms of Conversion, Minimum Aggregate Gross Proceeds Required for Automatic Conversion | $30,000,000 | $30,000,000 | |||||||||||||||||||||||||||
Preferred Stock, Shares Authorized (in Shares) | 227,000,000 | 227,000,000 | 227,000,000 | 227,000,000 | 227,000,000 | 227,000,000 | |||||||||||||||||||||||
December 2008 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 196,721 | 196,721 | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.61 | $0.61 | |||||||||||||||||||||||||||
November 2010 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 163,934 | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.61 | ||||||||||||||||||||||||||||
April 2012 Warrants [Member] | |||||||||||||||||||||||||||||
Note 9 - Convertible Preferred Stock (Details) [Line Items] | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 73,770 | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.61 |
Note_9_Convertible_Preferred_S3
Note 9 - Convertible Preferred Stock (Details) - Convertible Preferred Stock Warrants Outstanding (USD $) | 12 Months Ended | |||||||||||||||||
Dec. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Sep. 23, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2011 | Dec. 31, 2008 | Apr. 30, 2009 | Nov. 30, 2010 | Apr. 30, 2012 | 31-May-11 | Jun. 30, 2011 | Sep. 30, 2011 | Nov. 30, 2011 | Jan. 31, 2012 | Feb. 29, 2012 | Feb. 28, 2012 | |
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise Price | $0.06 | $0.53 | ||||||||||||||||
Number of Shares Outstanding under Warrants | 16,680,324 | 16,680,324 | 16,680,324 | 940,189 | ||||||||||||||
Fair Value | $623,672 | $623,672 | $685,213 | $580,187 | $602,188 | $646,844 | ||||||||||||
Series A Preferred Stock [Member] | December 2008 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration Date | 2-Dec-18 | 2-Dec-18 | 2-Dec-18 | |||||||||||||||
Exercise Price | $0.61 | $0.61 | $0.61 | $0.61 | ||||||||||||||
Number of Shares Outstanding under Warrants | 196,721 | 196,721 | 196,721 | 196,721 | ||||||||||||||
Fair Value | 44,066 | 44,066 | 50,951 | 53,863 | ||||||||||||||
Series A Preferred Stock [Member] | April 2009 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration Date | 2-Apr-19 | 2-Apr-19 | 2-Apr-19 | |||||||||||||||
Exercise Price | $0.61 | $0.61 | $0.61 | $0.61 | ||||||||||||||
Number of Shares Outstanding under Warrants | 245,900 | 245,900 | 245,900 | 245,900 | ||||||||||||||
Fair Value | 58,278 | 58,278 | 66,885 | 70,082 | ||||||||||||||
Series A Preferred Stock [Member] | November 2010 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration Date | 19-Nov-20 | 19-Nov-20 | 19-Nov-20 | |||||||||||||||
Exercise Price | $0.61 | $0.61 | $0.61 | $0.61 | ||||||||||||||
Number of Shares Outstanding under Warrants | 163,934 | 163,934 | 163,934 | 163,934 | ||||||||||||||
Fair Value | 46,393 | 46,393 | 48,524 | 46,721 | ||||||||||||||
Series A Preferred Stock [Member] | April 2012 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration Date | 19-Apr-22 | 19-Apr-22 | 19-Apr-22 | |||||||||||||||
Exercise Price | $0.61 | $0.61 | $0.61 | $0.61 | ||||||||||||||
Number of Shares Outstanding under Warrants | 73,770 | 73,770 | 73,770 | 73,770 | ||||||||||||||
Fair Value | 24,934 | 24,934 | 26,852 | 27,443 | ||||||||||||||
Series B Preferred Stock [Member] | May 2011 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration Date | 6-May-21 | 6-May-21 | 6-May-21 | |||||||||||||||
Exercise Price | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||
Number of Shares Outstanding under Warrants | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | ||||||||||||||
Fair Value | 54,000 | 54,000 | 60,000 | 84,000 | ||||||||||||||
Series B Preferred Stock [Member] | June 2011 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration Date | 30-Jun-21 | 30-Jun-21 | 30-Jun-21 | |||||||||||||||
Exercise Price | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||
Number of Shares Outstanding under Warrants | 4,000,000 | 4,000,000 | 4,000,000 | 4,000,000 | ||||||||||||||
Fair Value | 108,000 | 108,000 | 120,000 | 168,000 | ||||||||||||||
Series B Preferred Stock [Member] | September 2011 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration Date | 9-Sep-21 | 9-Sep-21 | 9-Sep-21 | |||||||||||||||
Exercise Price | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||
Number of Shares Outstanding under Warrants | 4,000,000 | 4,000,000 | 4,000,000 | 4,000,000 | ||||||||||||||
Fair Value | 108,000 | 108,000 | 120,000 | 168,000 | ||||||||||||||
Series B Preferred Stock [Member] | November 2011 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration Date | 30-Nov-21 | 30-Nov-21 | 30-Nov-21 | |||||||||||||||
Exercise Price | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||
Number of Shares Outstanding under Warrants | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | ||||||||||||||
Fair Value | 28,000 | 28,000 | 30,000 | 42,000 | ||||||||||||||
Series B Preferred Stock [Member] | December 2011 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration Date | 19-Dec-21 | 19-Dec-21 | 19-Dec-21 | |||||||||||||||
Exercise Price | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||
Number of Shares Outstanding under Warrants | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | ||||||||||||||
Fair Value | 28,000 | 28,000 | 30,000 | 41,000 | ||||||||||||||
Series B Preferred Stock [Member] | January 2012 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration Date | 31-Jan-22 | 31-Jan-22 | 31-Jan-22 | |||||||||||||||
Exercise Price | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||
Number of Shares Outstanding under Warrants | 910,445 | 910,445 | 910,445 | 910,445 | ||||||||||||||
Fair Value | 28,224 | 28,224 | 30,045 | 37,328 | ||||||||||||||
Series B Preferred Stock [Member] | February 2012 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration Date | 28-Feb-22 | 28-Feb-22 | 28-Feb-22 | |||||||||||||||
Exercise Price | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | |||||||||||||
Number of Shares Outstanding under Warrants | 738,535 | 738,535 | 738,535 | 738,535 | 738,535 | |||||||||||||
Fair Value | 22,895 | 22,895 | 24,372 | 31,018 | 31,018 | |||||||||||||
Series B Preferred Stock [Member] | April 2012 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration Date | 16-Apr-22 | 16-Apr-22 | 16-Apr-22 | |||||||||||||||
Exercise Price | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||
Number of Shares Outstanding under Warrants | 2,351,019 | 2,351,019 | 2,351,019 | 2,351,019 | ||||||||||||||
Fair Value | $72,882 | $72,882 | $77,584 | $98,743 | ||||||||||||||
December 2008 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise Price | $0.61 | |||||||||||||||||
Number of Shares Outstanding under Warrants | 196,721 | |||||||||||||||||
November 2010 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise Price | $0.61 | |||||||||||||||||
Number of Shares Outstanding under Warrants | 163,934 | |||||||||||||||||
April 2012 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise Price | $0.61 | |||||||||||||||||
Number of Shares Outstanding under Warrants | 73,770 |
Note_10_Summary_of_Stock_Optio2
Note 10 - Summary of Stock Options (Details) (USD $) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 87 Months Ended | 1 Months Ended | 12 Months Ended | 99 Months Ended | 12 Months Ended | 15 Months Ended | ||||||||||
Sep. 23, 2014 | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | Feb. 28, 2006 | Dec. 30, 2012 | Dec. 30, 2013 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2007 | Dec. 31, 2006 | Sep. 21, 2005 | Jun. 30, 2014 | |
Note 10 - Summary of Stock Options (Details) [Line Items] | ||||||||||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | 568,227,020 | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share) | $1.02 | $1.02 | $2.94 | |||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 9 years 244 days | 8 years 292 days | ||||||||||||||||||
Conversion of Stock, Exchange Ratio | 0.0080497 | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | 1,901,476 | |||||||||||||||||||
Allocated Share-based Compensation Expense | $113,346 | $16,284 | $143,643 | $66,001 | ||||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | 567,000 | 567,000 | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | 1,700,000 | 1,700,000 | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares) | 0 | 0 | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | ||||||||||||||||||
Dividends | 0 | 0 | ||||||||||||||||||
Employee Stock Option [Member] | ||||||||||||||||||||
Note 10 - Summary of Stock Options (Details) [Line Items] | ||||||||||||||||||||
Allocated Share-based Compensation Expense | 113,345 | 16,284 | 143,643 | 66,001 | ||||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 3 years 94 days | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||||||||||||
Incentive Stock Options [Member] | Minimum [Member] | The 2006 Stock Option Plan [Member] | ||||||||||||||||||||
Note 10 - Summary of Stock Options (Details) [Line Items] | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 100.00% | |||||||||||||||||||
Non Qualified Stock Options [Member] | Minimum [Member] | The 2006 Stock Option Plan [Member] | ||||||||||||||||||||
Note 10 - Summary of Stock Options (Details) [Line Items] | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 85.00% | |||||||||||||||||||
Holdings Greater than 10% of Shares Outstanding [Member] | The 2006 Stock Option Plan [Member] | ||||||||||||||||||||
Note 10 - Summary of Stock Options (Details) [Line Items] | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||||||||||||
Holdings Greater than 10% of Shares Outstanding [Member] | The 2013 Plan [Member] | ||||||||||||||||||||
Note 10 - Summary of Stock Options (Details) [Line Items] | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||||||||||||
Employees [Member] | ||||||||||||||||||||
Note 10 - Summary of Stock Options (Details) [Line Items] | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | 1,901,476 | 1,901,476 | 11,788,890 | 38,996,262 | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $0.32 | $0.32 | $0.01 | $0.03 | ||||||||||||||||
Allocated Share-based Compensation Expense | 94,021 | 102,511 | 282,032 | |||||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | 129,937 | 129,937 | ||||||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 1 year 270 days | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | 322 | 2,322 | 322 | |||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | 139,914 | 54,199 | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | 0 | 0 | ||||||||||||||||||
Nonemployees [Member] | ||||||||||||||||||||
Note 10 - Summary of Stock Options (Details) [Line Items] | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | 85,000 | 4,698,259 | ||||||||||||||||||
Allocated Share-based Compensation Expense | ($6,593) | $6,686 | $9,183 | |||||||||||||||||
2005 Plan [Member] | ||||||||||||||||||||
Note 10 - Summary of Stock Options (Details) [Line Items] | ||||||||||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | 22,095 | 22,095 | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares) | 22,095 | 22,095 | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share) | $12.83 | $12.83 | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 8 years 292 days | |||||||||||||||||||
The 2006 Stock Option Plan [Member] | ||||||||||||||||||||
Note 10 - Summary of Stock Options (Details) [Line Items] | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares) | 324,820 | 324,820 | 45,146,118 | 44,788,104 | 44,788,104 | 2,960,486 | 2,763,486 | 2,178,029 | 986,000 | 913,500 | 51,500 | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share) | $1.55 | $1.55 | $0.01 | 0.01 | 0.01 | $0.07 | $0.06 | $0.06 | $0.06 | $0.06 | $0.00 | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 8 years 21 days | 8 years 292 days | 9 years 270 days | 7 years 255 days | 8 years 146 days | 9 years | 8 years 317 days | 9 years 299 days | 9 years 350 days | |||||||||||
Conversion of Stock, Exchange Ratio | 0.0080497 | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 10 years | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum | 10.00% | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 110.00% | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares) | 1,000,000 | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | 11,873,890 | 43,694,521 | 345,000 | 771,412 | 1,892,029 | 72,500 | 867,000 | 51,500 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares) | 1,866,903 | 9,000 | 173,455 | 322,395 | ||||||||||||||||
The 2013 Plan [Member] | ||||||||||||||||||||
Note 10 - Summary of Stock Options (Details) [Line Items] | ||||||||||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | 839,148 | 839,148 | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares) | 1,947,619 | 1,947,619 | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share) | $0.80 | $0.80 | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 10 years | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum | 10.00% | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 110.00% | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares) | 3,111,587 | 3,111,587 | 113,826 |
Note_10_Summary_of_Stock_Optio3
Note 10 - Summary of Stock Options (Details) - Summary of Option Activity Under All Plans (USD $) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2014 | Dec. 31, 2013 | |
Summary of Option Activity Under All Plans [Abstract] | ||
Shares available for grant | 2,294,534 | 363,413 |
Number of shares | $1.02 | $2.94 |
Weighted average exercise price | 9 years 244 days | 8 years 292 days |
Options granted | 1,901,476 | |
Options granted | $0.60 | |
Options assumed from PLC | 68,238 | |
Options assumed from PLC | $10.24 | |
Options canceled | -38,593 | |
Options canceled | $1.75 |
Note_10_Summary_of_Stock_Optio4
Note 10 - Summary of Stock Options (Details) - Summary of Options Outstanding and Exercisable (USD $) | 9 Months Ended | |
Sep. 30, 2014 | Dec. 31, 2013 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Options Outstanding, Number (in Shares) | 2,294,535 | 45,146,118 |
Options Outstanding, Weighted-Average Exercise Price | $1.02 | |
Options Outstanding, Weighted Average Contractual Life (Years) | 9 years 244 days | |
Options Exercisable, Number (in Shares) | 413,059 | 15,025,985 |
Options Exercisable, Weighted-Average Exercise Price | $2.94 | $0.02 |
Range One [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Range of Exercise Price | $0.12 | |
Range of Exercise Price, Upper | $0.12 | |
Options Outstanding, Number (in Shares) | 320 | 40,000 |
Options Outstanding, Weighted-Average Exercise Price | $0.12 | $0.00 |
Options Outstanding, Weighted Average Contractual Life (Years) | 2 years 76 days | |
Options Exercisable, Number (in Shares) | 320 | 40,000 |
Options Exercisable, Weighted-Average Exercise Price | $0.12 | $0.00 |
Range Two [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Range of Exercise Price | $0.60 | |
Range of Exercise Price, Upper | $0.60 | |
Options Outstanding, Number (in Shares) | 1,901,476 | 980,250 |
Options Outstanding, Weighted-Average Exercise Price | $0.60 | $0.06 |
Options Outstanding, Weighted Average Contractual Life (Years) | 10 years | |
Options Exercisable, Number (in Shares) | 20,000 | 921,104 |
Options Exercisable, Weighted-Average Exercise Price | $0.60 | $0.06 |
Range Three [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Range of Exercise Price | $1.24 | |
Range of Exercise Price, Upper | $1.24 | |
Options Outstanding, Number (in Shares) | 314,036 | 514,833 |
Options Outstanding, Weighted-Average Exercise Price | $1.24 | $0.15 |
Options Outstanding, Weighted Average Contractual Life (Years) | 8 years 54 days | |
Options Exercisable, Number (in Shares) | 314,036 | 447,055 |
Options Exercisable, Weighted-Average Exercise Price | $1.24 | $0.15 |
Range Four [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Range of Exercise Price, Lower | $7 | |
Range of Exercise Price | $9 | |
Range of Exercise Price, Upper | $9 | |
Options Outstanding, Number (in Shares) | 59,372 | 43,611,035 |
Options Outstanding, Weighted-Average Exercise Price | $8.63 | $0.01 |
Options Outstanding, Weighted Average Contractual Life (Years) | 8 years 102 days | |
Options Exercisable, Number (in Shares) | 59,372 | 13,617,826 |
Options Exercisable, Weighted-Average Exercise Price | $8.63 | $0.01 |
Range Five [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Range of Exercise Price, Lower | $12 | |
Range of Exercise Price | $18.63 | |
Range of Exercise Price, Upper | $18.63 | |
Options Outstanding, Number (in Shares) | 19,081 | |
Options Outstanding, Weighted-Average Exercise Price | $15.29 | |
Options Outstanding, Weighted Average Contractual Life (Years) | 6 years 288 days | |
Options Exercisable, Number (in Shares) | 19,081 | |
Options Exercisable, Weighted-Average Exercise Price | $15.29 | |
Range Six [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Range of Exercise Price | $37 | |
Range of Exercise Price, Upper | $37 | |
Options Outstanding, Number (in Shares) | 250 | |
Options Outstanding, Weighted-Average Exercise Price | $37 | |
Options Outstanding, Weighted Average Contractual Life (Years) | 3 years 262 days | |
Options Exercisable, Number (in Shares) | 250 | |
Options Exercisable, Weighted-Average Exercise Price | $37 |
Note_10_Summary_of_Stock_Optio5
Note 10 - Summary of Stock Options (Details) - Valuation Assumptions for Stock Options | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 87 Months Ended | |
Sep. 30, 2014 | Dec. 30, 2013 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | |
Note 10 - Summary of Stock Options (Details) - Valuation Assumptions for Stock Options [Line Items] | ||||||
Dividend yield | 0.00% | 0.00% | ||||
Employee Stock Option [Member] | ||||||
Note 10 - Summary of Stock Options (Details) - Valuation Assumptions for Stock Options [Line Items] | ||||||
Expected term (in years) | 5 years | 5 years | 5 years | 5 years | ||
Average volatility | 61.00% | 67.00% | ||||
Risk-free interest rate | 1.80% | 0.87% | 0.84% | |||
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Note_10_Summary_of_Stock_Optio6
Note 10 - Summary of Stock Options (Details) - Stock-based Compensation Expense Included in the Statement of Income (USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Allocated share based compensation expense | $113,346 | $16,284 | $143,643 | $66,001 |
Research and Development Expense [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Allocated share based compensation expense | 101 | 976 | 667 | -7,016 |
General and Administrative Expense [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Allocated share based compensation expense | $113,245 | $15,308 | $142,976 | $73,017 |
Note_11_Income_Taxes_Details
Note 11 - Income Taxes (Details) (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2014 | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2014 | |
Note 11 - Income Taxes (Details) [Line Items] | |||||
Effective Income Tax Rate Reconciliation, Percent | 0.00% | 0.00% | |||
Unrecognized Tax Benefits | $78,000 | $78,000 | $70,000 | ||
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense | 0 | ||||
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | 1,642,000 | 1,789,000 | |||
Deferred Tax Assets, in Process Research and Development | 162,000 | 162,000 | |||
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | |||||
Note 11 - Income Taxes (Details) [Line Items] | |||||
Operating Loss Carryforwards | 11,188,000 | 11,188,000 | 10,554,000 | ||
Deferred Tax Assets, in Process Research and Development | 142,000 | ||||
Domestic Tax Authority [Member] | |||||
Note 11 - Income Taxes (Details) [Line Items] | |||||
Duration of Open Tax Years | 3 years | 3 years | |||
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member] | |||||
Note 11 - Income Taxes (Details) [Line Items] | |||||
Operating Loss Carryforwards | 11,176,000 | 11,176,000 | 10,543,000 | ||
Deferred Tax Assets, in Process Research and Development | $136,000 | ||||
State and Local Jurisdiction [Member] | |||||
Note 11 - Income Taxes (Details) [Line Items] | |||||
Duration of Open Tax Years | 4 years | 4 years | |||
Scenario, Forecast [Member] | |||||
Note 11 - Income Taxes (Details) [Line Items] | |||||
Effective Income Tax Rate Reconciliation, Percent | 0.00% |
Note_12_Related_Party_Transact1
Note 12 - Related Party Transactions (Details) (USD $) | 1 Months Ended | 9 Months Ended | 12 Months Ended | 15 Months Ended | 99 Months Ended | 1 Months Ended | 0 Months Ended | 12 Months Ended | 24 Months Ended | 99 Months Ended | 0 Months Ended | 12 Months Ended | 39 Months Ended | 1 Months Ended | |||
Sep. 23, 2014 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 30, 2013 | Dec. 31, 2006 | Sep. 30, 2012 | Dec. 30, 2013 | Jul. 31, 2012 | Oct. 04, 2007 | Dec. 31, 2013 | Dec. 31, 2012 | Oct. 04, 2007 | Dec. 31, 2013 | Mar. 14, 2013 | Dec. 31, 2008 | Dec. 31, 2008 | Apr. 30, 2012 | |
Note 12 - Related Party Transactions (Details) [Line Items] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues (in Shares) | 11,305,567 | ||||||||||||||||
Operating Leases, Rent Expense | $128,359 | $128,359 | $173,896 | $166,398 | $744,602 | ||||||||||||
Stock Issued During Period, Value, New Issues | 4,000 | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | 1,901,476 | ||||||||||||||||
Series B Preferred Stock [Member] | Donna Bella International, Limited [Member] | |||||||||||||||||
Note 12 - Related Party Transactions (Details) [Line Items] | |||||||||||||||||
Stock Issued During Period, Value, New Issues | 1,000,000 | ||||||||||||||||
Stellartech Research Corporation [Member] | |||||||||||||||||
Note 12 - Related Party Transactions (Details) [Line Items] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues (in Shares) | 300,000 | 300,000 | |||||||||||||||
Related Party Transaction, Amounts of Transaction | 345,472 | 33,000 | 33,000 | 325,936 | 6,920,619 | ||||||||||||
Chief Executive Officer [Member] | |||||||||||||||||
Note 12 - Related Party Transactions (Details) [Line Items] | |||||||||||||||||
Operating Leases, Rent Expense | 12,000 | 72,391 | |||||||||||||||
Employee-related Liabilities, Current | 271,346 | ||||||||||||||||
Monthly Severance Payment | 25,000 | ||||||||||||||||
Final Severance Payment | 21,346 | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in Shares) | 5,278,330 | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | 11,015,646 | ||||||||||||||||
Dr. Palmer [Member] | |||||||||||||||||
Note 12 - Related Party Transactions (Details) [Line Items] | |||||||||||||||||
Payments for Legal Settlements | 1,000,000 | ||||||||||||||||
Notes Payable, Related Parties | 150,000 | ||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 754,635 | ||||||||||||||||
Maximum Value of Shares to be Issued if Closing of Equity Financing | $150,000 |
Note_13_Subsequent_Events_Deta
Note 13 - Subsequent Events (Details) (USD $) | 0 Months Ended | |||
Jan. 31, 2014 | Oct. 01, 2014 | Mar. 05, 2014 | Sep. 30, 2014 | |
Related Party Convertible Bridge Notes [Member] | Subsequent Event [Member] | January 2014 Convertible Bridge Notes [Member] | ||||
Note 13 - Subsequent Events (Details) [Line Items] | ||||
Contingent Bridge Loan Proceeds | $500,000 | |||
Related Party Convertible Bridge Notes [Member] | Subsequent Event [Member] | March 2014 Convertible Promissory Notes [Member] | ||||
Note 13 - Subsequent Events (Details) [Line Items] | ||||
Maximum Authorized Convertible Promissory Notes Issuable | 500,000 | |||
Convertible Notes Payable | 100,000 | |||
Debt Instrument, Interest Rate, Stated Percentage | 9.00% | |||
Subsequent Event [Member] | Loan and Security Agreement [Member] | ||||
Note 13 - Subsequent Events (Details) [Line Items] | ||||
Proceeds from Issuance of Debt | 2,500,000 | |||
Subsequent Event [Member] | ||||
Note 13 - Subsequent Events (Details) [Line Items] | ||||
Repayments of Debt | 1,630,925 | |||
Loan and Security Agreement [Member] | ||||
Note 13 - Subsequent Events (Details) [Line Items] | ||||
Debt Instrument, Face Amount | $5,000,000 | |||
Number of Tranches | 3 |
Note_2_Summary_of_Significant_4
Note 2 - Summary of Significant Accounting Policies (Details) - Anti-dilutive Securities | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | |
Convertible Securities, Preferred Stock [Member] | ||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||||
Anti-dilutive securities | 462,331,603 | 462,331,603 | ||||
Equity Option [Member] | ||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||||
Anti-dilutive securities | 476,671 | 409,488 | 445,804 | 491,609 | 45,146,118 | 44,788,104 |
Convertible Preferred Stock [Member] | ||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||||
Anti-dilutive securities | 24,299,963 | 24,299,963 |
Note_3_Fair_Value_Measurements5
Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value [Line Items] | |||
Total assets | $190 | $324 | $503 |
Preferred stock warrant liabilities | 623,672 | 685,213 | |
Total liabilities | 623,672 | 685,213 | |
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member] | |||
Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value [Line Items] | |||
Money market fund | 190 | 324 | 503 |
Fair Value, Inputs, Level 1 [Member] | |||
Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value [Line Items] | |||
Total assets | 190 | 324 | 503 |
Fair Value, Inputs, Level 3 [Member] | |||
Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value [Line Items] | |||
Preferred stock warrant liabilities | 623,672 | 685,213 | |
Total liabilities | 623,672 | 685,213 | |
Money Market Funds [Member] | |||
Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value [Line Items] | |||
Money market fund | $190 | $324 | $503 |
Note_3_Fair_Value_Measurements6
Note 3 - Fair Value Measurements (Details) - Summary of Changes in Fair Value of Preferred Stock Warrant Liabilities (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | 99 Months Ended | ||||||
Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 30, 2013 | Dec. 31, 2011 | |
Summary of Changes in Fair Value of Preferred Stock Warrant Liabilities [Abstract] | ||||||||||
Fair value | $580,187 | $602,188 | $623,672 | $685,213 | $623,672 | $623,672 | $646,844 | |||
Fair value of warrants issued | 194,532 | |||||||||
Change in fair value recorded in other income (expense), net | $7,277 | $22,001 | $21,484 | ($50,762) | ($11,230) | ($61,541) | ($156,163) | ($622,824) |
Note_3_Fair_Value_Measurements7
Note 3 - Fair Value Measurements (Details) - Summary of the Valuation Techniques for Fair Value of Preferred Stock Warrant Liabilities (USD $) | 12 Months Ended | |||||||
Dec. 31, 2013 | Dec. 31, 2012 | Sep. 23, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 30, 2013 | Dec. 31, 2011 | Jan. 01, 2013 | |
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||||||||
Preferred stock warrant liabilities | $623,672 | $685,213 | $580,187 | $602,188 | $623,672 | $646,844 | ||
Preferred stock warrant liabilities | $0.06 | $0.53 | ||||||
76.00% | 83.00% | |||||||
Preferred Stock Warrant Liabilities [Member] | Minimum [Member] | ||||||||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||||||||
Preferred stock warrant liabilities | $0.04 | $0.04 | ||||||
Preferred Stock Warrant Liabilities [Member] | Maximum [Member] | ||||||||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||||||||
Preferred stock warrant liabilities | $0.44 | $0.44 | ||||||
Preferred Stock Warrant Liabilities [Member] | ||||||||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||||||||
Preferred stock warrant liabilities | $623,672 | $685,213 | $623,672 | |||||
Preferred stock warrant liabilities | $0.06 | $0.06 | ||||||
Minimum [Member] | ||||||||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||||||||
Preferred stock warrant liabilities | $0.04 | |||||||
70.62% | 74.20% | |||||||
Maximum [Member] | ||||||||
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ||||||||
Preferred stock warrant liabilities | $0.44 | |||||||
84.23% | 91.60% |
Note_4_Balance_Sheet_Component2
Note 4 - Balance Sheet Components (Details) (USD $) | 12 Months Ended | 99 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Disclosure Text Block Supplement [Abstract] | |||
Depreciation, Depletion and Amortization, Nonproduction | $66,120 | $57,173 | $239,475 |
Note_4_Balance_Sheet_Component3
Note 4 - Balance Sheet Components (Details) - Property and Equipment, Net (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | $321,879 | $259,803 | |
Less: Accumulated depreciation and amortization | -194,355 | -131,176 | |
Net property and equipment | 191,663 | 127,524 | 128,627 |
Medical Equipment [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | 276,443 | 215,639 | |
Computer Equipment [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | 32,143 | 30,871 | |
Furniture and Fixtures [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | $13,293 | $13,293 |
Note_4_Balance_Sheet_Component4
Note 4 - Balance Sheet Components (Details) - Accrued Liabilities (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Accrued Liabilities [Abstract] | |||
Accrued settlement related costs | $263,560 | ||
Accrued interest | 13,792 | 235,603 | 8,987 |
Accrued severence pay | 58,846 | ||
Accrued vacation | 73,809 | 81,499 | 54,153 |
Accrued loan restructuring fees | 47,500 | 27,288 | |
Deferred rent | 15,284 | 18,034 | |
Other accruals | 41,766 | 21,444 | 910 |
Total accrued liabilities | $387,538 | $516,152 | $345,644 |
Note_5_Note_Payable_Details_Su1
Note 5 - Note Payable (Details) - Summary of Note Payable (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 30, 2013 | Dec. 31, 2012 |
Summary of Note Payable [Abstract] | ||||
Less: Amount representing interest | ($146,292) | ($125,398) | ||
Present value of obligations | 1,471,799 | 1,471,798 | ||
Less: Unamortized debt discount | -8,554 | |||
1,471,799 | 1,463,244 | |||
Less: Notes payable, current portion | $1,471,799 | $1,463,244 | $1,462,244 | $1,581,390 |
Note_7_Commitments_and_Conting4
Note 7 - Commitments and Contingencies (Details) - Future Minimum Lease Payments (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
Future Minimum Lease Payments [Abstract] | ||
2014 | $46,428 | $184,002 |
2015 | 30,952 | 30,952 |
$77,380 | $214,954 |
Note_8_Common_Stock_Details_Su
Note 8 - Common Stock (Details) - Summary of Reserved Common Stock | Dec. 31, 2013 |
Note 8 - Common Stock (Details) - Summary of Reserved Common Stock [Line Items] | |
Reserved common stock | 568,227,020 |
Conversion of Series A Convertible Preferred Stock [Member] | |
Note 8 - Common Stock (Details) - Summary of Reserved Common Stock [Line Items] | |
Reserved common stock | 291,132,255 |
Conversion of Series B Convertible Preferred Stock [Member] | |
Note 8 - Common Stock (Details) - Summary of Reserved Common Stock [Line Items] | |
Reserved common stock | 171,199,348 |
Exercise of Options Under Stock Plan [Member] | |
Note 8 - Common Stock (Details) - Summary of Reserved Common Stock [Line Items] | |
Reserved common stock | 45,146,118 |
Issuance of Options Under Stock Plan [Member] | |
Note 8 - Common Stock (Details) - Summary of Reserved Common Stock [Line Items] | |
Reserved common stock | 36,449,336 |
Exercise and Conversion of Convertible Preferred Stock Warrants [Member] | |
Note 8 - Common Stock (Details) - Summary of Reserved Common Stock [Line Items] | |
Reserved common stock | 24,299,963 |
Note_9_Convertible_Preferred_S4
Note 9 - Convertible Preferred Stock (Details) - Convertible Preferred Stock Warrants Outstanding (USD $) | 12 Months Ended | |||||||||||||||||
Dec. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Sep. 23, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2011 | Dec. 31, 2008 | Apr. 30, 2009 | Nov. 30, 2010 | Apr. 30, 2012 | 31-May-11 | Jun. 30, 2011 | Sep. 30, 2011 | Nov. 30, 2011 | Jan. 31, 2012 | Feb. 29, 2012 | Feb. 28, 2012 | |
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $0.06 | $0.53 | ||||||||||||||||
Number of warrants outstanding | 16,680,324 | 16,680,324 | 16,680,324 | 940,189 | ||||||||||||||
Fair Value | $623,672 | $623,672 | $685,213 | $580,187 | $602,188 | $646,844 | ||||||||||||
Series A Preferred Stock [Member] | December 2008 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration date | 2-Dec-18 | 2-Dec-18 | 2-Dec-18 | |||||||||||||||
Exercise price | $0.61 | $0.61 | $0.61 | $0.61 | ||||||||||||||
Number of warrants outstanding | 196,721 | 196,721 | 196,721 | 196,721 | ||||||||||||||
Fair Value | 44,066 | 44,066 | 50,951 | 53,863 | ||||||||||||||
Series A Preferred Stock [Member] | April 2009 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration date | 2-Apr-19 | 2-Apr-19 | 2-Apr-19 | |||||||||||||||
Exercise price | $0.61 | $0.61 | $0.61 | $0.61 | ||||||||||||||
Number of warrants outstanding | 245,900 | 245,900 | 245,900 | 245,900 | ||||||||||||||
Fair Value | 58,278 | 58,278 | 66,885 | 70,082 | ||||||||||||||
Series A Preferred Stock [Member] | November 2010 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration date | 19-Nov-20 | 19-Nov-20 | 19-Nov-20 | |||||||||||||||
Exercise price | $0.61 | $0.61 | $0.61 | $0.61 | ||||||||||||||
Number of warrants outstanding | 163,934 | 163,934 | 163,934 | 163,934 | ||||||||||||||
Fair Value | 46,393 | 46,393 | 48,524 | 46,721 | ||||||||||||||
Series A Preferred Stock [Member] | April 2012 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration date | 19-Apr-22 | 19-Apr-22 | 19-Apr-22 | |||||||||||||||
Exercise price | $0.61 | $0.61 | $0.61 | $0.61 | ||||||||||||||
Number of warrants outstanding | 73,770 | 73,770 | 73,770 | 73,770 | ||||||||||||||
Fair Value | 24,934 | 24,934 | 26,852 | 27,443 | ||||||||||||||
Series B Preferred Stock [Member] | May 2011 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration date | 6-May-21 | 6-May-21 | 6-May-21 | |||||||||||||||
Exercise price | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||
Number of warrants outstanding | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | ||||||||||||||
Fair Value | 54,000 | 54,000 | 60,000 | 84,000 | ||||||||||||||
Series B Preferred Stock [Member] | June 2011 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration date | 30-Jun-21 | 30-Jun-21 | 30-Jun-21 | |||||||||||||||
Exercise price | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||
Number of warrants outstanding | 4,000,000 | 4,000,000 | 4,000,000 | 4,000,000 | ||||||||||||||
Fair Value | 108,000 | 108,000 | 120,000 | 168,000 | ||||||||||||||
Series B Preferred Stock [Member] | September 2011 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration date | 9-Sep-21 | 9-Sep-21 | 9-Sep-21 | |||||||||||||||
Exercise price | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||
Number of warrants outstanding | 4,000,000 | 4,000,000 | 4,000,000 | 4,000,000 | ||||||||||||||
Fair Value | 108,000 | 108,000 | 120,000 | 168,000 | ||||||||||||||
Series B Preferred Stock [Member] | November 2011 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration date | 30-Nov-21 | 30-Nov-21 | 30-Nov-21 | |||||||||||||||
Exercise price | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||
Number of warrants outstanding | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | ||||||||||||||
Fair Value | 28,000 | 28,000 | 30,000 | 42,000 | ||||||||||||||
Series B Preferred Stock [Member] | December 2011 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration date | 19-Dec-21 | 19-Dec-21 | 19-Dec-21 | |||||||||||||||
Exercise price | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||
Number of warrants outstanding | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | ||||||||||||||
Fair Value | 28,000 | 28,000 | 30,000 | 41,000 | ||||||||||||||
Series B Preferred Stock [Member] | January 2012 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration date | 31-Jan-22 | 31-Jan-22 | 31-Jan-22 | |||||||||||||||
Exercise price | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||
Number of warrants outstanding | 910,445 | 910,445 | 910,445 | 910,445 | ||||||||||||||
Fair Value | 28,224 | 28,224 | 30,045 | 37,328 | ||||||||||||||
Series B Preferred Stock [Member] | February 2012 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration date | 28-Feb-22 | 28-Feb-22 | 28-Feb-22 | |||||||||||||||
Exercise price | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | |||||||||||||
Number of warrants outstanding | 738,535 | 738,535 | 738,535 | 738,535 | 738,535 | |||||||||||||
Fair Value | 22,895 | 22,895 | 24,372 | 31,018 | 31,018 | |||||||||||||
Series B Preferred Stock [Member] | April 2012 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Expiration date | 16-Apr-22 | 16-Apr-22 | 16-Apr-22 | |||||||||||||||
Exercise price | $0.05 | $0.05 | $0.05 | $0.05 | ||||||||||||||
Number of warrants outstanding | 2,351,019 | 2,351,019 | 2,351,019 | 2,351,019 | ||||||||||||||
Fair Value | $72,882 | $72,882 | $77,584 | $98,743 | ||||||||||||||
December 2008 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $0.61 | |||||||||||||||||
Number of warrants outstanding | 196,721 | |||||||||||||||||
November 2010 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $0.61 | |||||||||||||||||
Number of warrants outstanding | 163,934 | |||||||||||||||||
April 2012 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right [Line Items] | ||||||||||||||||||
Exercise price | $0.61 | |||||||||||||||||
Number of warrants outstanding | 73,770 |
Note_10_Stock_Option_Plan_Deta
Note 10 - Stock Option Plan (Details) - Summary of Option Activity Under All Plans (USD $) | 9 Months Ended | 12 Months Ended | 15 Months Ended | ||||||||
Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2007 | Dec. 31, 2006 | Sep. 21, 2005 | |
Note 10 - Stock Option Plan (Details) - Summary of Option Activity Under All Plans [Line Items] | |||||||||||
Shares reserved at plan inception | 2,294,534 | 363,413 | |||||||||
Options granted | -1,901,476 | ||||||||||
Options granted | 1,901,476 | ||||||||||
Options granted (in Dollars per share) | $0.60 | ||||||||||
Options exercised | 0 | 0 | |||||||||
Options forfeited | 38,593 | ||||||||||
Options forfeited | -38,593 | ||||||||||
Options forfeited (in Dollars per share) | $1.75 | ||||||||||
Balances as of December 31 | 2,294,534 | 363,413 | |||||||||
Balances as of December 31 (in Dollars per share) | $1.02 | $2.94 | |||||||||
Balances as of December 31 | 9 years 244 days | 8 years 292 days | |||||||||
The 2006 Stock Option Plan [Member] | |||||||||||
Note 10 - Stock Option Plan (Details) - Summary of Option Activity Under All Plans [Line Items] | |||||||||||
Shares reserved at plan inception | 1,000,000 | ||||||||||
Shares reserved at plan inception | 36,449,336 | 36,807,350 | 501,871 | 202,621 | 499,576 | 2,014,000 | 2,086,500 | 948,500 | 0 | ||
Options granted | -11,873,890 | -43,694,521 | -345,000 | -771,412 | -1,892,029 | -72,500 | -867,000 | -51,500 | |||
Options granted | 11,873,890 | 43,694,521 | 345,000 | 771,412 | 1,892,029 | 72,500 | 867,000 | 51,500 | |||
Options granted (in Dollars per share) | $0.01 | $0.01 | $0.12 | $0.05 | $0.06 | $0.06 | $0.06 | $0.00 | |||
Options exercised | -1,866,903 | -9,000 | -173,455 | -322,395 | |||||||
Options exercised (in Dollars per share) | $0.07 | $0.00 | $0.00 | $0.06 | |||||||
Options forfeited | 11,515,876 | 139,000 | 12,500 | 377,605 | 5,000 | ||||||
Options forfeited | -11,515,876 | -139,000 | -12,500 | -377,605 | -5,000 | ||||||
Options forfeited (in Dollars per share) | $0.01 | $0.06 | $0.06 | $0.06 | $0.00 | ||||||
Repurchase of restricted stock options | 5,250 | ||||||||||
Balances as of December 31 | 36,449,336 | 36,807,350 | 501,871 | 202,621 | 499,576 | 2,014,000 | 2,086,500 | 948,500 | 0 | ||
Balances as of December 31 | 324,820 | 45,146,118 | 44,788,104 | 2,960,486 | 2,763,486 | 2,178,029 | 986,000 | 913,500 | 51,500 | ||
Balances as of December 31 (in Dollars per share) | $1.55 | $0.01 | $0.01 | $0.07 | $0.06 | $0.06 | $0.06 | $0.06 | $0.00 | ||
Balances as of December 31 | 8 years 21 days | 8 years 292 days | 9 years 270 days | 7 years 255 days | 8 years 146 days | 9 years | 8 years 317 days | 9 years 299 days | 9 years 350 days | ||
Options vested and expected to vest as of December 31, 2013 | 43,338,910 | ||||||||||
Options vested and expected to vest as of December 31, 2013 (in Dollars per share) | $0.01 | ||||||||||
Options vested and expected to vest as of December 31, 2013 | 8 years 292 days | ||||||||||
Options vested as of December 31, 2013 | 15,025,985 | ||||||||||
Options vested as of December 31, 2013 (in Dollars per share) | $0.02 | ||||||||||
Options vested as of December 31, 2013 | 8 years 219 days | ||||||||||
Additional shares reserved | 80,000,000 | 500,000 | 461,957 | 2,000,000 |
Note_10_Stock_Option_Plan_Deta1
Note 10 - Stock Option Plan (Details) - Summary of Options Outstanding and Exercisable (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Sep. 30, 2014 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in Dollars per share) | $1.02 | |
Number outstanding | 45,146,118 | 2,294,535 |
Weighted-average remaining contractual life | 8 years 292 days | |
Number of options | 15,025,985 | 413,059 |
Weighted-average exercise price (in Dollars per share) | $0.02 | $2.94 |
Range One [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in Dollars per share) | $0.00 | $0.12 |
Number outstanding | 40,000 | 320 |
Weighted-average remaining contractual life | 2 years 346 days | |
Number of options | 40,000 | 320 |
Weighted-average exercise price (in Dollars per share) | $0.00 | $0.12 |
Range Two [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in Dollars per share) | $0.06 | $0.60 |
Number outstanding | 980,250 | 1,901,476 |
Weighted-average remaining contractual life | 5 years 248 days | |
Number of options | 921,104 | 20,000 |
Weighted-average exercise price (in Dollars per share) | $0.06 | $0.60 |
Range Three [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in Dollars per share) | $0.15 | $1.24 |
Number outstanding | 514,833 | 314,036 |
Weighted-average remaining contractual life | 7 years 343 days | |
Number of options | 447,055 | 314,036 |
Weighted-average exercise price (in Dollars per share) | $0.15 | $1.24 |
Range Four [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Exercise price (in Dollars per share) | $0.01 | $8.63 |
Number outstanding | 43,611,035 | 59,372 |
Weighted-average remaining contractual life | 8 years 324 days | |
Number of options | 13,617,826 | 59,372 |
Weighted-average exercise price (in Dollars per share) | $0.01 | $8.63 |
Note_10_Stock_Option_Plan_Deta2
Note 10 - Stock Option Plan (Details) - Valuation Assumptions for Stock Options | 9 Months Ended | 12 Months Ended | 87 Months Ended | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2014 | Dec. 30, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2013 | |
Note 10 - Stock Option Plan (Details) - Valuation Assumptions for Stock Options [Line Items] | ||||||
Dividend yield | 0.00% | 0.00% | ||||
Employee Stock Option [Member] | Minimum [Member] | ||||||
Note 10 - Stock Option Plan (Details) - Valuation Assumptions for Stock Options [Line Items] | ||||||
Expected term (in years) | 5 years | |||||
Expected volatility | 60.00% | |||||
Risk-free interest rate | 0.76% | 0.76% | ||||
Employee Stock Option [Member] | Maximum [Member] | ||||||
Note 10 - Stock Option Plan (Details) - Valuation Assumptions for Stock Options [Line Items] | ||||||
Expected term (in years) | 6 years 3 months | |||||
Expected volatility | 79.00% | |||||
Risk-free interest rate | 0.84% | 4.70% | ||||
Employee Stock Option [Member] | ||||||
Note 10 - Stock Option Plan (Details) - Valuation Assumptions for Stock Options [Line Items] | ||||||
Expected term (in years) | 5 years | 5 years | 5 years | 5 years | ||
Expected volatility | 68.00% | 67.00% | ||||
Risk-free interest rate | 1.80% | 0.87% | 0.84% | |||
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Note_10_Stock_Option_Plan_Deta3
Note 10 - Stock Option Plan (Details) - Valuation Assumptions for Nonemployee Stock Options | 9 Months Ended | 12 Months Ended | 99 Months Ended | ||
Sep. 30, 2014 | Dec. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Note 10 - Stock Option Plan (Details) - Valuation Assumptions for Nonemployee Stock Options [Line Items] | |||||
Dividend yield | 0.00% | 0.00% | |||
Nonemployee Stock Option [Member] | Minimum [Member] | |||||
Note 10 - Stock Option Plan (Details) - Valuation Assumptions for Nonemployee Stock Options [Line Items] | |||||
Contractual term (in years) | 3 years | 4 years | 3 years | ||
Expected volatility | 60.00% | ||||
Risk-free interest rate | 0.78% | 0.72% | 0.56% | ||
Nonemployee Stock Option [Member] | Maximum [Member] | |||||
Note 10 - Stock Option Plan (Details) - Valuation Assumptions for Nonemployee Stock Options [Line Items] | |||||
Contractual term (in years) | 10 years | 10 years | 10 years | ||
Expected volatility | 79.00% | ||||
Risk-free interest rate | 3.04% | 1.78% | 4.70% | ||
Nonemployee Stock Option [Member] | |||||
Note 10 - Stock Option Plan (Details) - Valuation Assumptions for Nonemployee Stock Options [Line Items] | |||||
Expected volatility | 67.00% | 68.00% | |||
Dividend yield | 0.00% | 0.00% | 0.00% |
Note_11_Income_Taxes_Details_D
Note 11 - Income Taxes (Details) - Deferred Tax Assets and Liabilities (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Deferred Tax Assets and Liabilities [Abstract] | ||
Net operating loss carryforwards | $4,203,000 | $3,951,000 |
Research and development credits | 162,000 | 162,000 |
Start-up expenses capitalized | 7,156,000 | 5,726,000 |
Accruals and reserves | 99,000 | 150,000 |
Property and equipment | -11,000 | -22,000 |
11,609,000 | 9,967,000 | |
Less: Valuation allowance | -11,609,000 | -9,967,000 |
$0 | $0 |